---
document_datetime: 2023-09-21 19:03:51
document_pages: 87
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/invega-h-c-746-ii-0037-epar-assessment-report-variation_en.pdf
document_name: invega-h-c-746-ii-0037-epar-assessment-report-variation_en.pdf
version: success
processing_time: 112.3777214
conversion_datetime: 2025-12-22 14:14:45.843508
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
25 April 2014 EMA/339041/2014

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Invega

International non-proprietary name: PALIPERIDONE

Procedure No. EMEA/H/C/000746/II/0037

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0)20 7523 7455

E-mail

info@ema.europa.eu

Website

www.ema.europa.eu

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................5                               |                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| 1.1. Requested Type II variation.................................................................................        | 5                                                                                                    |
| 1.2. Steps taken for the assessment............................................................................          | 5                                                                                                    |
| 2. Scientific discussion ................................................................................6               |                                                                                                      |
| 2.1. Introduction ...................................................................................................... | 6                                                                                                    |
| 2.2. Non-clinical aspects............................................................................................    | 7                                                                                                    |
| 2.2.1. Toxicology......................................................................................................  | 7                                                                                                    |
| 2.2.2. Ecotoxicity/environmental risk assessment..........................................................               | 9                                                                                                    |
| 2.2.3. Discussion on non-clinical aspects......................................................................          | 9                                                                                                    |
| 2.2.4. Conclusion on the non-clinical aspects                                                                            | .............................................................. 10                                    |
| 2.3. Clinical aspects ................................................................................................   | 10                                                                                                   |
| 2.3.1. Introduction                                                                                                      | ................................................................................................. 10 |
| 2.3.2. Pharmacokinetics ..........................................................................................       | 11                                                                                                   |
| 2.3.3. PK/PD Modelling............................................................................................       | 13                                                                                                   |
| 2.3.4. Additional analyses........................................................................................       | 17                                                                                                   |
| 2.3.5. Discussion on clinical pharmacology .................................................................             | 19                                                                                                   |
| 2.3.6. Conclusions on clinical pharmacology ...............................................................              | 21                                                                                                   |
| 2.4. Clinical efficacy ................................................................................................  | 21                                                                                                   |
| 2.4.1. Dose response study......................................................................................         | 21                                                                                                   |
| 2.4.2. Main studies .................................................................................................    | 21                                                                                                   |
| 2.4.3. Analysis performed across trials (pooled analyses and meta-analysis)...................                           | 47                                                                                                   |
| 2.4.4. Supportive study...........................................................................................       | 48                                                                                                   |
| 2.4.5. Additional analyses........................................................................................       | 54                                                                                                   |
| 2.4.6. Discussion on clinical efficacy ..........................................................................        | 63                                                                                                   |
| 2.4.7. Conclusions on the clinical efficacy...................................................................           | 69                                                                                                   |
| 2.5. Clinical safety ..................................................................................................  | 69                                                                                                   |
| 2.5.1. Patient exposure ...........................................................................................      | 69                                                                                                   |
| 2.5.2. Adverse events                                                                                                    | ............................................................................................. 70     |
| 2.5.3. Serious adverse event/deaths/other significant events........................................                     | 77                                                                                                   |
| 2.5.4. Laboratory, ECG and other findings..................................................................              | 77                                                                                                   |
| 2.5.5. Discontinuation due to adverse events..............................................................               | 79                                                                                                   |
| 2.5.6. Post marketing experience..............................................................................           | 80                                                                                                   |
| 2.5.7. Discussion on clinical safety                                                                                     | ............................................................................ 80                      |
| 2.5.8. Conclusions on clinical safety ..........................................................................         | 82                                                                                                   |
| 2.5.9. PSUR cycle ...................................................................................................    | 82                                                                                                   |
| 2.6. Risk management plan......................................................................................          | 82                                                                                                   |
| 2.6.1. PRAC advice .................................................................................................     | 82                                                                                                   |
| 2.7. Update of the product information ......................................................................            | 83                                                                                                   |
| 3. Benefit-risk balance                                                                                                  | ..............................................................................84                     |
| 4. Recommendations.................................................................................87                    |                                                                                                      |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADR       | Adverse Drug Reactions                                                    |
|-----------|---------------------------------------------------------------------------|
| AE        | Adverse Event                                                             |
| AIMS      | Abnormal Involuntary Movement Scale                                       |
| ANCOVA    | Analysis of Covariance                                                    |
| AUC       | Area Under Curve                                                          |
| BMI       | Body Mass Index                                                           |
| BW        | Body Weight                                                               |
| C-CASA    | Columbia Classification Algorithm of Suicide Assessment                   |
| CCDS      | Company Core Data Sheet                                                   |
| CGA-S     | Children's Global Assessment Scale                                        |
| CGI-S     | Clinical Global Impression Scale                                          |
| CHMP      | Committee for Human Medicinal Products                                    |
| CI        | Confidence Interval                                                       |
| Cl/F      | Total apparent clearance                                                  |
| Cl/r      | Renal clearance of drug                                                   |
| ClCr      | Creatinine clearance                                                      |
| Cmax      | Maximum Plasma Concentration                                              |
| CNS       | Central Nervous System                                                    |
| CONai     | Estimated Consumption Of Active Substance In Geographic Region Per Year   |
| Css       | Steady State Concentration                                                |
| C-SSRS    | Columbia-Suicide Severity Rating Scale                                    |
| DB        | Double Blind                                                              |
| DSM IV    | Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition     |
| EC        | European Commission                                                       |
| ECG       | Electrocardiogram European Medicines                                      |
| EMA       | Agency                                                                    |
| EPS       | Extrapyramidal Symptoms                                                   |
| ER        | Extended Release                                                          |
| ERA       | Environmental Risk Assessment                                             |
| EU        | European Union                                                            |
| Fpen      | Fraction of a Population receiving drug substance during a given time     |
| Fu        | Unbound Fraction                                                          |
| GLP       | Good Laboratory Practices                                                 |
| GOF       | Godness of Fit                                                            |
| HOMA      | Homeostatic Model Assessment                                              |
| IM        | Intramuscular                                                             |
| ITT       | Intention to Treat                                                        |
| K-SADS-PL | Kiddie-Sads-Present and Lifetime Version                                  |
| LBM       | Lean body mass                                                            |
| LOCF      | Last Observation Carried Forward                                          |
| LS        | Least Squares                                                             |
| MA        | Marketing Authorisation                                                   |
| MAH       | Marketing Authorisation Holder                                            |
| MATRICS   | Measurements and Treatment Research to Improve Cognition in Schizophrenia |
| MMRM      | Mixed-effects Model for Repeated Measures                                 |
| MO        | Major Objection                                                           |
| NMS       | Neuroleptic Malignant Syndrome                                            |
| NO DB     | No Double Blind                                                           |
| NOAEL     | No Observed Adverse Effect Level                                          |
| NONMEM    | Non linear mixed effects modeling Label                                   |
| OL        | Open                                                                      |
| PANSS     | Positive and Negative Syndrome Scale for Schizophrenia Pharmacodynamics   |
| PD        |                                                                           |
| PDCO      | Paediatric                                                                |

<div style=\"page-break-after: always\"></div>

| PECsw   | Predicted Environmental Concentration in Surface Water   |
|---------|----------------------------------------------------------|
| PI      | Product Information                                      |
| PK      | Pharmacokinetic                                          |
| PL      | Package Leaflet                                          |
| PopK    | Population Pharmacokinetic                               |
| PP      | Per Protocol                                             |
| PR      | Prolonged Release                                        |
| PRAC    | Pharmacovigilance Risk Assessment Committee              |
| PSP     | Personal and Social Performance                          |
| PSRE    | Potentially Suicide related events                       |
| PTs     | Preferred Terms                                          |
| QRD     | Quality Review Document                                  |
| QTc     | Corrected QT                                             |
| QTcB    | QT interval corrected Bazett                             |
| QTcF    | QT interval corrected Fridericia                         |
| QTcLD   | QTc linear derived correction                            |
| QTlc    | Linear corrected QT                                      |
| RMP     | Risk Management Plan                                     |
| RMP     | Risk Management Plan                                     |
| SAE     | Serious Adverse Event                                    |
| SD      | Standard Deviation                                       |
| SE      | Standard Error                                           |
| SmPC    | Summary of Product Characteristics                       |
| SOC     | System Organ Class                                       |
| TEAE    | Treatment Emergent Adverse Event                         |
| US      | United States                                            |
| VAS     | Visual Analog Scale                                      |
| VPC     | Visual Predictive Check                                  |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Requested Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Janssen-Cilag International N.V. submitted to the European Medicines Agency on 8 March 2013 an application for a variation.

This application concerns the following medicinal product:

| Medicinal product:   | International non-proprietary name:   | Presentations:   |
|----------------------|---------------------------------------|------------------|
| Invega               | PALIPERIDONE                          | See Annex A      |

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

The MAH proposed an extension of indication to add the treatment of schizophrenia in adolescents 12 years and older.

Consequently, the MAH proposed the update of sections 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC. Sections 1, 2, 3 and 4 of the Package Leaflet was proposed to be updated in accordance.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet.

Rapporteur:

Filip Josephson

CoRapporteur: Martina Weise

## 1.2. Steps taken for the assessment

| Submission date:                                                                                   | 8 March 2013     |
|----------------------------------------------------------------------------------------------------|------------------|
| Start of procedure:                                                                                | 29 March 2013    |
| Rapporteur's preliminary assessment report circulated on:                                          | 23 May 2013      |
| CoRapporteur's preliminary assessment report circulated on:                                        | 17 May 2013      |
| Rapporteur's RMP assessment report adopted by PRAC on :                                            | 13 June 2013     |
| Request for supplementary information and extension of timetable adopted by the CHMP on:           | 27 June 2013     |
| MAH's responses submitted to the CHMP on:                                                          | 18 October 2013  |
| Rapporteurs' joint preliminary assessment report circulated on:                                    | 3 December 2013  |
| Rapporteurs' joint updated assessment report on the MAH's responses circulated on:                 | 13 December 2013 |
| Follow on Request for supplementary information and extension of timetable adopted by the CHMP on: | 19 December 2013 |
| MAH's responses submitted to the CHMP on:                                                          | 21 February 2014 |
| Rapporteurs' joint preliminary assessment report on the MAH's responses circulated on:             | 8 April 2014     |
| Rapporteurs' joint updated assessment report on the MAH's responses circulated on:                 | 15 April 2014    |
| CHMP opinion on:                                                                                   | 25 April 2014    |

<div style=\"page-break-after: always\"></div>

## Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/154/2011 on the agreement of a paediatric investigation plan (PIP).

The PDCO issued an opinion on compliance for the PIP P/154/2011 eligible for the reward.

## 2. Scientific discussion

## 2.1. Introduction

Invega  (paliperidone)  is  a  monoaminergic  antagonist  with  a  high  affinity  for  serotoninergic  (5hydroxytryptamine  Type  2A)  and  dopaminergic  Type  2  receptors.    It  belongs  to  the  atypical, antipsychotic  class  of  psychotropic  drugs.  It  is  the  major  active  metabolite  of  risperidone  which  is authorised for the treatment of schizophrenia. Paliperidone have been developed as an oral prolongedrelease  formulation  (paliperidone  ER  or  PR  tablets)  and  a  long-acting  IM  injectable  formulation (paliperidone palmitate). Paliperidone palmitate (Xeplion) is subject to a separate marketing authorisation (MA).

Invega tablets (1.5, 3, 6, 9, and 12 mg) are currently approved in the European Union (EU) for the treatment of schizophrenia and schizoaffective disorder (psychotic or manic symptoms) in adults with recommended dose of 6 mg once daily. Dosage adjustment may be required within the recommended range of 3-12 mg once daily in patients with schizophrenia and 6-12 mg once daily in patients with schizoaffective disorder.

In  December  2009,  the  MAH  submitted  one  completed  paediatric  study, R076477-PSZ-3001, for Invega (paliperidone) in accordance with Article 46 of the Paediatric Regulation (EC) No1901/2006, as amended (EMEA/H/C/746/P46/011). No further actions were required by the CHMP awaiting for the completion  of  the  phase  III  study R076477-PSZ-3003 to  consider  an  update  of  the  Product Information (PI). The procedure was concluded in March 2010.

In December 2010, the MAH submitted two other completed paediatric studies, R076477-PSZ-3002 and  R076477-PSZ-3003, for  Invega  (paliperidone)  in  accordance  with  Article  46  of  the  Paediatric Regulation (EC) No1901/2006, as amended (EMEA/H/C/746/P46/017). The CHMP agreed in February 2013 to assess these data within the planned submission for an extension of indication in March 2013.

Subsequently, the MAH submitted the present application. Within this procedure (EMEA/H/C/746/II/37),  the  MAH  initially  applied  for  an  extension  of  indication  of  Invega  (new indication is underlined) as follows:

'INVEGA is indicated for the treatment of schizophrenia in adults and in adolescents 12 years and older.'

For  the  extension  of  indication  applied  for,  the  MAH  initially  proposed  the  following  posology  for Invega:

'The recommended starting dose is 3 mg once daily, administered in the morning. Some patients may benefit from a higher dose of 6 mg to 12 mg once daily. Dosage adjustment, if indicated, should occur only after clinical reassessment based on the individual need of the patient. When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of 5 days or more.'

This application is based  on the previously mentioned  clinical studies ( R076477-PSZ-3001, R076477-PSZ-3002 and R076477-PSZ-3003) which are part of the agreed Paediatric Investigation

<div style=\"page-break-after: always\"></div>

Plan  (PIP)  for  paliperidone  ER.  An  open-label  single  and  multiple  dose  Phase  1  study (PALIOROSPSZ-1001) was also conducted to investigate the pharmacokinetics (PK) properties of paliperidone ER and  its  safety  profile  in  paediatric  subjects  (aged  10  to  17  years)  and  is  also  referred  in  this application.  This  study  was  previously  submitted  in  accordance  with  article  45  of  the  Paediatric Regulation (FUM 10). Additionally, 2 non-clinical studies ( TOX8691, TOX8145 ) were submitted in this application, TOX8691 being part of the PIP.

During  the  evaluation,  the  MAH  proposed  to  restrict  the  proposed  indication  to  treatment  of schizophrenia  in  adolescents 15  years  and  older. The  posology  was  also  revised  and  is  further discussed below.

## 2.2. Non-clinical aspects

The MAH provided one toxicity study with repeated oral administration of paliperidone for seven weeks in juvenile rats. Furthermore, another toxicity study with oral treatment of risperidone for 40 weeks in juvenile dogs was submitted. Both juvenile toxicities studies were conducted in compliance with Good Laboratory Practices (GLP).

## 2.2.1. Toxicology

These data are summarised in Table 1. Tables 2 and 3 present the toxicokinetic results.

Table  1:  Summary  of  the  toxicity  studies  performed  with  paliperidone  and  risperidone  in juvenile rats and dogs.

| Study number (tested drug)   | Species/ Strain Number/ Sex/Grou p                | Route/Dose/Du ration (mg/kg)                                                                                                                                                                                    | Major Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------------|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TOX8691 (paliperidone)       | Rats, 24 days of age at Day 1 32 female and males | Oral gavage 0.16, 0.63 or 2.5 mg/kg/day Controls: vehicle, tartaric acid and NaOH Seven weeks from Day 24 to Day 73 of age (12 males, 12 females) 4 extra weeks for recovery/repro phase (20 males, 20 females) | No treatment related deaths. Apart from below, all other parameters were unaffected by treatment. Clinical observations: Pharmacological effects, such as ptosis, underactivity, piloerection and reddening of the skin at 0.63 or 2.5 mg/kg, throughout the treatment period. Food consumption and body weight gain: Slightly increased in females. Morris Maze: Impaired learning and memory in females at 2.5 mg/kg from days 67 to 69 of age,but no effects in males or at lower dosages. Performance of the females was similar to controls after three weeks of recovery. Prolactin: Higher than controls in all treated groups of males and females, no dose response. In males at 2.5 mg/kg/day increase statistical significant. Oestrous cycles: Reduced cycle activity in all treated groups, 2.5 mg/kg group least affected. Normal after cessation of treatment. Histopathology: Glandular development and persistent corpora lutea in females. |
| TOX8145 (risperidone)        | Beagle dogs, 10 weeks of age at Day 1             | Oral gavage 0.31, 1.25 or 5 mg/kg/day                                                                                                                                                                           | No treatment related deaths. Apart from below, all other parameters were unaffected by treatment. Clinical observations: Dose dependent reduced activity,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Study number (tested drug)   | Species/ Strain Number/ Sex/Grou p                               | Route/Dose/Du ration (mg/kg)                                          | Major Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------------------|------------------------------------------------------------------|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              | 8 females and males/group, 4 females and males were for recovery | Controls: vehicle, tartaric acid and NaOH 40 weeks Recovery: 12 weeks | pupil constriction, visible third eyelid, reddening of the sclera and loose or liquid faeces. Body weight gain: Reduced at 0.31 and 1.25 mg/kg, reversible. Femur growth: Reduced in females at 5 mg/kg, lower mineral density in femur and femoral diaphysis in females at 1.25 and 5 mg/kg, trend to reversibility during recovery period. Shoulder height: Reduced in females at 1.25 and 5 mg/kg and in males at 5 mg/kg; reversible in males but not in females during recovery. Serum chemistry: Increased prolactin at all dose levels in both males and females, reversible. Reduced testosterone levels in males at all dose levels, reversible. After 8 weeks of recovery, females at 0.31 and 1.25 mg/kg/day showed increased progesterone concentrations for the first time. Females at 5 mg/kg/day showed no detectable progesterone after up to 12 weeks of recovery. Oestrous cycles: Oestrus in majority of controls W32 to W40, only in one female at 0.31 mg/kg/day and in no females at 1.25 or 5 mg/kg/day. During the recovery in one female at 0.31 and in one at 1.25 mg/kg/day, not seen for any females at 5 mg/kg/day. Organ weights: Low epididymides and testes weights and reduction of total sperm counts at 1.25 and 5 mg/kg/day, low prostate weights at 5 mg/kg/day, no definite reversibility. Low ovary, uterus and cervix weights at all dose levels, no definite reversibility. Histopathology: Low colloid amount/atrophy in the prostate at 5 mg/kg/day, reversible. Active glandular development in the mammary, prominent luteal cells and endometrial gland hyperplasia in controls but not in any treated females. |

Table 2: The mean Cmax and AUC values of paliperidone after repeated oral dosing at 0.16, 0.63 and 2.5 mg/kg/day in male and female juvenile rats.

| Day 31   | Day 31       | Day 31   | Day 31   | Day 31   | Day 31   | Day 31   | Day 31   |
|----------|--------------|----------|----------|----------|----------|----------|----------|
|          |              | Male     | Male     | Male     | Female   | Female   | Female   |
| Dose     | (mg/kg/dlay) | 0.16     | 0.63     | 2.5      | 0.16     | 0.63     | 2.5      |
| m        | (ng/ml)      | 16.8     | 94.1     | 426      | 23.7     | 90.7     | 428      |
| AUC24h   | (ng.h/ml)    | 76.7     | 385      | 1543     | 131      | 525      | 2056a    |

AUCo-8h

<div style=\"page-break-after: always\"></div>

Table  3:  The  mean  Cmax  and  AUC  values  of  risperidone+9-hydroxy-risperidone  (active moieties)  after  repeated  oral  dosing  at  0.31,  1.25  and  5  mg/kg/day  in  male  and  female juvenile dogs.

|                     | Male    | Male    | Male    | Female   | Female   | Female   |
|---------------------|---------|---------|---------|----------|----------|----------|
|                     | Day 1   | Day 1   | Day 1   | Day 1    | Day 1    | Day 1    |
| Dose (mg/kg/day)    | 0.31    | 1.25    | 5       | 0.31     | 1.25     | 5        |
| Cmx (ng/ml)         | 126     | 351     | 2010    | 116      | 418      | 2505     |
| AUCo-nf (ng.h/ml)   | 918     | 3024    | 17327   | 797      | 4572     | 22047    |
|                     | Day 106 | Day 106 | Day 106 | Day 106  | Day 106  | Day 106  |
| Dose (mg/kg/day)    | 0.31    | 1.25    | 5       | 0.31     | 1.25     | 5        |
| Cmx (ng/ml)         | 123     | 500     | 1257    | 214      | 377      | 1445     |
| AUCo-24 h (ng.h/ml) | 1345    | 4623    | 15000   | 1466     | 4472     | 17032    |
|                     | Day 208 | Day 208 | Day 208 | Day 208  | Day 208  | Day 208  |
| Dose (mg/kg/day)    | 0.31    | 1.25    | 5       | 0.31     | 1.25     | 5        |
| Cmax (ng/ml)        | 154     | 531     | 1398    | 144      | 648      | 1637     |
| AUCo-24 h (ng.h/ml) | 1405    | 5351    | 16492   | 1317     | 6333     | 16951    |

## 2.2.2. Ecotoxicity/environmental risk assessment

No  new  ERA  data  were  initially  submitted  by  the  MAH.  However,  considering  this  application  is  to extend  the  use  in  the  paediatric  population  with  schizophrenia,  the  CHMP  requested  the  MAH  to provide  an  updated  medical  statistical  data  for  the  new  estimated  market  penetration  and  the calculation of the refined Predicted Environmental Concentration in the surface water (PECsw) in Phase II tier A. Using an estimated consumption of active substance in geographic region per year (CONai) of 289 kg (the highest predicted usage of paliperidone from 2013-2019), the Fpen was found lower than previous  calculation  based  on  a  predicted  CONai  of  775  kg  for  2014.  Consequently  the  PEC  of paliperidone in surface water was 0.0001 µ g/L (compared with 0.003 µ g/L calculated in previous ERA). Therefore, the CHMP concluded that no further ERA data were required with the proposed extension of indication and agreed that adding a patient population of 12-17 year old would not significantly alter the  exposure  of  paliperidone  to  the  environment,  also  taking  into  account  that  schizophrenia  only exists  very  rarely  in  children  and  adolescents  (estimated  1  in  10,000)  compared  with  a  lifetime prevalence of 0.5 to 1 in 100 in adults.

## 2.2.3. Discussion on non-clinical aspects

In  juvenile  rats,  dosing  by  oral  gavage  at  0.16,  0.63  and  2.5  mg/kg/day,  no  new  findings  were observed, compared to what is already known for paliperidone. The findings observed were expected pharmacological  effects.  A  possibly  treatment-related  effect  on  learning  and  memory  was  seen  in females only and the CHMP considered necessary to include this effect in the SmPC of paliperidone, although  the  clinical  significance  of  this  finding  was  unclear.  Whilst  learning  and  memory  was  not compromised in males in this study, the CHMP noted that slight effects on learning and memory were previously evident in juvenile rats of both genders administered with 1.25 mg/kg risperidone. Based on these  results,  the  No  Observed  Adverse  Effect  Level  (NOAEL)  for  males  and  females  was  2.5 mg/kg/day and 0.63 mg/kg/day, respectively.

In  juvenile  dogs,  dosed  by  oral  gavage  at  0.31,  1.25  or  5  mg/kg  risperidone  /day,  no  new  findings were observed, compared to what is already known for risperidone/paliperidone.    Testosterone  and progesterone levels together with histopathological findings in the prostate, mammary gland, ovaries

<div style=\"page-break-after: always\"></div>

and uterus indicated that sexual maturity was delayed in dogs at all dose levels. A trend to reversibility was seen during the recovery period for males and the low and mid dose females, whereas recovery was not seen in females administered 5 mg/kg/day.

In  dogs,  overall  femur  growth  was  reduced  during  treatment  for  females  at  5  mg/kg/day  and  the overall change in shoulder height was also less for males and females at this dose level. Furthermore, at 40 weeks, the femurs of females at 5 mg/kg/day had lower mineral density for the proximal femur and  the  femoral  diaphysis.  These  findings  on  bone  development  are  expected  effects  of  atypical antipsychotics such as paliperidone and likely due to increased levels of prolactin.

All  the  effects  seen  in  dog  were  reversible  during  the  recovery  period.  Based  on  these  results  the NOAEL for males and females was 0.31 mg/kg/day.

In  previous  studies  conducted  in  adult  animals,  effects  were  seen  at  or  below  clinical  exposure.  In adolescents,  the  Cmax  was  23.2  (9.62-89.3)  ng/mL  and  the  AUC0-24  was  486  (215-1750)  ng*h/mL. Comparing the  clinical  exposure  with  the  exposures  reached  in  the  rat  study,  no  margin  to  human exposure was reached at NOAEL in female rats, whereas a margin of 3 was reached in males (NOAEL was the highest dose tested). In dogs, at NOAEL, the margin to clinical exposure was approximately 3.

The  nervous  and  reproductive  systems  are  the  main  organ  systems  which  are  under  development between 12-18 years. The rats were 3.5 weeks at the beginning of the study and the study lasted for 7 weeks, thus the critical maturation period regarding nervous and reproductive systems in the rats is considered  covered.  In  the  dog  study,  the  critical  period  for  skeletal  and  reproductive  system development was covered.

Overall,  available  non-clinical  data  obtained  in  juvenile  rats  with  paliperidone  are  consistent  with previous results from treatment of juvenile rats and dogs with the parent compound risperidone. For this  reason,  these  data  are  regarded  sufficient  to  support  the  proposed  therapy  of  schizophrenia  in adolescents  of  12 years  and  older  initially  applied  for.  It  should  be  noted,  however,  that  effects  in juvenile  animals  already  occurred  at  exposures  (based  on  AUC),  which  are  either  close  (delay  of physical  development  and  sexual  maturation  in  risperidone-treated  dogs)  or  equal  (learning  and memory deficits in rats administered either paliperidone or risperidone) to the level achieved at the maximum recommended dose in adolescents. The CHMP therefore considered necessary to include a description of the findings from the juvenile toxicity studies in the SmPC. In addition, SmPC warnings related to hyperprolactinaemia- and sedation-related side effects were added in view of the non-clinical findings that were further supported by clinical data (see 2.5).

## 2.2.4. Conclusion on the non-clinical aspects

Overall,  the  non-clinical  aspects  of  Invega  have  been  adequately  documented  and  meet  the requirements to support this application.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

Table 4: Tabular overview of clinical studies in paediatric population with schizophrenia

| Protocol Number     | Study Design Objective                                                                                                                                                                    | and Study Treatments                                                                                                                                              | No. of Subjects (N)                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| R076477-PSZ- 3001   | 6-week, randomized, double-blind, parallel- group, placebo-controlled multicenter efficacy and safety study in adolescents (12-17 years) with schizophrenia                               | Placebo or fixed doses of paliperidone ER (1.5, 3, 6, or 12 mg/day). Randomization to paliperidone ER Low, Medium, or High based on non-overlapping mg/kg groups. | Placebo, N=51 Paliperidone ER Low (1.5 mg) , N=54 Paliperidone ER Medium (3 or 6 mg), N=48 Paliperidone ER High (6 or 12 mg), N=48 Total N=201 |
| R076477-PSZ- 3003   | 26-week, randomized, double-blind, active- controlled, parallel-group, multicenter, efficacy and safety study in adolescents (12-17 years) with schizophrenia                             | Flexible doses of paliperidone ER (range, 3 to 9 mg/day) or aripiprazole (range, 5 to 15 mg/day)                                                                  | Paliperidone ER, N=113 Aripiprazole, N=114 Total N=227                                                                                         |
| R076477-PSZ- 3002 a | 2-year, long-term, open- label study of safety and tolerability of paliperidone ER in adolescents (12-17 years) with schizophrenia ER tolerated 12 mg/day)                                | Flexible doses of paliperidone titrated to maximum dose (range, 1.5 to                                                                                            | Paliperidone ER, Total N=400                                                                                                                   |
| PALIOROS-PSZ- 1001  | Open-Label, Safety and Pharmacokinetics of Single- and Multiple-Dose in children and adolescents (10-17 years) with schizophrenia, schizoaffective disorder, or schizophreniform disorder | 0.086, 0.129, and 0.171 mg/kg/day paliperidone ER, corresponding to approximately 6, 9, and 12 mg/day in adults                                                   | Paliperidone ER (0.086 mg/kg), N=8 Paliperidone ER (0.129 mg/kg), N=9 Paliperidone ER (0.171 mg/kg), N=8                                       |

## 2.3.2. Pharmacokinetics

The pharmacokinetics of paliperidone in children and adolescents (10 to 17 years of age inclusive) was investigated  in  study  PALIOROS-PSZ-1001  and  R076477-PSZ-3001.  The  data  were  analysed  both using non-compartmental analysis and population pharmacokinetic (popPK) modeling in NONMEM. In study PALIOROS-PSZ-1001, only one subject was below 12 years, hence the CHMP considered that the presented data characterised the PK in adolescents (12-17 years inclusive) and the term 'adolescents' is used throughout the report as a reference to the studied population.

## Absorption

The absolute bioavailability of paliperidone ER in adolescents has not been investigated.

Following single-dose administration, peak plasma concentration was reached after approximately 24 hours (Figure 1). Based on a popPK analysis the intra-individual variability in relative bioavailability (F1) is 46.4%.

<div style=\"page-break-after: always\"></div>

Figure 1: Mean (±SD) Paliperidone Plasma Concentration-Time Profile (Dose-Normalized to 6 mg/day) in Adolescents (Study PSZ-1001)

Analyte=PALIPERIDONE

<!-- image -->

Based  on  observed  data,  steady-state  plasma  exposure  (dose-normalized  to  6  mg/day)  was  on average 50% higher in adolescents compared to adults (see Table 5).

Table 5: Steady-State Plasma (Dose-Normalized to 6 mg/day) and Urine PK Parameters of Paliperidone in Pediatric (Adolescent) and Adult Subjects

| PK parameter    | N                                   | Mean ± SD                           | Median                              | Min-Max                             |
|-----------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                 | Pediatric Subjects (Study PSZ-1001) | Pediatric Subjects (Study PSZ-1001) | Pediatric Subjects (Study PSZ-1001) | Pediatric Subjects (Study PSZ-1001) |
| Cmax, ng/mL     | 23                                  | 34.2 ± 22.3                         | 23.2                                | 9.62-89.3                           |
| AUC24h ng.h/mL  | 23                                  | 686 ± 448                           | 486                                 | 215-1750                            |
| CL/F, mL/min    | 23                                  | 209± 117                            | 206                                 | 57.1-465                            |
| CLR, mL/min     | 23                                  | 42.4 + 17.4                         | 37.8                                | 8.01-68.5                           |
|                 | Adult Subjectsa                     | Adult Subjectsa                     | Adult Subjectsa                     | Adult Subjectsa                     |
| Cmax ng/mL      | 172                                 | 23.7± 12.3                          | 21.0                                | 5.86-86.7                           |
| AUC24h, ng.h/mL | 172                                 | 457± 235                            | 396                                 | 115-1563                            |
| CL/F, mL/min    | 173                                 | 268 ± 119                           | 252                                 | 54.0-869                            |
| CLR, mL/minb    | 74                                  | 36.2± 15.8                          | 34.5                                | 11.4-86.7                           |

a Pooled PK dataset from Studies R076477-P01-1005, PAL-SCH-101, R076477-SCH-102, PALIOROS-SCH-1011.

pooled data from Studies R076477-P01-1005 and PALIOROS-SCH-1011

Source: Mod5.3.3.2\\PALIOROS-PSZ-1001\\Att2.3,Att2.5, Table11, Table13

## Distribution

The volume of distribution in adolescents was found to be large; Vss (sum of central and peripheral volume  in  the  popPK  model)  is  approximately  440  L.  The  corresponding  figure  for  adults  is approximately 490 L.

The  steady-state  AUC24h  (+)/(-)  enantiomer  ratio  and  fraction  unbound  (fu)  of  paliperidone  in adolescents  were similar to  values  obtained  in  adults.  The  enantiomer  ratio  was  approximately  1.4,

<div style=\"page-break-after: always\"></div>

compared to 1.6 in adults. The mean fu of paliperidone was approximately 26% in both adolescents and adults.

## Elimination

In adolescents, the observed average CL/F in study PSZ-1001 was 12.5 L/h (209 mL/min). The fraction excreted, fe, was approximately 20%.

## Dose proportionality and time dependencies

In  study  PSZ-1001, steady-state drug concentrations were attained within 4 to 5 days of dosing as seen  in  Figure  1.  Plasma  exposure  (Cmax  and  AUC24h)  increased  with  increasing  dose.  The accumulation ratio, based on visual inspection of the peak plasma concentrations following single vs. multiple dosing, was  approximately  3.7. The  popPK  model  indicated  linear, dose-proportional pharmacokinetics.

## Special populations

The effect of renal or hepatic impairment has not been studied in adolescents.

According to the MAH, given that maturation of renal function is completed by early childhood and the PK and plasma protein binding of paliperidone are similar in adolescents and adults, it is expected that the impact of renal or hepatic impairment on the PK of paliperidone in adolescents will be similar to that  in  the  adult  population.  In  the  popPK  modeling  the  effects  of  body  weight,  age  and  creatinine clearance were investigated (see 2.3.3).

## Pharmacokinetic interaction studies

No  pharmacokinetic  interaction  studies  have  been  performed  in  adolescents.  This  was  considered acceptable  by  the  CHMP,  given  the  available  interaction  data  in  adults  (paroxetine,  trimethoprim, carbamazepine and divalproex sodium).

## 2.3.3. PK/PD Modelling

## PK modeling

Exploratory popPK modeling was carried out using data from PSZ-1001 and PSZ-3001. An adult popPK model  developed  on  Phase  3  data  was  used  as  a  starting  point.  The  final  PK  model  was  further validated taking into account the observed data from study PSZ-3003.

A  total  of  105  male  and  57  female  adolescent  subjects  were  included  in  the  PK  dataset  which  also included  adult  data  (110  male  and  43  female  subjects).  The  racial  composition  of  the  adolescent population was about 66.0% White, 10.5% Black (including African-American), 1.2% Hispanic-Latinos and  22.2%  Asian.  The  median  age  was  16.1  years  and  ranged  from  10.3  to  17.9  years.  Only  one subject in the dataset was &lt; 12 years of age. The median BMI was 21 kg/m2 and ranged from 13.5 to 35.1  kg/m2.  The  median  BW  was  58.1  kg  (range:  29.0  to  104.6  kg).  The  median  CrCLc  was  141 mL/min and ranged from 29.8 to 231 mL/min.

The distribution of continuous covariates for Adolescents is shown in Figure 2.

<div style=\"page-break-after: always\"></div>

Figure 2: Distribution of Continuous Covariates From the Adolescents in the popPK Dataset

<!-- image -->

The  available  adult  PK  model  was  first  used  to  simulate  the  adolescent  data  under  the  observed covariate values and design but with fixed model parameters. The model was found applicable since the prediction error (precision) and absolute prediction error (bias) were within the defined criteria.

The model was then executed on adolescent data only but the run was terminated. Body weight was used as covariate on CL/F instead of lean body mass. To improve stability adult data was included and the  model  was  reduced  in  terms  of  random  effects  on  structural  parameters.  After  successful termination, the effect of age alone was tested n CL/F but was not found to be statistically significant.

The  final  model  included  body  weight  (BW)  and  calculated  creatinine  clearance  (CLCr,  Schwartz formula) as covariates on CL/F according to the equation below:

<!-- formula-not-decoded -->

The  parameters  estimates  from  the  final  model,  relative  standard  error  (RSE%)  and  calculated shrinkage are shown in Table 6.

<div style=\"page-break-after: always\"></div>

Table 6: Parameter Estimates of the Model 3 (Final Model)

IIV

| Parameter                      | Estimate   | RSE %   | %CV      | RSE %   | n-Shrinkage %   |
|--------------------------------|------------|---------|----------|---------|-----------------|
| CL/F (L/hr) intercept          | 10.9       | 11.5    |          |         |                 |
| PoweronCL/FforBW               | 0.727      | 21.7    | 44.4     | 18.1    | 13.8            |
| Linear Slope on CL/F for CrCLc | 0.024      | 46.3    |          |         |                 |
| V2 (L)                         | 198        | 6.67    | 34.5     | 31.3    | 52.1            |
| V3 (L)                         | 244        | 6.84    | 28.6     | 24.5    | 47.6            |
| KA                             | 0.63       | 12.0    | 59.9     | 20.3    | 41.0            |
| Q (L/hr)                       | 22         | 10.0    |          |         |                 |
| D1                             | 25.4       | 0.728   | IOV      | IOV     |                 |
| ALAG1                          | 0.761      | 8.66    | Estimate | RSE %   |                 |
| F1                             | NE         |         | 46.4     | 14.1    |                 |

Residual Variability %

20.5

Minimum Value Objective Function = -12670

NE = not estimated, set equal to 1

The final PK model was further validated taking into consideration the observed data from study PSZ3003 (Figure 3).

Figure  3:  Comparisons  of  Population  PK  Simulation  vs.  Actual  Plasma  Concentration  Data from Study PSZ-3003

<!-- image -->

The x-axis represents time (days) and the y-axis represents plasma concentrations of paliperidone (ng/mL). The solid red line and the shaded area represent the median and the 90% prediction interval based on the population PK simulations. Open symbols represent actual plasma concentration data from clinical trial subjects in study PSZ3003.

4.58

<div style=\"page-break-after: always\"></div>

The  final  population  PK  model  was  used  to  simulate  the  exposure  in  the  adult  and  adolescent populations.

Simulation of a once-daily dose of 6 mg in adults and in adolescents weighing at least 51 kg resulted in comparable plasma exposure to paliperidone. Similarly, paliperidone plasma exposure following oncedaily  dose  of  6  mg  in  adults  and  adolescents  weighing  &lt;51 kg  was  comparable.  In  adolescents weighing &lt;51 kg, a 23% higher mean average plasma concentration was observed than in adolescents weighing ≥51 kg.  Based on these results, no PK -based dose adjustments were proposed by the MAH in adolescents (12 to 17 years). See Figures 4 and 5.

Figures 4 and 5: Simulations with Final Model with Phase 3 Adult and Adolescent Data of a once daily dose of 6 mg

<!-- image -->

The shaded area depicts the prediction interval (5th and 95th percentiles and median shown) (solid for adults and hatched for adolescents)

Simulation of a once-daily dose of 6 mg in adults and 3 mg in adolescents resulted in lower plasma exposure  to  paliperidone  in  adolescents,  even  in  the  lower-weight  group,  indicating  that  the  lower clearance in adolescents &lt; 51 kg is overcompensated by dividing dose in half. See Figures 6 and 7.

Figures 6 and 7: Simulations with Final Model with Phase 3 Data of a once daily dose of 6 mg for adults and once daily dose of 3 mg for adolescents

<!-- image -->

<div style=\"page-break-after: always\"></div>

## PKPD modeling

## Safety - Incidence of Extrapyramidal Symptoms

Data from study PSZ-3001 were used to explore the PK/PD-relationship between the risk of having EPS-related treatment emergent adverse events and paliperidone exposure. To assess the similarity of the PK/PD-relationship in adolescents and adults, the percentage of subjects with EPS-related AEs in the  PSZ-3001  study  was  simulated  using  the  model  that  was  previously  developed  for  adults.  The individual  predicted  average  steady  state  concentration  (Css)  was  calculated  using  empirical  Bayes estimates derived from the popPK model (previous section).

There were no EPS-related AEs observed in the placebo group. The incidence of EPS-related AEs was low in the exposure groups with a median Css &lt; 20 ng/mL. The EPS incidence was higher in exposure groups with a median Css &gt; 20 ng/mL . Overall, 41% of subjects had a Css &gt; 20 ng/mL, but there was a major difference in the distribution of Css between treatment groups: 0% in the low dose group had a Css &gt; 20 ng/mL, while 49% in the medium dose group and 77% in the high dose group had a Css &gt; 20 ng/mL. See Figure 8.

Figure  8:  Observed  incidence  of  EPS-related  AEs  by  exposure  group  overlaying  the  95% prediction interval (and median) of the EPS-incidence obtained by simulation of PSZ-3001 using the adult PK/PD-model

<!-- image -->

## 2.3.4. Additional analyses

During the evaluation, the MAH provided a revised popPK model using only the data in adolescents ie excluding the adult data and the data in renal impaired subjects (Studies PSZ-1001, PSZ-3001 and

<div style=\"page-break-after: always\"></div>

PSZ-3003) to address the CHMP concern over the validity of the model for the purpose of simulation. An adapted covariate model was developed (see Table 7).

Table 7. Modeling of adolescent population PK with different covariates

| Description                              |   RunNo | Reference Run   |   Objective Function | Delta Objective Function   |
|------------------------------------------|---------|-----------------|----------------------|----------------------------|
| Base model without covariates            |       8 |                 |              219.114 |                            |
| Base model with BW on CL                 |       9 | 8               |              207.876 | -11.238                    |
| Base model with AGE on CL                |      10 | 8               |              218.82  | -0.294                     |
| Base model with CrCL on CL               |      11 | 8               |              212.848 | -6.266                     |
| Base model with BW and AGE on CL         |      12 | 6               |              207.877 | 0.001                      |
| Base model with BW and CrCL on CL        |      13 | 6               |              206.854 | -1.022                     |
| Base model with BW and CrCL and AGEon CL |      14 | 13              |              206.854 | 0                          |

When testing BW, age and CrCL independently as covariates on CL/F in the adolescent dataset, only BW was statistically significant as a covariate. Including BW, and testing age and CrCL in addition to BW did not result in further statistical improvements of the model fit. However, as more than 60% of paliperidone is eliminated unchanged through the kidney, CrCL was included as a prior covariate on CL/F,  and  BW  and  age  in  addition  to  CrCL  were  tested.  BW  in  addition  to  CrCL  was  found  to  be statistically significant, but age was not. Therefore, the final covariate model that had been developed using the adolescent data only, remained the same as presented in the original submission.

According to the MAH, the population PK parameter values derived from the adolescent dataset only are  well  in  line  with  those  of  the  original  analysis,  in  which  both  adolescents  and  adult  data  were included (see Table 8).

Table 8 Population PK parameters based on data from adolescent studies PSZ-1001, PSZ3001 and PSZ-3003

| Parameter                                 | Estimate                                  | RSE %   | IIV %CV   | RSE %   |
|-------------------------------------------|-------------------------------------------|---------|-----------|---------|
| CL/F (L/hr) intercept                     | 9.29                                      | 63.9    |           |         |
| Power on CL/F for BW                      | 0.681                                     | 32.7    | 57.4      | 19.3    |
| Linear Slope on CL/F for CrCL             | 0.0236                                    | 171.6   |           |         |
| V2 (L)                                    | 208                                       | 27.2    | 19.7      | 403     |
| V3 (L)                                    | 337                                       | 46.3    |           |         |
| KA                                        | 0.63 fixed                                |         |           |         |
| Q (L/hr)                                  | 12                                        | 36.6    |           |         |
| D1                                        | 23.6                                      | 14.1    | 10V       | 10V     |
| ALAG1                                     | 0.142                                     | 3401    | Estimate  | RSE %   |
| F1                                        | NE                                        |         | 47.5      | 22.5    |
| Residual Variability %                    | 43.2                                      | 19.0    |           |         |
| NE = not estimated, set equal to 1 for F1 | NE = not estimated, set equal to 1 for F1 |         |           |         |

The Goodness of Fit (GOF) plots (Figure 9 also indicates that the model describes the data well. For the MAH, this confirms that the developed population PK model describes the adolescent data effectively, and can be used for simulation purposes.

<div style=\"page-break-after: always\"></div>

Figure 9 Goodness of Fit Plots Using Data from adolescent studies PSZ-1001, PSZ-3001 and PSZ-3003

<!-- image -->

## 2.3.5. Discussion on clinical pharmacology

In  study  PSZ-1001,  3  dosage  groups  were  included  (approximately  0.086,  0.129,  and  0.171 mg/kg/day paliperidone ER) corresponding to daily doses of 6, 9, and 12 mg, respectively, for a 70-kg adult  on  a  milligram  per  kilogram  basis.  Consistent  findings  between  adolescents  and  adults  were observed in relation to the plasma concentration-time profile and time to reach the steady-state drug concentrations (within 4-5 days). However, the mean CL/F was lower in paediatric subjects compared to healthy adults over the dose range 4 to 12 mg daily, resulting in 44% higher mean steady-state Cmax of paliperidone and 50% higher AUC24h.The range of plasma exposures for Cmax was similar whereas the upper threshold of the AUC range was higher in adolescents in comparison to adults (1750 versus  1563  ng.h/mL).  The  overall  findings  led  the  MAH  to  a  weight-based  dosing  for  the  phase  3 study PSZ-3001 with a threshold of 51 kg to ensure that lower-weight subjects were not given too high a dose. Because the substantial inter-individual PK variability was only partly explained by differences in body weight in the phase 3 study PSZ-3001, a weight-based dosing approach was not used in the other  phase  III  study  PSZ-3003.  In  addition,  the  effect  of  body  weight  on  CL/F  was  found  to  be relatively small in the combined PSZ-1001/PSZ-3001 dataset as compared to the PSZ-1001 alone.

<div style=\"page-break-after: always\"></div>

Overall, the mean age of adolescents included in study PSZ-1001 was 14 years. Sixteen patients were 14 years and older in comparison to 8 patients aged 12 and 13 years old. Only 5 patients were both younger than 14 years and had a body weight less than 51 kg. However, patients younger than 14 years were included in the phase 3 study PSZ-3001. Taking into account the combined PSZ-1001/PSZ3001  dataset,  the  CHMP  considered  that  sufficient  information  was  available  to  characterise  the influence  of  body  weight  and  age  on  the  pharmacokinetics  in  the  full  population  from  12-17  years inclusive.

In the popK analysis, the final model initially presented for adolescents was actually a model combining adult and adolescent data. The estimated parameters did not represent the PK in adolescents and were rather  representative  of  the  PK  in  the  broader  population.  The  effect  of  renal  function  on  total clearance was incorporated in the model. The estimated slope for the relation between CL/F and CLCr did not seem to be in line with the reduction in CL/F observed in subjects with varying degree of renal impairment. The observed decrease in CL/F was 32% in mild (CLCr = 50 to &lt; 80 mL/min), 64% in moderate (CLCr = 30 to &lt; 50 mL/min), and 71% in severe (CLCr = &lt; 30 mL/min) renal impairment. The  estimate  of  the  slope  in  the  adult  model  was  0.0512.  Assuming  a  CLCr  of  120  mL/min  as  the reference, the model predicted decrease in CL/F was approximately 20%, 30% and 40% for adults. For the combined adult and adolescent data the slope was 0.0240, predicting an even lower decrease in CL/F due to renal impairment. Furthermore, the model did not account for the effect of body weight on volume of distribution.  From  the  CHMP  viewpoint, the  initial  model  was  not  sufficiently  qualified  for purpose of simulation unless it could give a correct description of the pharmacokinetic properties of paliperidone.  To  address  this  concern,  the  MAH  provided  a  revised  model  using  only  the  data  in adolescents ie  excluding  the  adult  data  and  the  data  in  renal  impaired  subjects  (Studies  PSZ-1001, PSZ-3001 and PSZ-3003). To this extent, an adapted covariate model was developed and resulted in a final covariate model that remained the same as presented in the original submission (see Tables 7-8, Figure 9). As more than 60% of paliperidone is eliminated unchanged through the kidney, CrCL was included as a prior covariate on CL/F, and BW and age in addition to CrCL were tested. However, the CHMP remained concerned that the proposed model including CrCL on CL/F was misleading because the relation between Cl/F and renal elimination capacity (expressed as creatinine clearance) that had been  established  in  adults  could  not  be  confirmed  in  adolescents  due  to  lack  of  data.  The  CHMP therefore concluded that the presented model could be used for simulations of exposure in adolescents with normal renal function only. In this model, it was sufficiently well demonstrated that the clearance of paliperidone is related to body size (weight). The exponent describing relation between body weight and  CL/F  is  0.68,  a  value  close  to  the  theoretical  allometric  relation  (0.75).  However,  due  to  the substantial inter-individual variability in CL/F (CV% 57.4), the explanatory value of weight on CL/F was reduced although it was still a valid factor on the population level. The MAH illustrated the variability with simulations showing that there was a large overlap in exposure comparing adolescents to adults as well as when comparing adolescents &lt;51 kg to adolescents ≥ 51 kg. Thus, individual dose titration was considered by the CHMP sufficiently motivated from a pharmacokinetic viewpoint.

When investigating independently the effect of age and body weight on the clearance of paliperidone to accurately  characterise  the  dose-response,  body  weight,  and  not  age,  was  a  significant  predictor  of clearance. In the study samples there was evidence that age and body weight was not as correlated as might be expected from the healthy population. There were no signs that patients below 14 years of age deviate from the relation between CL/F and body weight. Therefore, the PK of paliperidone could be considered to have been sufficiently characterized in patients down to 12 years of age.

Following the restriction of the proposed indication to the paediatric age range of 15 years and older (see 2.4.6), the MAH proposed that same dosing adjustments in case of renal impairment should be recommended  for  adolescent  and  adults  patients,  because  the  maturation  of  the  renal  function  is

<div style=\"page-break-after: always\"></div>

considered  completed  by  early  childhood  and  the  pharmacokinetic  and  plasma  protein  binding  of paliperidone were found similar in these populations. This proposal was accepted by the CHMP.

In addition, the time course of PANSS score and the influence of exposure to paliperidone and other covariates had not been evaluated by modelling as compared to the presented popPK analysis. This made it difficult to draw any conclusion about the relation between paliperidone exposure and clinical effect.  In  adults,  a  continuous  relation  between  plasma  exposure  to  paliperidone  and  the  risk  of developing EPS has been previously established. For adolescents, a similar pattern was seen but with the risk of EPS sharply increasing at exposure levels &gt; 20 ng/mL. In addition, there was a slight trend towards adolescents having a higher risk of EPS compared to adults at exposure levels &gt; 20 ng/mL. A higher  frequency  of  EPS  was  reported  more  often  in  adolescents  than  in  adults  based  on  a  pooled safety analysis. This is further discussed in 2.5.7.

## 2.3.6. Conclusions on clinical pharmacology

Overall,  the  clinical  pharmacology  of  Invega  has  been  adequately  documented  and  meet  the requirements to support this application.

## 2.4. Clinical efficacy

The development program completed to support the proposed extension of indication consisted of:

- -a  Phase  I,  multicenter  and  open-label  study  ( PALIOROS-PSZ-1001 )  to  investigate  the pharmacokinetic profile, safety  and  tolerability  of  paliperidone  ER  in  children  and  adolescent patients  (10-17  years)  with  schizophrenia,  schizoaffective  disorder,  or  schizophreniform disorder.
- -a phase III, multicenter, randomised, double-blind, placebo-controlled, 6 week study ( R076477-PSZ3001 ) evaluating 3 fixed oral doses of paliperidone ER (low: 1.5 mg; medium: 3 mg or 6 mg;  high: 6  mg or 12 mg) in the treatment of children and adolescent patients, aged 12-17 years, with schizophrenia;
- -a phase III, multicenter, randomised, double-blind, active-controlled, 26 week study ( R076477-PSZ3003 )  evaluating  flexible  oral  doses  of  paliperidone  ER  (3-9mg)  versus aripiprazole  (5-15mg)  in  the  treatment  of  children  and  adolescent  patients,  aged  12-17 yearswith schizophrenia
- -a phase III, multicenter, open-label, 2 year study ( R076477-PSZ-3002) , designed to provide additional long term safety data of paliperidone ER in the paediatric population. Patients who had completed study R076477-PSZ3001 were offered to continue in this study.

## 2.4.1. Dose response study

No  specific  dose  response  study  was  performed  in  the  intended  paediatric  population.  Dosing recommendation is derived from the combined clinical data (PSZ-3001, PSZ-3003 and PSZ-3002) and the  population  PK  simulations  previously  presented  (see  2.3.2).  This  approach  was  considered  in principle  acceptable  by  the  CHMP,  provided  the  presented  data  adequately  support  the  proposed dosing recommendation in the intended paediatric population. This is further discussed in 2.4.6.

## 2.4.2. Main studies

## STUDY PSZ3001

<div style=\"page-break-after: always\"></div>

The study design is presented in Figure 10.

Figure 10

<!-- image -->

This study was conducted at 12 study sites in Russia, 9 sites in the United States, 7 sites in India, 6 sites in the Ukraine, and 1 site in Romania.

## 2.4.2.1. Methods

## Study participants

Subjects  were  to  be  male  or  female  aged  12-17  years  inclusive  with  a  diagnosis  of  schizophrenia according to DSM-IV at least one year prior to screening. Diagnosis had to be established using the semi  structured  K-SADS-PL  questionnaire  and  the  subject  should  have  had  at  least  one  adequate treatment course with antipsychotic drug prior to enrolment.  There should be an acute exacerbation of schizophrenia with PANSS score total between 60-120 inclusive at the time of enrolment (screening) and at the time of randomisation (baseline).

## Treatments

The subjects were randomised to receive paliperidone ER 1.5 mg, 3 mg, 6 mg or 12 mg as  tablets or placebo.  During  screening  and  washout  the  subjects  were  outpatients  or  hospitalized  if  judged necessary  by  the  investigator.  The  study  consisted  of  three  phases;  a  screening  phase  of  up  to  3 weeks to assess eligibility criteria, a six week double blind treatment phase with an end of study or early withdrawal visit and finally a 1 week follow up visit for subjects who did not enter the open label safety  study  PSZ  -3002.  Subjects  were  able  to  enrol  into  the  long  term  study  PSZ-3002  after completing at least 21 days of treatment in study PSZ-3001.

No dosage adjustment was permitted during the study. The study allowed early rescue. Subjects who did not have any response to treatment or whose symptoms worsened could drop out after at least 21 days of the double-blind phase and were eligible to participate in open-label safety study PSZ-3002. Subjects  who  did  not  respond  to  treatment  or  whose  symptoms  worsened  before  21  days  of  the double-blind phase discontinued the study at any time and were treated by their physicians as clinically appropriate. In addition, the protocol allowed the use of rescue medications including benzodiazepines for insomnia and anticholinergic medications for EPS.

## Objectives

The primary objective was to assess the efficacy, safety and tolerability of 3 weight based fixed -dose groups of paliperidone ER (to fully explore tolerability);  1.5mg,  3mg,  6mg  and  12  mg  compared  to placebo in adolescents 12-17 years with DSM-IV based diagnosis of schizophrenia who were currently experiencing an acute exacerbation.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

These are presented in Table 9.

## Table 9:

| Variable   | Description                                                                                                                                                                                                                                                                                                                                                                                                                                       | Endpoint                          |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| PANSS      | • Change from baseline in total score at endpoint (LOCF) • Change from baseline in total score at each post- baseline visit (LOCF and observed case) • Change from baseline in subscales and Marder factor scores at endpoint and at each post-baseline visit (LOCF and observed case) • Number and percentage of subjects with ≥20% or ≥30% reduction from baseline in PANSS total score at endpoint (LOCF) • Onset of therapeutic effect (LOCF) | Primary Other Other Other Other   |
| CGI-S      | • Change from baseline in overall score at endpoint and each postbaseline visit (LOCF) • Change from baseline in overall score at each post- baseline study visit (LOCF and observed case) • Frequency distribution of overall score at endpoint and at each post-baseline visit (LOCF and observed case)                                                                                                                                         | Secondary Other Other             |
| CGAS       | • Change from baseline in overall score at endpoint and each post-baseline visit (LOCF) • Change from baseline in overall score at each post- baseline visit (observed case) • Change from baseline in 10- point categories at endpoint and at each post-baseline visit (LOCF) • Frequency distribution of overall scores (≥70 or <70) at endpoint and at each post-baseline visit (LOCF and observed case) • Frequency distribution of           | Secondary Other Other Other Other |

<div style=\"page-break-after: always\"></div>

|     | overall scores by 10-point categories at endpoint and at each post-baseline visit (LOCF and observed case)                                                                                                                             |                 |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| VAS | • Change from baseline in Quality of Sleep and Daytime Drowsiness total scores at endpoint (LOCF) • Change from baseline in Quality of Sleep and Daytime Drowsiness total scores at each post-baseline visit (LOCF and observed case ) | Secondary Other |

## Sample size

The estimated sample size of 200 subjects (approximately 50 in each blinded group) assumed that the standard deviation (SD) of the change from baseline to endpoint in PANSS total score would be 20 points.  If  there  were  approximately  49  subjects  per  treatment  group  who  had  Week  6  (LOCF  or endpoint) PANSS total measurements, the study was expected to have approximately 80% power to detect a clinically relevant difference of 13.2 points between any paliperidone ER group compared with placebo  in  the  change  from  baseline  in  PANSS  total  score,  applying  Dunnett's  adjustment  for multiplicity (2-sided family wise α level of 0.05).

## Randomisation

The randomisation was centralised, balanced by using permuted blocks of treatment and was stratified by study centre.

## Blinding (masking)

Double blinding was used during the 6-week treatment period (i.e., subjects, parents, legal guardians, investigators, and the sponsor remained blinded to the study drug). Tablets containing different dose strengths of paliperidone ER and tablets containing placebo were identical in appearance.

## Statistical methods

Efficacy and safety analyses were performed using the randomly assigned, weight-based, fixed-dose treatment groups. Additional analyses were performed using the actual paliperidone ER dose received.

The  ITT  analysis  set  was  the  analysis  set  for  the  efficacy  analyses.  This  analysis  set  included  all randomized  subjects  who  received  at  least  one  dose  of  double-blind  study  drug  and  had  both  a baseline and at least one post-baseline assessment in the double-blind phase on any of the following scales: PANSS, CGAS, CGI-S or sleep VAS.

Efficacy analysis involving changes from baseline to the final double-blind phase visit (Day 43) used the last observation carried forward (LOCF) approach.

The primary variable was the change in PANSS total score from baseline to the end of the double-blind phase  (Day  43  or  the  last  post-baseline  assessment).  Treatment  effects  were  estimated  based  on least-squares (LS) means using an analysis of covariance (ANCOVA) model with treatment and country as factors and baseline PANSS total score as a covariate. A closed testing procedure using Dunnett's

<div style=\"page-break-after: always\"></div>

test  was  used  to  adjust  for  multiple  comparisons  in  testing  the  3  paliperidone  ER  treatment  groups against placebo for the primary efficacy variable.

Responders are defined as those who achieved a 20% or higher reduction from baseline in the PANSS total  score  at  the  last  post-baseline  assessment  in  the  double-blind  phase.  The  percent  change  of PANSS  was  defined  as  [100*CHANGE  /  (BASELINE-30)],  as  30  is  the  lowest  possible  value  for PANSS.Differences at endpoint in percentage of responders between each active treatment group and placebo were evaluated using a Cochran-Mantel-Haenszel test controlling for country.

A worst-rank analysis was also performed where subjects who discontinued due to lack of efficacy were assigned a rank that represented a 'worst-rank score' relative to those actually observed. These ranks reflected the relative inverse ordering of the actual times to discontinuation, so that the earlier times of withdrawal were assigned a worse ranking than the later points in time. In addition, a Kaplan-Meier plot of the time to discontinuation for those who discontinued due to lack of efficacy was generated by treatment group.

To assess the sensitivity of the results, a repeated measures mixed effects model was carried out on the observed data. Changes from baseline over time (observed case) were modelled using a mixed effects  model  with  time,  country,  and  treatment  as  factors  and  baseline  PANSS  total  score  as  a covariate.  In  addition,  a  treatment-by-time  interaction  term  was  added  to  evaluate  the  changes  in treatment effect over time. An unstructured variance-covariance matrix was employed.

## 2.4.2.2. Results

## Participant flow

A total of 201 subjects met the eligibility criteria and were enrolled and randomly assigned to double blind  treatment  with  placebo  or  paliperidone  ER.  A  total  of  200  subjects  were  randomised  into  the study. All but one subject (from the paliperidone ER high group) received at least one dose of study medication,  provided  both  baseline  and  at  least  one  post-baseline  efficacy  assessments  and  were included in the ITT analysis set.

Information on number of subjects who completed or withdrew the study and reasons for withdrawal is provided in Table 10. Time to withdrawal is presented in Figure 11.

Table 10: Study completion/withdrawal information for PSZ-3001 (All randomised subjects analysis set)

| Subject Completed Treatment/trial ReasonforWithdrawal/termination   | Placebo (N=51) n (%)   | PaliperidoneER Low (N=54) n (%)   | Paliperldone ER Medium (N=48) n (%)   | Paliperidone ER High (N=48) n (%)   | Total (N=201) n (%)   |
|---------------------------------------------------------------------|------------------------|-----------------------------------|---------------------------------------|-------------------------------------|-----------------------|
| Completed                                                           | 26 (51)                | 35 (65)                           | 40 (83)                               | 37 (77)                             | 138 (69)              |
| Withdrawn                                                           | 25 (49)                | 19 (35)                           | 8 (17)                                | 11 (23)                             | 63 (31)               |
| Lack of efficacy                                                    | 20 (39)                | 14 (26)                           | 2 (4)                                 | 4 (8)                               | 40 (20)               |
| Subject choice (subject withdrew consent)                           | 2 (4)                  | 1(2)                              | 2 (4)                                 | 4(8)                                | 9 ( 4)                |
| Lost to follow-up                                                   | 3 ( 6)                 | 0                                 | 2 ( 4)                                | 1(2)                                | 6 (3)                 |
| Adverse event                                                       | 0                      | 1(2)                              | 1(2)                                  | 1(2)                                | 3(1)                  |
| Other                                                               | 0                      | 3 ( 6)                            | 1 (2)                                 | 1 ( 2)                              | 5 ( 2)                |

<div style=\"page-break-after: always\"></div>

Figure 11: Time to withdrawal in study PSZ-3001

<!-- image -->

## Recruitment

The study was conducted between 8 August 2007 and 30 March 2009.

## Conduct of the study

There was one major protocol amendment prior study enrolment. This was related to the study design with the objective of testing the entire range of effective doses of paliperidone ER in adults (3-12mg) as  well  as  a  lower  dose  (1.5mg)  to  determine  the  least  effective  dose.  Weight  based  doses  were chosen to minimize the risk of exposing lower weight adolescents (≥ 29 kg and &lt; 51 kg) to high doses of  paliperidone  ER  and  higher  weight  adolescents  (≥  51  kg)  to  too  low  of  a  dose,  considering  that lower-weight subjects could have nearly double the drug exposure of higher-weight subjects on the basis of available PK data from PSZ-1001.

## Baseline data

These are presented in Tables 11 and 12.

<div style=\"page-break-after: always\"></div>

Table 11:  Baseline characteristics

|                                        | Placebo (N=51)                   | Paliperidone ER Low (N=54)   | Paliperidone ER Medium (N=48)   | Paliperidone ER High (N=47)   | Total (N=200)   |
|----------------------------------------|----------------------------------|------------------------------|---------------------------------|-------------------------------|-----------------|
| Age (years) Category, n (%)            |                                  |                              |                                 |                               |                 |
| 12-14                                  | 9(18)                            | 16 (30)                      | 15 (31)                         | 13 (28)                       | 53 (27)         |
| 15-17                                  | 42 (82)                          | 38 (70)                      | 33 (69)                         | 34 (72)                       | 147 (74)        |
| Mean (SD)                              | 15.7 (1.40)                      | 15.1 (1.50)                  | 15.3 (1.60)                     | 15.5 (1.60)                   | 15.4 (1.53)     |
| Median                                 | 16.0                             | 16.0                         | 16.0                            | 16.0                          | 16.0            |
| Range                                  | (12;17)                          | (12;17)                      | (12;17)                         | (12;17)                       | (12;17)         |
| Sex, n (%)                             |                                  |                              |                                 |                               |                 |
| Male                                   | 23 (45)                          | 30 ( 56)                     | 31(65)                          | 33 (70)                       | 117 (59)        |
| Female                                 | 28 (55)                          | 24 (44)                      | 17 (35)                         | 14 (30)                       | 83 (42)         |
| Country, n (%)                         |                                  |                              |                                 |                               |                 |
| India                                  | 11 (22)                          | 13 (24)                      | 11 (23)                         | 10 (21)                       | 45 (23)         |
| Romania                                | 2( 4)                            | 2 ( 4)                       | 3( 6)                           | 3(6)                          | 10( 5)          |
| Russia                                 | 21 (41)                          | 22 (41)                      | 20 (42)                         | 19 (40)                       | 82 (41)         |
| Ukraine                                | 8(16)                            | 9 (17)                       | 8(17)                           | 9 (19)                        | 34 (17)         |
| United States                          | 9(18)                            | 8(15)                        | 6 (13)                          | 6 (13)                        | 29 (15)         |
| Race, n (%)                            |                                  |                              |                                 |                               |                 |
| White                                  | 35 (69)                          | 35 ( 65)                     | 34 (71)                         | 32 (68)                       | 136 (68)        |
| Black                                  | 4( 8)                            | 5(9)                         | 3( 6)                           | 5(11)                         | 17( 9)          |
| Asian a                                | 12 (24)                          | 14 (26)                      | 11(23)                          | 10 (21)                       | 47 (24)         |
| Baseline body weight category, n (%)   |                                  |                              |                                 |                               |                 |
| <51kg                                  | 14 (27)                          | 19 (35)                      | 16 (33)                         | 13 (28)                       | 62 (31)         |
| ≥51 kg                                 | 37 (73)                          | 35 (65)                      | 32 (67)                         | 34 (72)                       | 138 (69)        |
| Baseline body mass index (kg/m?)       | Baseline body mass index (kg/m?) |                              |                                 |                               |                 |
| Category, n (%)                        |                                  |                              |                                 |                               |                 |
| Normal <25                             | 45 (88)                          | 43 (80)                      | 39 (81)                         | 38 (81)                       | 165 (83)        |
| Overweight 25-<30                      | 4( 8)                            | 8 (15)                       | 8 (17)                          | 5(11)                         | 25 (13)         |
| Obese ≥30                              | 2( 4)                            | 3( 6)                        | 1(2)                            | 4( 9)                         | 10( 5)          |
| Mean (SD)                              | 21.85 (5.578)                    | 22.19 (4.861)                | 21.36 (3.964)                   | 21.91 (4.315)                 | 21.84 (4.714)   |
| Median                                 | 21.10                            | 20.80                        | 20.90                           | 20.90                         | 20.95           |
| Range                                  | (14.0;53.4)                      | (13.9;39.6)                  | (15.2;34.9)                     | (14.4;34.6)                   | (13.9;53.4)     |
| Schizophrenia type, n (%)              |                                  |                              |                                 |                               |                 |
| Paranoid (295.30)                      | 37 (73)                          | 39 ( 72)                     | 35 (73)                         | 31 (66)                       | 142 ( 71)       |
| Disorganized (295.10)                  | 3(6)                             | 3( 6)                        | 6 (13)                          | 7 (15)                        | 19 (10)         |
| Catatonic (295.20)                     | 2( 4)                            | 1(2)                         | 1( 2)                           | 1( 2)                         | 5(3)            |
| Undifferentiated (295.90)              | 9 (18)                           | 9 (17)                       | 5 (10)                          | 8 (17)                        | 31 (16)         |
| Residual (295.60)                      | 0                                | 2(4)                         | 1(2)                            | 0                             | 3(2)            |
| Age at diagnosis of schizophrenia (yr) |                                  |                              |                                 |                               |                 |
| Mean (SD)                              | 13.4 (2.44)                      | 12.5 (2.85)                  | 13.0 (1.87)                     | 12.8 (3.19)                   | 12.9 (2.64)     |
| Median                                 | 14.0                             | 13.0                         | 13.0                            | 14.0                          | 13.0            |
| Range                                  | (5;16)                           | (5;16)                       | (8;16)                          | (3;16)                        | (3;16)          |

* Asian Indian and Asian Other (Taiwanese, Vietnamese and Chinese-Vietnamese) categories grouped as Asian.

<div style=\"page-break-after: always\"></div>

Table 12: Baseline disease severity in the different treatment groups

|                           | Placebo (N=51)   | Paliperidone ER Low (N=54)   | Paliperidone ER Medium (N=48)   | Paliperidone ER High (N=47)   | Total (N=200)   |
|---------------------------|------------------|------------------------------|---------------------------------|-------------------------------|-----------------|
| BaselinePANSS total score |                  |                              |                                 |                               |                 |
| Mean (SD)                 | 90.6 (12.13)     | 91.6 (12.54)                 | 90.6 (14.01)                    | 91.5 (13.80)                  | 91.1 (13.03)    |
| Median                    | 88.0             | 89.5                         | 88.0                            | 90.0                          | 89.0            |
| Range                     | (65;118)         | (70;118)                     | (69:119)                        | (63;119)                      | (63;119)        |
| Baseline CGI-S, n (%)     |                  |                              |                                 |                               |                 |
| Very mild                 | 0                | 1 ( 2)                       | 0                               | 0                             | 1( 1)           |
| Mild                      | 3(6)             | 3(0)                         | 3(0)                            | 2( 4)                         | 11 ( 6)         |
| Moderate                  | 27 ( 53)         | 28 ( 52)                     | 19 ( 40)                        | 26 ( 55)                      | 100 ( 50)       |
| Marked                    | 19 (37)          | 19 (35)                      | 21 (44)                         | 14 ( 30)                      | 73 (37)         |
| Severe                    | 2(4)             | 3(0)                         | 5 (10)                          | 5 (11)                        | 15 ( 8)         |

Cross-reference: Mod5.3.5.1PSZ-3001\\Tabs10 and 11

## Outcomes and estimation

PANSS Total Score related endpoints

Results on the primary endpoint are presented in Table 13.

Table 13: PANSS Total score -change from baseline to End Point (LOCF) used closed testing procedure with Dunnett´s test (study PSZ-3001 ITT analysis set)

|                          | Placebo (N=51)   | Paliperidone ER Low (N=54)   | Paliperidone ER Medium (N=48)   | Paliperidone ER High (N=47)   |
|--------------------------|------------------|------------------------------|---------------------------------|-------------------------------|
| Baseline                 |                  |                              |                                 |                               |
| N                        | 51               | 54                           | 48                              | 47                            |
| Mean (SD)                | 90.6 (12.13)     | 91.6 (12.54)                 | 90.6 (14.01)                    | 91.5 (13.86)                  |
| Median (Range)           | 88.0 (65:118)    | 89.5 (70;118)                | 88.0 (69;119)                   | 90.0 (63;119)                 |
| End Point                |                  |                              |                                 |                               |
| N                        | 51               | 54                           | 48                              | 47                            |
| Mean (SD)                | 82.7 (21.45)     | 81.9 (19.54)                 | 73.3 (21.99)                    | 77.7 (18.24)                  |
| Median (Range)           | 81.0 (36;129)    | 80.0 (45;121)                | 70.0 (33;126)                   | 75.0 (49;135)                 |
| Change From Baseline     |                  |                              |                                 |                               |
| N                        | 51               | 54                           | 48                              | 47                            |
| Mean (SD)                | -7.9 (20.15)     | -9.8 (16.31)                 | -17.3 (14.33)                   | -13.8 (15.74)                 |
| Median (Range)           | -5.0 (-59;28)    | -5.5 (-52;23)                | -16.0 (-53;19)                  | -12.0 (-62:30)                |
| p value (minus Placebo)a |                  | 0.508                        | 0.006                           | 0.086                         |
| Diff. of LS Means (SE)   |                  | -2.1 (3.17)                  | -10.1 (3.27)                    | -6.6 (3.29)                   |
| 95% CIb                  |                  | (-8.36;4.16)                 | (-16.58;-3.67)                  | (-13.07;-0.09)                |

b The 95% confidence intervals are unadjusted for multiplicity.

Based on ANCOVA model with treatment (Placebo, Paliperidone ER Low,Paliperidone ER Medium,Paliperidone ER High) and country as factors, and baseline value as a covariate. P values associated with closed testing procedure using Dunnett's test.

Note: Negative change in score indicates improvement.

Source: CSr psz-3001

<div style=\"page-break-after: always\"></div>

Table 14 presents data for the primary endpoint by actual dose group.

Table 14: PANSS Total Score- Change from baseline to endpoint (LOCF) by actual dosing, ANCOVA model (ITT)

|                           | Placebo (N=51)   | Paliperidone ER 1.5 mg (N=54)   | Paliperidone ER 3 mg (N=16)   | Paliperidone ER 6 mg (N=45)   | Paliperidone ER 12 mg (N=34)   |
|---------------------------|------------------|---------------------------------|-------------------------------|-------------------------------|--------------------------------|
| Baseline                  |                  |                                 |                               |                               |                                |
| N                         | 51               | 54                              | 16                            | 45                            | 34                             |
| Mean (SD)                 | 90.6 (12.13)     | 91.6 (12.54)                    | 92.1 (16.88)                  | 90.8 (13.66)                  | 91.0 (13.00)                   |
| Median (Range)            | 88.0 (65;118)    | 89.5 (70;118)                   | 91.0 (70;119)                 | 90.0 (63;118)                 | 89.0 (70;119)                  |
| End Point                 |                  |                                 |                               |                               |                                |
| N                         | 51               | 54                              | 16                            | 45                            | 34                             |
| Mean (SD)                 | 82.7 (21.45)     | 81.9 (19.54)                    | 73.1 (26.55)                  | 77.0 (20.59)                  | 74.7 (16.57)                   |
| Median (Range)            | 81.0 (36;129)    | 80.0 (45;121)                   | 70.0 (33;115)                 | 75.0 (42;135)                 | 73.0 (49;115)                  |
| Change From Baseline      |                  |                                 |                               |                               |                                |
| N                         | 51               | 54                              | 16                            | 45                            | 34                             |
| Mean (SD)                 | -7.9 (20.15)     | -9.8 (16.31)                    | -19.0 (15.45)                 | -13.8 (14.75)                 | -16.3 (15.41)                  |
| Median (Range)            | -5.0 (-59;28)    | -5.5 (-52;23)                   | -19.0 (-53;3)                 | -12.0 (-51;30)                | -15.0 (-62;18)                 |
| p value (minus Placebo) a |                  | 0.507                           | 0.016                         | 0.044                         | 0.014                          |
| Diff. of LS Means (SE)    |                  | -2.1 (3.18)                     | -11.5 (4.75)                  | -6.8 (3.34)                   | -9.0 (3.64)                    |
| 95% CI b                  |                  | (-8.39;4.16)                    | (-20.85;-2.13)                | (-13.35;-0.19)                | (-16.23;-1.86)                 |

a Test for no difference between treatments (Placebo, Paliperidone ER 1.5 mg, Paliperidone ER 3 mg, Paliperidone ER 6 mg, Paliperidone ER 12 mg) from ANCOVA model with factors for treatment and country, and with baseline value as a covariate.

b Comparison with placebo without multiplicity adjustment.

Note: Negative change in score indicates improvement

Figure 12 shows the estimated LS mean changes (LOCF) from baseline in PANSS total scores over time by actual dose.

Figure 12: Estimated LS mean changes (LOCF) from baseline in PANSS total scores

<!-- image -->

Vhiskers above and below the box indicate the 9oth and 10th percentiles. The solid line within the box marks the median and the dash line marks the mean value. Outlying data points are extreme values.

<div style=\"page-break-after: always\"></div>

Figure  13  shows  the  estimated  LS  means  changes  from  baseline  in  PANSS  total  scores  by  baseline body weight.

Figure 13: Least square means changes in PANSS total score at endpoint by baseline body weight (ITT analysis)

Negativechangeinscoreindicatedimprovement

<!-- image -->

Regarding the onset of therapeutic effect, a statistically significant improvement (p&lt;0.05, LOCF) over placebo was first noted on Day 22 for the paliperidone ER Medium group and at the first assessment time  point  (Day  8)  for  the  paliperidone  ER  High  group.  The  statistically  significant  between-group differences  were  maintained  from  Day  22  to  the  Day  43  endpoint  for  the  paliperidone  ER  Medium group but were not maintained from Day 8 for the paliperidone ER High group (p=0.079 on Day 22 and p=0.075 on Day 29, LOCF).

Regarding the responder rate, 64.4% of subjects in the paliperidone ER Medium group and 51.1% of those  in  the  paliperidone  ER  High  group  had  achieved  a  treatment  response.  This  compared  with 38.9% of subjects in the paliperidone ER Low group and and 33.3% of the placebo subjects.

## Other endpoints

Results are presented in Table 15.

<div style=\"page-break-after: always\"></div>

Table  15:  Overview  of  key  secondary  and  other  efficacy  results  for  study  R076477-PSZ-3001  (ITT Analysis Set)

|                                                            |                            | Paliperidone ER            | Paliperidone ER            | Paliperidone ER            | Paliperidone ER            |
|------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                            | Placebo (N=51)             | Low (N=54)                 | Medium (N=48)              | High (N=47)                | 3-12 mg (N=95)             |
| SecondaryEfficacyVariables                                 | SecondaryEfficacyVariables | SecondaryEfficacyVariables | SecondaryEfficacyVariables | SecondaryEfficacyVariables | SecondaryEfficacyVariables |
| CGI-S Score, n                                             | 51                         | 54                         | 48                         | 47                         | 95                         |
| Median (range) baseline                                    | 4.0 (3;6)                  | 4.0 (2;6)                  | 5.0 (3;6)                  | 4.0 (3;6)                  | 4.0 (3;0)                  |
| Median (range) change at End Point (LOCF)                  | 0.0 (-3;1)                 | 0.0 (-3;1)                 | -1.0 (-3;0)                | -1.0 (-3;1)                | -1.0 (-3;1)                |
| p value (vs placebo)                                       |                            | 0.968                      | <0.001                     | 0.021                      | <0.001                     |
| CGAS Score                                                 | 51                         | 54                         | 48                         | 47                         | 95                         |
| Mean (SD) baseline                                         | 48.8 (11.23)               | 48.4 (11.82)               | 47.2 (11.36)               | 46.5 (11.96)               | 46.8 (11.60)               |
| Mean (SD) change at End Point (LOCF)d                      | 5.0 (13.82)                | 4.4 (10.72)                | 13.1 (12.07)               | 8.6 (11.18)                | 10.9 (11.79)               |
| p value (vs placebo)                                       |                            | 0.846                      | <0.001                     | 0.067                      | <0.001                     |
| SleepVASScore                                              |                            |                            |                            |                            |                            |
| Quality of Sleep, n                                        | 50                         | 54                         | 48                         | 47                         | 95                         |
| Mean (SD) baseline                                         | 64.9 (27.30)               | 66.8 (25.07)               | 65.5 (25.55)               | 63.3 (26.69)               | 64.4 (26.01)               |
| Mean (SD) change at End Point (LOCF)d p value (vs placebo) | -0.3 (34.21)               | 6.6 (24.57) 0.058          | 16.0 (27.06) <0.001        | 14.4 (22.72) 0.003         | 15.2 (24.89) <0.001        |
| Daytime Drowsiness, n                                      | 50                         | 54                         | 48                         | 47                         | 95                         |
| Mean (SD) baseline                                         | 29.7 (25.84)               | 27.6 (26.10)               | 26.1 (22.92)               | 21.1 (21.21)               | 23.6 (22.12)               |
| Mean (SD) change at End Point (LOCF)b                      | -2.8 (30.27)               | -6.2 (24.69)               | -7.2 (25.22)               | 1.0 (29.55)                | -3.1 (27.61)               |
| p value (vs placebo)                                       |                            | 0.237                      | 0.119                      | 0.574                      | 0.214                      |
| Other Efficacy Variables                                   | Other Efficacy Variables   | Other Efficacy Variables   | Other Efficacy Variables   | Other Efficacy Variables   | Other Efficacy Variables   |
| Responder Ratef n (%)                                      | 17 (33.3%)                 | 21 (38.9%)                 | 31 (64.6%)                 | 24 (51.1%)                 | 55 (57.9%)                 |
| p value (vs placebo)                                       |                            | 0.479                      | 0.001                      | 0.043                      | 0.003                      |
| PANSS Factor-Positive symptoms                             |                            |                            |                            |                            |                            |
| Mean (SD) baseline                                         | 25.4 (4.89)                | 25.0 (4.86)                | 24.6 (4.50)                | 24.5 (4.33)                | 24.6 (4.39)                |
| Mean (SD) change at End Point (LOCF)                       | -3.3 (7.00)                | -3.1 (6.53)                | -6.0 (5.39)                | -5.0 (5.30)                | -5.5 (5.34)                |
| p value (minus Placebo)                                    |                            | 0.960                      | 0.003                      | 0.033                      | 0.003                      |
| PANSSFactor'-Negative symptoms                             |                            |                            |                            |                            |                            |
| Mean (SD) baseline                                         | 22.8 (5.16)                | 22.9 (5.32)                | 23.9 (5.26)                | 24.0 (5.10)                | 23.9 (5.15)                |
| Mean (SD) change at End Point (LOCF)b                      | -1.8 (5.30)                | -2.4 (4.31)                | -3.7 (3.85)                | -2.4 (5.56)                | -3.1 (4.79)                |
| p value (minus Placebo)                                    |                            | 0.430                      | 0.048                      | 0.586                      | 0.142                      |
| PANSS Factor'-Hostility/excitement                         |                            |                            |                            |                            |                            |
| Mean (SD) baseline                                         | 11.8 (3.45)                | 12.0 (3.81)                | 10.9 (2.69)                | 11.4 (3.72)                | 11.1 (3.23)                |
| Mean (SD) change at End Point (LOCF)                       | -0.6 (4.49)                | -1.0 (3.44)                | -2.2 (2.63)                | -2.0 (3.76)                | -2.1 (3.22)                |
| p value (minus Placebo)                                    |                            | 0.595                      | 0.004                      | 0.017                      | 0.002                      |
| PANSSFactor-Anxiety/depression                             |                            |                            |                            |                            |                            |
| Mean (SD) baseline                                         | 9.7 (3.32)                 | 9.5 (2.41)                 | 9.7 (2.98)                 | 9.8 (3.38)                 | 9.8 (3.17)                 |
| Mean (SD) change at End Point (LOCF)                       | -1.1 (2.69)                | -1.4 (2.22)                | -1.9 (3.25)                | -1.8 (3.19)                | -1.9 (3.20)                |
| p value (minus Placebo)                                    |                            | 0.348                      | 0.074                      | 0.134                      | 0.056                      |
| PANSS Factor - Disorganized thoughts                       |                            |                            |                            |                            |                            |
| Mean (SD) baseline                                         | 20.9 (4.23)                | 22.3 (4.64)                | 21.6 (5.23)                | 21.8 (5.68)                | 21.7 (5.43)                |
| Mean (SD) change at End Point (LOCF)                       | -1.1 (4.65)                | -1.8 (3.58)                | -3.5 (3.26)                | -2.6 (3.73)                | -3.0 (3.51)                |
| p value (minus Placebo)                                    |                            | 0.510                      | 0.002                      | 0.060                      | 0.004                      |

Paliperidone ER Medium and High groups combined.

p values for between-treatment group comparisons are from an ANCoVA model on ranks with treatment and country as factors, and baseline value as a covariate; no adjustment for multiplicity.

Negativechangeinscoreindicatesimprovement.

Positivechangeinscoreindicatesimprovement.

Responderdefinedasthosewhoachieved a2o%orhigherreductionfrombaselineinthePANSStotalscore atend point.

p valuesfor between-treatment group comparisons are from an ANCOVA model with fixed effects for treatment and country,andbaselinevalue asacovariate;noadjustmentformultiplicity.

pvaluesforpairwisecomparisonswithplacebousingageneralizedCMH test forrowmeanscoredifferences controllingforcountry.

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

Worst  rank  analysis  showed  that  the  paliperidone  ER  Medium  and  High  treatment  groups  were statistically significantly different from the placebo group. The magnitude of the median change was larger in both the paliperidone ER Medium and High treatment groups than the placebo group, and the difference from placebo was statistically significant for each group. The largest mean change occurred in the paliperidone ER Medium treatment group (-16 on PANSS).

Results from the longitudinal linear models (MMRM) corroborated the findings from the LOCF analysis of the primary efficacy endpoint (paliperidone ER Low, p=0.4039; paliperidone ER Medium, p=0.0034; paliperidone ER High, p=0.065).

## STUDY PSZ3003

The study design is presented in Figure 14.

Figure 14:

<!-- image -->

A total of 41 sites in 7 countries participated in the study including 6 sites in India, 1 site in Romania, 16 sites in Russian Federation, 1 site in Slovakia, 3 sites in Spain, 8 sites in Ukraine, and 6 sites in the United States.

## 2.4.2.3. Methods

## Study participants

Subjects  were  to  be  male  or  female  aged  12-17  years  inclusive  with  a  diagnosis  of  schizophrenia according to DSM-IV at least one year prior to screening. Diagnosis had to be established using the semi  structured  K-SADS-PL  questionnaire  and  the  subject  should  have  had  at  least  one  adequate treatment course with antipsychotic drug prior to enrolment.  There should be an acute exacerbation of schizophrenia with PANSS score total between 60-120 inclusive at the time of enrolment (screening).

## Treatments

The study design consisted of 3 phases: a screening phase up to 3 weeks (with a possible overlapping washout period), a double-blind acute phase of 8 weeks, and a double-blind maintenance phase of 18 weeks. The total duration of the study was approximately 29 weeks. The subjects in the paliperidone ER treatment group received 6 mg/day on Days 1 through 7 (Week 1), and subjects in the aripiprazole treatment group received 2 mg/day on Days 1 and 2, 5 mg/day on Days 3 and 4, and 10 mg/day on Days 5, 6, and 7.

<div style=\"page-break-after: always\"></div>

Beginning at Week 2 and throughout the treatment period, paliperidone ER could be given at doses of 3, 6, or 9 mg/day, and aripiprazole may be given at doses of 5, 10, or 15 mg/day.

## Objectives

The  primary  objective  was  to  assess  the  efficacy  of  paliperidone  ER  relative  to  aripiprazole  in  the treatment of symptoms of schizophrenia in adolescent subjects (from 12 to 17 years of age, inclusive, ie, from 12 to less than 18 years of age) at the Week 8 (Day 56) endpoint as measured by the change from baseline in the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) total score.

## Outcomes/endpoints

These are presented in Table 16.

Table 16: Overview Efficacy Variables in PSZ-3003

| Variable           | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | End Point         |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| PANSS              | • Change from baseline in total score at endpoint acute (Day 56) • Change from baseline in total score at endpoint (Day 182) • Change from baseline in total score at all other time points • Responders (reduction from baseline in total score ≥20% and ≥30%) • Change from baseline in Marder factor negative symptoms score at endpoint acute (Day 56) and endpoint (Day 182) • Change from baseline in other Marder factor scores (positive symptoms, disorganised thought, uncontrolled hostility/excitement, anxiety/depression) • Change from baseline in positive negative and psychopathology subscale | Primary Secondary |
| Clinical Stability | scores • PANSS 20% responder and CGI-S ≤ 4 at Days 56 and 182, with no psychiatric hospitalization or clinically significant suicidal/homicidal ideation during the maintenance period                                                                                                                                                                                                                                                                                                                                                                                                                           | Secondary         |
| CGI-S              | • Change from baseline in overall score at endpoint acute (Day 56) and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Secondary         |

<div style=\"page-break-after: always\"></div>

|     | endpoint (Day 182) • Change from baseline at all other time points • Frequency distribution of overall score at endpoint and at each postbaseline visit (LOCF and observed case)                                             |           |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| PSP | • Change from baseline in overall score at endpoint acute (Day 56) and endpoint (Day 182) • Change from baseline in score at all other time points • Responders (PSP score≥71) • Change from baseline in 10 point categories | Secondary |

## Sample size

The estimated sample size of 228 subjects (114 subjects in each of 2 blinded groups) assumed that the  standard  deviation  (SD)  of  the  change  from  baseline  to  endpoint  acute  (Day  56)  LOCF  in  the PANSS total score would be 20 points. With approximately 100 subjects per treatment group who had an endpoint acute (Day 56) PANSS total score, the study was expected to have at least 80% power to detect  a  clinically  relevant  difference  of  8  points  between  paliperidone  ER  and  aripiprazole  in  the change from baseline in PANSS total score, with a 2-sided α-level of 0.05.

With an estimate of approximately 12% of randomized subjects who could discontinue before providing post-baseline  PANSS  total  score  measurements,  the  number  of  randomly  assigned  subjects  was adjusted from 100 to 114 in each treatment group.

## Randomisation

The randomisation was centralised, balanced by using permuted blocks of treatment and was stratified by study centre.

## Blinding (masking)

Double blinding was used during the 26-week treatment period (i.e., subjects, parents, legal guardians, investigators, and the sponsor remained blinded to the study drug). Study medication was packaged in blister cards containing over-encapsulated tablets.

## Statistical methods

The primary and secondary efficacy analyses were performed based on the ITT analysis set, including all  randomized  subjects  who  received  at  least  one  dose  of  double-blind  study  drug  and  had  both  a baseline and at least one post-baseline assessment in the double-blind phase on any of the following scales: PANSS, CGI-S, or PSP. Endpoint (Day 182) was defined as the last post-baseline observation during  the  double-blind  treatment  phase.  Endpoint  acute  (Day  56)  was  defined  as  the  last  postbaseline assessment in the acute double-blind phase, ie, up to the Day 56 Visit.

The primary efficacy endpoint was the change in the PANSS total score from baseline to the Week 8 (Day 56) endpoint. The changes from baseline in PANSS total score at both endpoint acute (Day 56) and endpoint (Day 182) were analysed using an ANCOVA model with treatment group and country as fixed factors and baseline PANSS total score as a covariate. Treatment effect was estimated based on the difference between LS means with the 95% confidence interval.

<div style=\"page-break-after: always\"></div>

To assess the sensitivity of the results, a repeated measures mixed effects model was carried out using the observed data collected through the Day 56 visit. Changes from baseline over time (observed case) were modelled using a mixed effects model with time, country, and treatment as factors and baseline PANSS total score as a covariate. In addition, a treatment-by-time interaction term was included to evaluate the changes in treatment effect over time. An unstructured variance-covariance matrix was employed.

A  worst-rank  analysis  was  also  performed,  where  subjects  who  discontinued  due  to  lack  of  efficacy prior to the Day 56 visit were assigned a rank that represented a 'worst-rank score' relative to those actually  observed.  These  ranks  reflected  the  relative  inverse  ordering  of  the  actual  times  to discontinuation, so that the earlier times of withdrawal were assigned a worse ranking than the later points in time.

The proportion of subjects maintaining clinical stability at Week 26 (as measured from Week 8) as well as the proportion of symptom responders (defined as subjects with ≥20% (or ≥30%) reduction from baseline  in  PANSS  total  score  at  Week  8  and  Week  26)  was  analysed  using  the  Cochran-MantelHaenszel  test, controlling for country.

## 2.4.2.4. Results

## Participant flow

A  total  of  228  subjects  were  included  in  the  all  randomised  analysis  set;  113  subjects  in  the paliperidone  ER  group  and  115  subjects  in  the  aripiprazole  group.  Of  the  subjects  recruited  9  were from Romania, 5 from Spain and 1 Slovakia. See table 17.

Table 17: Country of origin and percentage of participants in each dose group

| Country   | PaliER(N=113)   | Ari (N=115)   | TOTAL (N=228)   |
|-----------|-----------------|---------------|-----------------|
| 20 (18%)  | 19(17%)         | 39 (17%)      | India           |
| 3(3%)     | 2 (2%)          | 5(2%)         | Spain           |
| 56(50%)   | 58(50%)         | 114 (50%)     | Russia          |
| 17(15%)   | 20 (17%)        | 37(16%)       | Ukraine         |
| 12 (11%)  | 11(10%)         | 23 (10%)      | US              |
| 1(1%)     | 0               | 1(<1%)        | Slovakia        |
| 4(4%)     | 5(4%)           | 9(4%)         | Romania         |

Information on number of subjects who completed or withdrew the study and reasons for withdrawal is provided in Table 18.

<div style=\"page-break-after: always\"></div>

Table 18: Study completion/withdrawal information for PSZ-3003

(StudyR076477-PSZ-3003:Al1 Randomized Subjects)

| SubjectCompletedTrial           | Paliperidone ER (N=113)   | Aripiprazole (N=115) n (%)   | Total (N=228) n (%)   |
|---------------------------------|---------------------------|------------------------------|-----------------------|
| ReasonForWithdrawal/Termination | n (%)                     |                              |                       |
| Completed                       | 85 (75)                   | 89 (77)                      | 174 (76)              |
| Withdrawn                       | 28 (25)                   | 26 (23)                      | 54 (24)               |
| Adverse event                   | 5 (4)                     | 0                            | 5 (2)                 |
| Lack of efficacy                | 4 (4)                     | 11 (10)                      | 15 (7)                |
| Lost to follow-up               | 0                         | 2 (2)                        | 2 (1)                 |
| Withdrawalofconsent             | 16 (14)                   | 11 (10)                      | 27 (12)               |
| Other                           | 3 (3)                     | 2 (2)                        | 5 (2)                 |

In the paliperidone ER group, a higher proportion of subjects (47%) receiving the 3 mg mode dose withdrew from the study compared with those receiving the mode dose of 6 mg (21%) or 9 mg (20%). In the aripiprazole group, approximately 25% of subjects withdrew from the study at the mode dose of 10 mg or 15 mg, whereas no subject withdrew at the 5 mg mode dose. The proportion of subjects withdrew from the study due to lack of efficacy was slightly higher at the paliperidone ER mode dose of 3 mg (7%) compared to those at the mode dose of 6 mg (2%) or 9 mg (4%). In contrast, a higher withdrawal rate was observed for subjects receiving the aripiprazole mode dose of 10 mg (12%) or 15 mg (10%) compared to those receiving the 5 mg mode dose (0%).

## Recruitment

The study was conducted between 19 November 2009 and 11 June 2012.

## Conduct of the study

## Baseline data

These are presented in Tables 19 and 20.

<div style=\"page-break-after: always\"></div>

Table 19: Baseline characteristics

|                                       | Paliperidone ER (N=112)   | Aripiprazole (N=114)   | Total (N=226)   |
|---------------------------------------|---------------------------|------------------------|-----------------|
| Age                                   |                           |                        |                 |
| Category, n (%)                       |                           |                        |                 |
| 12-14                                 | 33 (29)                   | 30 (26)                | 63 (28)         |
| 15-17                                 | 79 (71)                   | 84 (74)                | 163 (72)        |
| Mean (SD)                             | 15.3 (1.46)               | 15.4 (1.45)            | 15.3 (1.46)     |
| Median                                | 16.0                      | 16.0                   | 16.0            |
| Range                                 | (12; 17)                  | (12; 17)               | (12; 17)        |
| Sex, n (%)                            |                           |                        |                 |
| Male                                  | 73 (65)                   | 76 (67)                | 149 (66)        |
| Female                                | 39 (35)                   | 38 (33)                | 77 (34)         |
| Race, n (%)                           |                           |                        |                 |
| White                                 | 84 (75)                   | 88 (77)                | 172 (76)        |
| Black or African American             | 6 (5)                     | 7 (6)                  | 13 (6)          |
| Asian                                 | 20 (18)                   | 19 (17)                | 39 (17)         |
| Other                                 | 1 (1)                     | 0                      | 1 (<1)          |
| Multiple                              | 1 (1)                     | 0                      | 1 (<1)          |
| Ethnicity, n (%)                      |                           |                        |                 |
| Hispanic or Latino                    | 4 (4)                     | 3 (3)                  | 7 (3)           |
| Not Hispanic or Latino                | 108 (96)                  | 111 (97)               | 219 (97)        |
| Country, n (%)                        |                           |                        |                 |
| India                                 | 20 (18)                   | 19 (17)                | 39 (17)         |
| Romania                               | 4 (4)                     | 5 (4)                  | 9 (4)           |
| Russian Federation                    | 56 (50)                   | 58 (51)                | 114 (50)        |
| Slovakia                              | 1 (1)                     | 0                      | 1 (<1)          |
| Spain                                 | 3 (3)                     | 2 (2)                  | 5 (2)           |
| Ukraine                               | 16 (14)                   | 20 (18)                | 36 (16)         |
| United States of America              | 12 (11)                   | 10 (9)                 | 22 (10)         |
| Baseline bodly weight category, n (%) |                           |                        |                 |
| <51 kg                                | 37 (33)                   | 29 (25)                | 66 (29)         |
| ≥51 kg                                | 75 (67)                   | 85 (75)                | 160 (71)        |
| Baseline BMI (kg/m')                  |                           |                        |                 |
| Category, n (%)                       |                           |                        |                 |
| Normal<25                             | 95 (85)                   | 95 (83)                | 190 (84)        |
| Overweight 25-<30                     | 11 (10)                   | 15 (13)                | 26 (12)         |
| Obese ≥30                             | 6 (5)                     | 4 (4)                  | 10 (4)          |
| Mean (SD)                             | 21.23 (3.910)             | 21.40 (4.462)          | 21.32 (4.189)   |
| Median                                | 20.15                     | 20.60                  | 20.30           |
| Range                                 | (14.2; 35.0)              | (14.7; 47.6)           | (14.2; 47.6)    |
| Schizophrenia type, n (%)             |                           |                        |                 |
| Paranoid (295.30)                     | 82 (73)                   | 76 (67)                | 158 (70)        |
| Disorganized (295.10)                 | 4 (4)                     | 8 (7)                  | 12 (5)          |
| Catatonic (295.20)                    | 2 (2)                     | 1(1)                   | 3 (1)           |
| Undifferentiated (295.90)             | 21 (19)                   | 27 (24)                | 48 (21)         |
| Residual (295.60)                     | 3 (3)                     | 2 (2)                  | 5 (2)           |

<div style=\"page-break-after: always\"></div>

Table 20: Baseline disease severity in the different treatment groups

| Outcomes and estimation                                |     |
|--------------------------------------------------------|-----|
| PANSS Total Score related endpoints                    |     |
| Results on the primary endpoint are presented in Table | 21. |

## Table  21:  PANSS  total  score-Change  from  baseline  to  endpoint  acute  (Day  56)  ITT-LOCF analysis 37 (33) 29 (25) 66 (29)

* Based on analysis of covariance (ANCOVA) model with treatment (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate.

|                              | Paliperidone ER (N=112)   | Aripiprazole (N=114)   | 1)   |
|------------------------------|---------------------------|------------------------|------|
| Baseline                     |                           |                        |      |
| N                            | 112                       | 114                    |      |
| Mean (SD)                    | 89.6 (12.22)              | 92.0 (12.09)           | 4)   |
| Median (Range)               | 89.0 (63; 122)            | 93.0 (65; 116)         | 2) ) |
| End Point Acute (Day 56)     |                           |                        | 189) |
| N                            | 112                       | 114                    | D    |
| Mean (SD)                    | 70.3 (16.93)              | 72.2 (16.76)           | 7.6) |
| Median (Range)               | 70.0 (35; 106)            | 70.5 (30; 128)         |      |
| Change from Baseline         |                           |                        | 0)   |
| N                            | 112                       | 114                    |      |
| Mean (SD)                    | -19.3 (13.80)             | -19.8 (14.56)          |      |
| Median (Range)               | -18.0 (-79; 5)            | -18.0 (-53; 26)        | 1)   |
| P-value(minus Aripiprazole)a | 0.935                     |                        |      |
| Diff. of LS Means (SE)       | 0.1 (1.83)                |                        |      |
| 95% CI                       | (-3.46; 3.76)             |                        |      |

Note: Negative change in score indicates improvement.

Source: Summary of Clinical efficacy

<div style=\"page-break-after: always\"></div>

When using the mode dose (ie the dose that was most frequently taken), the changes from baseline were very similar across all mode doses for both treatment groups (see Table 21).  This indicates that the approach of flexible dosing worked. It is noted that the most frequent mode dose for paliperidone ER is 6 mg.

Table 22: PANSS total score change from baseline to endpoint acute by mode dose

| Mode dose*                | Paliperidone 3mg (N=20)   |   Ari 5 mg (N=13) | Paliperidone 6 mg (N=54)   |   Ari 10mg (N=49) |   Paliperidone 9mg (N=38) |   Ari 15 mg (N=52) |
|---------------------------|---------------------------|-------------------|----------------------------|-------------------|---------------------------|--------------------|
| Baseline mean             | 88.2 87.1                 |              90.3 |                            |              90.3 |                      89.2 |               94.8 |
| Endpoint Acute mean       | 71.1                      |              66.2 | 70.3                       |              70.9 |                      69.8 |               74.9 |
| Change from baseline mean | -17.2                     |             -20.9 | -20.0                      |             -19.4 |                     -19.4 |              -19.9 |

When  conducting  a  subgroup  analysis  of the primary efficacy variable there was  a  greater improvement  in  the  younger  subjects  (12-14  yrs)  in  the  aripiprazole  group  (-23.7)  than  in  the paliperidone  ER  group  (-17.5).    In  older  subjects  (15-17  yrs)  there  was  a  greater  improvement  in mean PANSS total score in the paliperidone ER group than in the aripiprazole group (-20.1 vs -18.5). in both weight groups (&lt;51kg and ≥51 kg) improvement was similar in the mean PANSS total score at day 56 (around -20).

Figure  15  shows  the  estimated  LS  mean  changes  (LOCF)  from  baseline  in  PANSS  total  scores  over time.

<div style=\"page-break-after: always\"></div>

Figure  15:  Estimated  LS  mean  changes  (LOCF)  from  baseline  to  endpoint  (Day  182)  in PANSS total scores

<!-- image -->

No statistically significant differences between treatment groups were observed at the two-sided 0.05 level.

## Other endpoints

These are presented in Table 23.

<div style=\"page-break-after: always\"></div>

Table 23: Key secondary Variables at Day 182 (ITT analysis set)

|                                          | Paliperidone ER (N=112)   | Aripiprazole (N=114)   |
|------------------------------------------|---------------------------|------------------------|
| PANSS total score at End Point (Day 182) |                           |                        |
| Mean baseline (SD)                       | 89.6 (12.22)              | 92.0 (12.09)           |
| Mean change (SD)                         | -25.6 (16.88)             | -26.8 (18.82)          |
| p value (minus Aripiprazole)             | 0.877                     |                        |
| PANSS Marder Factors                     |                           |                        |
| Positive symptoms                        |                           |                        |
| Mean baseline (SD)                       | 24.6 (4.08)               | 24.9 (4.32)            |
| Mean change (SD)                         | -7.8 (5.82)               | -7.8 (6.03)            |
| p value(minus Aripiprazole)a             | 0.691                     |                        |
| Negative symptoms                        |                           |                        |
| Mean baseline (SD)                       | 23.2 (4.92)               | 23.3 (4.54)            |
| Mean change (SD)                         | -6.0 (5.51)               | -6.2 (5.84)            |
| p value (minus Aripiprazole)a            | 0.723                     |                        |
| Disorganized thoughts                    |                           |                        |
| Mean baseline (SD)                       | 21.4 (4.40)               | 22.1 (3.86)            |
| Mean change (SD)                         | -5.5 (4.18)               | -5.7 (4.46)            |
| p value (minus Aripiprazole)a            | 0.766                     |                        |
| Uncontrolledhostility/excitement         |                           |                        |
| Mean baseline (SD)                       | 10.7 (3.19)               | 11.7 (3.48)            |
| Mean change (SD)                         | -3.2 (3.11)               | -3.8 (3.97)            |
| p value (minus Aripiprazole)a            | 0.985                     |                        |
| Anxiety/depression                       |                           |                        |
| Mean baseline (SD)                       | 9.7 (3.17)                | 10.0 (3.26)            |
| Mean change (SD)                         | -3.0 (3.29)               | -3.2 (3.17)            |
| p value (minus Aripiprazole)a            | 0.745                     |                        |
| Clinical Stability at Days 56 and 182b   |                           |                        |
| Yes: n (%)                               | 58 (51.8%)                | 68 (59.6%)             |
| No: n ( %)                               | 54 (48.2%)                | 46 (40.4%)             |
| p value (vs Aripiprazole)c               | 0.296                     |                        |
| CGI-S Score                              |                           |                        |
| Baseline Median (Range)                  | 4.0 (3; 6)                | 4.0 (3; 6)             |
| ChangefromBaseline                       |                           |                        |
| Median (Range)                           | -1.0 (-4; 1)              | -1.0 (-4; 1)           |
| p value (minus aripiprazole)d            | 0.914                     |                        |
| PSP                                      |                           |                        |
| Mean Baseline(SD)                        | 49.8 (10.32)              | 49.2 (10.21)           |
| Mean Change (SD)                         | 17.1 (14.46)              | 17.1 (14.03)           |
| p value (minus Aripiprazole)             | 0.705                     |                        |
| Responder Ratef                          |                           |                        |
| n (%)                                    | 86 (76.8%)                | 93 (81.6%)             |
| p value (vs Aripiprazole)*               | 0.444                     |                        |

a Based on analysis of covariance (ANCOVA) model with treatment (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate.

Negative change in score indicates improvement. Factors derived from Marder Criteria.

b Clinical stability is defined as a decrease of 20% or more from baseline PANSS total score and a CGI-S score ≤4 at Day 56 and Day 182, and no hospitalizations due to psychiatric illness and no emergence of clinically significant suicidal or homicidal ideation during the maintenance phase. ITT subjects who do not meet these criteria are classified as not achieving clinical stability.

c Generalized Cochran-Mantel-Haenszel test for row mean score differences controlling for country.

d Based on analysis of covariance (ANCOVA) model on ranks with treatment (paliperidone ER, aripiprazole) and country as factors, and baseline value (unranked) as a covariate.

Negative change in score indicates improvement.

e Based on analysis of covariance (ANCOVA) model with treatment (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate. Positive change in score indicates improvement.

f Responder defined as those who achieved a 20% or higher reduction from baseline in the PANSS total score at endpoint (Day 182).

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

There was no statistically significant difference in the change from baseline to endpoint acute (Day 56) in  the  PANSS  total  score  based  on  the  worst  rank  analysis  between  the  paliperidone  ER  and aripiprazole groups (p=0.465), which is consistent with the primary analysis.

Results  from  the  MMRM  analysis  corroborated  the  findings  from  the  LOCF  analysis  of  the  primary efficacy  endpoint.  Using  an  unstructured  variance-covariance  matrix  for  the  MMRM  analysis,  the estimated LS mean change in PANSS total score at Day 56 was -22.4 for paliperidone ER and -24.2 for aripiprazole (p=0.313) which is consistent with the primary analysis result.

## Summary of main study(ies)

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 24: Summary of Efficacy for trial PSZ-3001

| Title: A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo- Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age   | Title: A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo- Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age   | Title: A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo- Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age   | Title: A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo- Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                   | PSZ-3001                                                                                                                                                                                                                                                           | PSZ-3001                                                                                                                                                                                                                                                           | PSZ-3001                                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                                                                                             | 6 week, randomized, double-blind, parallel-group, placebo-controlled multicentre efficacy and safety study                                                                                                                                                         | 6 week, randomized, double-blind, parallel-group, placebo-controlled multicentre efficacy and safety study                                                                                                                                                         | 6 week, randomized, double-blind, parallel-group, placebo-controlled multicentre efficacy and safety study                                                                                                                                                         |
| Design                                                                                                                                                                                                                                                             | Duration of main phase: Duration of run-in phase: Duration of extension phase:                                                                                                                                                                                     | Duration of main phase: Duration of run-in phase: Duration of extension phase:                                                                                                                                                                                     | 6 weeks 3 weeks screening phase See PSZ-3002, for patients who did not enter the open- label safety study there was a one-week follow-up visit                                                                                                                     |
| Hypothesis                                                                                                                                                                                                                                                         | Superiority of PAL over Placebo                                                                                                                                                                                                                                    | Superiority of PAL over Placebo                                                                                                                                                                                                                                    | Superiority of PAL over Placebo                                                                                                                                                                                                                                    |
| Treatment groups                                                                                                                                                                                                                                                   | Placebo                                                                                                                                                                                                                                                            | Placebo                                                                                                                                                                                                                                                            | n = 51                                                                                                                                                                                                                                                             |
| Treatment groups                                                                                                                                                                                                                                                   | Paliperidone ER low (1.5 mg)                                                                                                                                                                                                                                       | Paliperidone ER low (1.5 mg)                                                                                                                                                                                                                                       | n = 54                                                                                                                                                                                                                                                             |
| Treatment groups                                                                                                                                                                                                                                                   | Paliperidone ER medium (3 or 6 mg)                                                                                                                                                                                                                                 | Paliperidone ER medium (3 or 6 mg)                                                                                                                                                                                                                                 | n = 48                                                                                                                                                                                                                                                             |
| Treatment groups                                                                                                                                                                                                                                                   | Paliperidone ER high (6                                                                                                                                                                                                                                            | Paliperidone ER high (6                                                                                                                                                                                                                                            | n = 47                                                                                                                                                                                                                                                             |
| Endpoints and definitions                                                                                                                                                                                                                                          | Primary endpoint                                                                                                                                                                                                                                                   | ΔPANSS total score                                                                                                                                                                                                                                                 | Change from baseline to the acute endpoint in the double-blind period                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                                                                                          | Secondary                                                                                                                                                                                                                                                          | ΔCGI-S score ΔCGAS score                                                                                                                                                                                                                                           | Change from baseline to endpoint in the CGI-S score Change from baseline to endpoint in the CGAS score                                                                                                                                                             |
| Endpoints and definitions                                                                                                                                                                                                                                          | Exploratory endpoint                                                                                                                                                                                                                                               | ΔVAS sleep                                                                                                                                                                                                                                                         | Change from baseline to endpoint                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                                                             |                                                                                                                                                                                                                                                                                                                    | Responder Rate                                                                                                                                                                                                                                                                                                     | 20% reduction from baseline in PANSS total score                                                                                                                                                                                                                                                                   | 20% reduction from baseline in PANSS total score                                                                                                                                                                                                                                                                   | 20% reduction from baseline in PANSS total score                                                                                                                                                                                                                                                                   | 20% reduction from baseline in PANSS total score                                                                                                                                                                                                                                                                   | 20% reduction from baseline in PANSS total score                                                                                                                                                                                                                                                                   |
|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Results and analysis                                        | Results and analysis                                                                                                                                                                                                                                                                                               | Results and analysis                                                                                                                                                                                                                                                                                               | Results and analysis                                                                                                                                                                                                                                                                                               | Results and analysis                                                                                                                                                                                                                                                                                               | Results and analysis                                                                                                                                                                                                                                                                                               | Results and analysis                                                                                                                                                                                                                                                                                               | Results and analysis                                                                                                                                                                                                                                                                                               |
| Analysis description                                        | Primary analysis                                                                                                                                                                                                                                                                                                   | Primary analysis                                                                                                                                                                                                                                                                                                   | Primary analysis                                                                                                                                                                                                                                                                                                   | Primary analysis                                                                                                                                                                                                                                                                                                   | Primary analysis                                                                                                                                                                                                                                                                                                   | Primary analysis                                                                                                                                                                                                                                                                                                   | Primary analysis                                                                                                                                                                                                                                                                                                   |
| Analysis population and time point                          | Intent to treat (ITT) population which included all subjects who received at least 1 dose of double-blind study drug and had both a baseline and at least 1 post- baseline assessment in the double-blind phase on any of the following scales: PANSS, CGI-S, CGAS, or sleep VAS. Week 6 primary efficacy endpoint | Intent to treat (ITT) population which included all subjects who received at least 1 dose of double-blind study drug and had both a baseline and at least 1 post- baseline assessment in the double-blind phase on any of the following scales: PANSS, CGI-S, CGAS, or sleep VAS. Week 6 primary efficacy endpoint | Intent to treat (ITT) population which included all subjects who received at least 1 dose of double-blind study drug and had both a baseline and at least 1 post- baseline assessment in the double-blind phase on any of the following scales: PANSS, CGI-S, CGAS, or sleep VAS. Week 6 primary efficacy endpoint | Intent to treat (ITT) population which included all subjects who received at least 1 dose of double-blind study drug and had both a baseline and at least 1 post- baseline assessment in the double-blind phase on any of the following scales: PANSS, CGI-S, CGAS, or sleep VAS. Week 6 primary efficacy endpoint | Intent to treat (ITT) population which included all subjects who received at least 1 dose of double-blind study drug and had both a baseline and at least 1 post- baseline assessment in the double-blind phase on any of the following scales: PANSS, CGI-S, CGAS, or sleep VAS. Week 6 primary efficacy endpoint | Intent to treat (ITT) population which included all subjects who received at least 1 dose of double-blind study drug and had both a baseline and at least 1 post- baseline assessment in the double-blind phase on any of the following scales: PANSS, CGI-S, CGAS, or sleep VAS. Week 6 primary efficacy endpoint | Intent to treat (ITT) population which included all subjects who received at least 1 dose of double-blind study drug and had both a baseline and at least 1 post- baseline assessment in the double-blind phase on any of the following scales: PANSS, CGI-S, CGAS, or sleep VAS. Week 6 primary efficacy endpoint |
| description Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                    | PBO                                                                                                                                                                                                                                                                                                                | PAL low (1.5 mg)                                                                                                                                                                                                                                                                                                   | PAL low (1.5 mg)                                                                                                                                                                                                                                                                                                   | PAL medium PAL high (6 or 12                                                                                                                                                                                                                                                                                       | PAL medium PAL high (6 or 12                                                                                                                                                                                                                                                                                       | mg)**                                                                                                                                                                                                                                                                                                              |
| description Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                 | 51                                                                                                                                                                                                                                                                                                                 | 54                                                                                                                                                                                                                                                                                                                 | 54                                                                                                                                                                                                                                                                                                                 | 48                                                                                                                                                                                                                                                                                                                 | 48                                                                                                                                                                                                                                                                                                                 | 47                                                                                                                                                                                                                                                                                                                 |
| description Descriptive statistics and estimate variability | ΔPANSS total score; mean (LOCF)                                                                                                                                                                                                                                                                                    | -7.9                                                                                                                                                                                                                                                                                                               | -9.8                                                                                                                                                                                                                                                                                                               | -9.8                                                                                                                                                                                                                                                                                                               | -17.3                                                                                                                                                                                                                                                                                                              | -17.3                                                                                                                                                                                                                                                                                                              | -13.8                                                                                                                                                                                                                                                                                                              |
| description Descriptive statistics and estimate variability | SD                                                                                                                                                                                                                                                                                                                 | 20.15                                                                                                                                                                                                                                                                                                              | 16.31                                                                                                                                                                                                                                                                                                              | 16.31                                                                                                                                                                                                                                                                                                              | 14.33                                                                                                                                                                                                                                                                                                              | 14.33                                                                                                                                                                                                                                                                                                              | 15.74                                                                                                                                                                                                                                                                                                              |
| description Descriptive statistics and estimate variability | ΔCGI-S score Median (LOCF)                                                                                                                                                                                                                                                                                         | 0.0                                                                                                                                                                                                                                                                                                                | 0.0                                                                                                                                                                                                                                                                                                                | 0.0                                                                                                                                                                                                                                                                                                                | -1.0                                                                                                                                                                                                                                                                                                               | -1.0                                                                                                                                                                                                                                                                                                               | -1.0                                                                                                                                                                                                                                                                                                               |
| description Descriptive statistics and estimate variability | range                                                                                                                                                                                                                                                                                                              | -3.1                                                                                                                                                                                                                                                                                                               | -3.1                                                                                                                                                                                                                                                                                                               | -3.1                                                                                                                                                                                                                                                                                                               | -3.0                                                                                                                                                                                                                                                                                                               | -3.0                                                                                                                                                                                                                                                                                                               | -3.1                                                                                                                                                                                                                                                                                                               |
| description Descriptive statistics and estimate variability | ΔCGAS score; mean (LOCF)                                                                                                                                                                                                                                                                                           | 5.0                                                                                                                                                                                                                                                                                                                | 4.4                                                                                                                                                                                                                                                                                                                | 4.4                                                                                                                                                                                                                                                                                                                | 13.1                                                                                                                                                                                                                                                                                                               | 13.1                                                                                                                                                                                                                                                                                                               | 8.6                                                                                                                                                                                                                                                                                                                |
| description Descriptive statistics and estimate variability | SD                                                                                                                                                                                                                                                                                                                 | 13.82                                                                                                                                                                                                                                                                                                              | 10.72                                                                                                                                                                                                                                                                                                              | 10.72                                                                                                                                                                                                                                                                                                              | 12.07                                                                                                                                                                                                                                                                                                              | 12.07                                                                                                                                                                                                                                                                                                              | 11.18                                                                                                                                                                                                                                                                                                              |
| description Descriptive statistics and estimate variability | Δ Sleep VAS Mean (LOCF)                                                                                                                                                                                                                                                                                            | -0.3                                                                                                                                                                                                                                                                                                               | 6.6                                                                                                                                                                                                                                                                                                                | 6.6                                                                                                                                                                                                                                                                                                                | 16.0                                                                                                                                                                                                                                                                                                               | 16.0                                                                                                                                                                                                                                                                                                               | 14.4                                                                                                                                                                                                                                                                                                               |
| description Descriptive statistics and estimate variability | SD                                                                                                                                                                                                                                                                                                                 | 34.21                                                                                                                                                                                                                                                                                                              | 24.57                                                                                                                                                                                                                                                                                                              | 24.57                                                                                                                                                                                                                                                                                                              | 27.06                                                                                                                                                                                                                                                                                                              | 27.06                                                                                                                                                                                                                                                                                                              | 22.72                                                                                                                                                                                                                                                                                                              |
| description Descriptive statistics and estimate variability | Responder Rate (20% reduction from baseline in PANSS total ); n(%)                                                                                                                                                                                                                                                 | 17 (33.3%)                                                                                                                                                                                                                                                                                                         | 21 (38.9%)                                                                                                                                                                                                                                                                                                         | 21 (38.9%)                                                                                                                                                                                                                                                                                                         | 31 (64.6%) 24                                                                                                                                                                                                                                                                                                      | 31 (64.6%) 24                                                                                                                                                                                                                                                                                                      | (51.1%)                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                              | Primary endpoint                                                                                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                                                                  | PAL low                                                                                                                                                                                                                                                                                                            | PAL low                                                                                                                                                                                                                                                                                                            | PAL medium PAL high                                                                                                                                                                                                                                                                                                | PAL medium PAL high                                                                                                                                                                                                                                                                                                |
|                                                             | ΔPANSS total score                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                    |
|                                                             | ΔPANSS total score                                                                                                                                                                                                                                                                                                 | Diff. of LS means to PBO (95% CI) LOCF                                                                                                                                                                                                                                                                             | Diff. of LS means to PBO (95% CI) LOCF                                                                                                                                                                                                                                                                             | -2.1 (-8.36;                                                                                                                                                                                                                                                                                                       | -2.1 (-8.36;                                                                                                                                                                                                                                                                                                       | -10.1 (-16.58;- 3.67) -6.6 (-13.07;- 0.09) ±3.27 ±3.29                                                                                                                                                                                                                                                             | -10.1 (-16.58;- 3.67) -6.6 (-13.07;- 0.09) ±3.27 ±3.29                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                |                                                                                                                                                | P-value                                                                                                                                        | 0.508                                                                                                                                          | 0.006                                                                                                                                          | 0.086                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                | Secondary endpoint ΔCGI-S score                                                                                                                | Diff. to PBO (95% CI), median LOCF                                                                                                             | 0.0                                                                                                                                            | -1.0                                                                                                                                           | -1.0                                                                                                                                           |
|                                                                                                                                                | Median                                                                                                                                         | range                                                                                                                                          | -3.1                                                                                                                                           | -3.0                                                                                                                                           | -3.1                                                                                                                                           |
|                                                                                                                                                |                                                                                                                                                | P-value                                                                                                                                        | 0.968                                                                                                                                          | <0.001                                                                                                                                         | 0.021                                                                                                                                          |
|                                                                                                                                                | Secondary endpoint ΔCGAS score                                                                                                                 | Diff. of LS means to PBO (95% CI) LOCF                                                                                                         | -0.4 (- 4.54;3.73)                                                                                                                             | 8.6 (4.28;12.82)                                                                                                                               | 4.0 (-0.28;8.33)                                                                                                                               |
|                                                                                                                                                |                                                                                                                                                | SE                                                                                                                                             | ±2.10                                                                                                                                          | ±2.17                                                                                                                                          | ±2.18                                                                                                                                          |
|                                                                                                                                                |                                                                                                                                                | P-value                                                                                                                                        | 0.846                                                                                                                                          | <0.001                                                                                                                                         | 0.067                                                                                                                                          |
|                                                                                                                                                | Exploratory endpoint Sleep VAS                                                                                                                 | Diff. of LS means to PBO (95% CI) LOCF                                                                                                         | 8.1 (- 0.29;16.56 )                                                                                                                            | 16.8 (8.08;25.43)                                                                                                                              | 13.6 (4.76;22.23 )                                                                                                                             |
|                                                                                                                                                |                                                                                                                                                | SE                                                                                                                                             | ±4.27                                                                                                                                          | ±4.40                                                                                                                                          | ±4.43                                                                                                                                          |
|                                                                                                                                                |                                                                                                                                                | p-value                                                                                                                                        | 0.058                                                                                                                                          | <0.001                                                                                                                                         | <0.003                                                                                                                                         |
|                                                                                                                                                | Responder                                                                                                                                      | Diff to PBO in %                                                                                                                               | 5.6%                                                                                                                                           | 31.3%                                                                                                                                          | 17.8%                                                                                                                                          |
|                                                                                                                                                | Rate (20% reduction from baseline in PANSS total)                                                                                              | p-value                                                                                                                                        | 0.479                                                                                                                                          | 0.001                                                                                                                                          | 0.043                                                                                                                                          |
| Notes                                                                                                                                          |                                                                                                                                                | Additional analyses by actual dose revealed that the improvement in the 3, 6 and 12 mg dose groups achieved statistical significance.          | Additional analyses by actual dose revealed that the improvement in the 3, 6 and 12 mg dose groups achieved statistical significance.          | Additional analyses by actual dose revealed that the improvement in the 3, 6 and 12 mg dose groups achieved statistical significance.          | Additional analyses by actual dose revealed that the improvement in the 3, 6 and 12 mg dose groups achieved statistical significance.          |
| Analysis description                                                                                                                           |                                                                                                                                                | The primary efficacy analysis was ANCOVA/LOCF. As additional sensitivity analysis MMRM and Worst Rank analysis were undertaken.                | The primary efficacy analysis was ANCOVA/LOCF. As additional sensitivity analysis MMRM and Worst Rank analysis were undertaken.                | The primary efficacy analysis was ANCOVA/LOCF. As additional sensitivity analysis MMRM and Worst Rank analysis were undertaken.                | The primary efficacy analysis was ANCOVA/LOCF. As additional sensitivity analysis MMRM and Worst Rank analysis were undertaken.                |
| Medium dose group: 3 mg for subjects < 51 kg, 6mg for subjects ≥51 kg ** High dose group: 6 mg for subjects < 51 kg, 12 mg for subjects ≥51 kg | Medium dose group: 3 mg for subjects < 51 kg, 6mg for subjects ≥51 kg ** High dose group: 6 mg for subjects < 51 kg, 12 mg for subjects ≥51 kg | Medium dose group: 3 mg for subjects < 51 kg, 6mg for subjects ≥51 kg ** High dose group: 6 mg for subjects < 51 kg, 12 mg for subjects ≥51 kg | Medium dose group: 3 mg for subjects < 51 kg, 6mg for subjects ≥51 kg ** High dose group: 6 mg for subjects < 51 kg, 12 mg for subjects ≥51 kg | Medium dose group: 3 mg for subjects < 51 kg, 6mg for subjects ≥51 kg ** High dose group: 6 mg for subjects < 51 kg, 12 mg for subjects ≥51 kg | Medium dose group: 3 mg for subjects < 51 kg, 6mg for subjects ≥51 kg ** High dose group: 6 mg for subjects < 51 kg, 12 mg for subjects ≥51 kg |

Δ: change from baseline to endpoint, PAL: paliperidone, PBO: placebo, SE: standard error

<div style=\"page-break-after: always\"></div>

Table 25: Summary of Efficacy for trial PSZ-3003

| Title: A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Symptoms of Schizophrenia in   | Title: A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Symptoms of Schizophrenia in                                                                                                  | Title: A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Symptoms of Schizophrenia in                                                                                                  | Title: A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Symptoms of Schizophrenia in                                                                                                  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                       | PSZ-3003                                                                                                                                                                                                                                                                                                              | PSZ-3003                                                                                                                                                                                                                                                                                                              | PSZ-3003                                                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                                                                                 | A randomized, double blind, active controlled, parallel group, flexible dose, multicenter efficacy and safety. The study consisted of three phases: an up to 3 weeks screening phase (with a possible overlapping washout period), an 8 Week double-blind acute phase, and an 18 Week double-blind maintenance phase. | A randomized, double blind, active controlled, parallel group, flexible dose, multicenter efficacy and safety. The study consisted of three phases: an up to 3 weeks screening phase (with a possible overlapping washout period), an 8 Week double-blind acute phase, and an 18 Week double-blind maintenance phase. | A randomized, double blind, active controlled, parallel group, flexible dose, multicenter efficacy and safety. The study consisted of three phases: an up to 3 weeks screening phase (with a possible overlapping washout period), an 8 Week double-blind acute phase, and an 18 Week double-blind maintenance phase. |
| Design                                                                                                                                                                                                                 | Duration of main phase: Duration of run-in phase: Duration of                                                                                                                                                                                                                                                         | extension phase:                                                                                                                                                                                                                                                                                                      | 8 weeks double blind acute and 18 weeks double blind maintenance phase. 3 week screening phase NA                                                                                                                                                                                                                     |
| Hypothesis                                                                                                                                                                                                             | Superiority versus Aripiprazole                                                                                                                                                                                                                                                                                       | Superiority versus Aripiprazole                                                                                                                                                                                                                                                                                       | Superiority versus Aripiprazole                                                                                                                                                                                                                                                                                       |
| Treatment groups                                                                                                                                                                                                       | Paliperidone 3, 6 or 9 mg                                                                                                                                                                                                                                                                                             | Paliperidone 3, 6 or 9 mg                                                                                                                                                                                                                                                                                             | Paliperidone ER was administered at a fixed dose of 6 mg/day during the first week followed by flexible dosing (3, 6, or 9 mg/day) thereafter, n=113                                                                                                                                                                  |
| Treatment groups                                                                                                                                                                                                       | Aripiprazole 5, 10 or 15 mg                                                                                                                                                                                                                                                                                           | Aripiprazole 5, 10 or 15 mg                                                                                                                                                                                                                                                                                           | Aripiprazole was titrated from 2 mg/day to 10 mg/day during the first week, followed by flexible dosing (5, 10, or 15 mg/day) thereafter, n=115                                                                                                                                                                       |
| Endpoints and definitions                                                                                                                                                                                              | Primary endpoint                                                                                                                                                                                                                                                                                                      | ΔPANSS total score                                                                                                                                                                                                                                                                                                    | Change from baseline to week 8                                                                                                                                                                                                                                                                                        |
| Endpoints and definitions                                                                                                                                                                                              | Secondary endpoint                                                                                                                                                                                                                                                                                                    | Proportion of subjects maintaining stability 1                                                                                                                                                                                                                                                                        | Maintenance of effect (as measured from Week 8) at Week 26                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                       | ΔPANSS negative symptom factor score                                                                                                                                                                                                                                                                                  | Change from baseline at Week 8 and Week 26                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                       | ΔPANSS total score                                                                                                                                                                                                                                                                                                    | Change from baseline to week 26                                                                                                                                                                                                                                                                                       |
| Endpoints and definitions                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                       | ΔCGI-S score                                                                                                                                                                                                                                                                                                          | Change from baseline at Week 8 and Week 26                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                       | Δ PSP score                                                                                                                                                                                                                                                                                                           | Change from baseline at Week 8 and Week 26                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                              | Exploratory endpoint                                                                                                                                                                                                                                                                                                  | Responder rate                                                                                                                                                                                                                                                                                                        | 20% reduction from baseline in PANSS total score                                                                                                                                                                                                                                                                      |

1 Defined as decrease of 20% or more from baseline PANSS total, CGI score ≤ 4 at Day 56 and 182, no hospitalisation or emergence of clinically significant suicidal or homicidal ideation

<div style=\"page-break-after: always\"></div>

| Database lock                                   | 10 July 2012                                                                  | 10 July 2012          | 10 July 2012          |
|-------------------------------------------------|-------------------------------------------------------------------------------|-----------------------|-----------------------|
| Results and analysis                            | Results and analysis                                                          | Results and analysis  | Results and analysis  |
| Analysis description                            | Primary analysis                                                              | Primary analysis      | Primary analysis      |
| Analysis population and time point description  | Intent to treat (ITT)                                                         | Intent to treat (ITT) | Intent to treat (ITT) |
| Descriptive statistics and estimate variability | Treatment group                                                               | Paliperidone 3-9 mg   | Aripiprazole 5-15 mg  |
| Descriptive statistics and estimate variability | Number of subjects                                                            | 112                   | 114                   |
| Descriptive statistics and estimate variability | ΔPANSS total score; mean (LOCF)                                               | -19.3                 | -19.8                 |
| Descriptive statistics and estimate variability | SD                                                                            | 13.80                 | 14.56                 |
| Descriptive statistics and estimate variability | Proportion of subjects maintaining stability at Days 56 and 182; n (%)        | 58 (51.8)             | 68 (59.6)             |
| Descriptive statistics and estimate variability | variability statistic                                                         | NA                    | NA                    |
| Descriptive statistics and estimate variability | ΔPANSS negative symptom factor score; mean change from baseline (LOCF) Day 56 | -4.3                  | -4.7                  |
| Descriptive statistics and estimate variability | SD                                                                            | 4.56                  | 4.61                  |
| Descriptive statistics and estimate variability | ΔPANSS total score at week 26; mean (LOCF)                                    | -25.6                 | -26.8                 |
| Descriptive statistics and estimate variability | SD                                                                            | 16.88                 | 18.82                 |
| Descriptive statistics and estimate variability | ΔCGI-S score, median (LOCF)                                                   | -1.0                  | -1.0                  |
| Descriptive statistics and estimate variability | range                                                                         | (-4;1)                | (-4;1)                |
| Descriptive statistics and estimate variability | Δ PSP score; mean (LOCF)                                                      | 17.1                  | 17.1                  |
| Descriptive statistics and estimate variability | SD                                                                            | (14.46)               | (14.03)               |

<div style=\"page-break-after: always\"></div>

|                                | Responder rate; n (%)                                                               | 86 (76.8%)                                      | 93 (81.6%)                                      |
|--------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                | variability statistic                                                               | NA                                              | NA                                              |
| Effect estimate per comparison | Primary endpoint ΔPANSS total score                                                 | Comparison groups                               | PAL minus ARI                                   |
| Effect estimate per comparison | Primary endpoint ΔPANSS total score                                                 | Diff of LS means to ARI (95% CI)                | 0.1 (-3.46; 3.76)                               |
| Effect estimate per comparison | Primary endpoint ΔPANSS total score                                                 | SE                                              | 1.83                                            |
| Effect estimate per comparison | Primary endpoint ΔPANSS total score                                                 | P-value                                         | 0.935                                           |
| Effect estimate per comparison | Secondary endpoint, Proportion of subjects maintaining stability at Days 56 and 182 | Comparison groups                               | PAL minus ARI                                   |
| Effect estimate per comparison | Secondary endpoint, Proportion of subjects maintaining stability at Days 56 and 182 | P-value                                         | 0.296                                           |
| Effect estimate per comparison | ΔPANSS negative symptom factor score; Day 56                                        | Comparison groups                               | PAL minus ARI                                   |
| Effect estimate per comparison | ΔPANSS negative symptom factor score; Day 56                                        | P-value                                         | 0.341                                           |
| Effect estimate per comparison | ΔPANSS total score at week 26                                                       | Comparison groups                               | PAL minus ARI                                   |
| Effect estimate per comparison | ΔPANSS total score at week 26                                                       | p-value                                         | 0.877                                           |
| Effect estimate per comparison | ΔCGI-S score                                                                        | Comparison groups                               | PAL minus ARI                                   |
| Effect estimate per comparison | ΔCGI-S score                                                                        | p-value                                         | 0.914                                           |
| Effect estimate per comparison | Δ PSP score                                                                         | Comparison groups                               | PAL minus ARI                                   |
| Effect estimate per comparison | Δ PSP score                                                                         | p-value                                         | 0.705                                           |
| Effect estimate per comparison | Responder Rate                                                                      | Comparison groups                               | PAL minus ARI                                   |
| Effect estimate per comparison | Responder Rate                                                                      | p-value                                         | 0.444                                           |
| Notes                          | Negative change in score indicates improvement.                                     | Negative change in score indicates improvement. | Negative change in score indicates improvement. |
| Analysis description           | LOCF                                                                                | LOCF                                            | LOCF                                            |

## 2.4.3. Analysis performed across trials (pooled analyses and metaanalysis)

## Comparison on the change in the PANSS total score

A meta-analysis based on studies: PSZ-3001, PSZ-3003 and the only published aripiprazole placebocontrolled study of adolescent schizophrenia (Findling RL et al (2008)) was presented. However, the CHMP was in disagreement with the MAH consideration that the designs of the pooled studies were similar: study PSZ-3001 and the aripiprazole placebo-controlled study were 6 week studies with fixed doses while PSZ-3003 was an 8 week study with flexible dosing; fixed dose groups were pooled posthoc within studies PSZ-3001 and the aripiprazole placebo-controlled study.  Furthermore, the approach

<div style=\"page-break-after: always\"></div>

to perform a pooled analysis of subject level data based on simulated data as if these were observed data  is  generally  not  considered  valid.  For  the  indirect  comparison  of  paliperidone  with  aripiprazole using the data from their respective placebo-controlled trials, the assumption has also to be made that the treatment effects of paliperidone and aripiprazole would have been the same in the trial where the respective  treatment  was  not  included  as  observed  in  the  placebo  controlled  trial  where  it  was included,  which  is  not  verifiable.Hence,  taking  into  account  the  different  study  designs  and  the additional  assumptions  that  have  to  be  made  to  conduct  the  meta-analysis,  the  CHMP  considered highly questionable whether the meta-analysis of these studies was valid and meaningful, and whether it provides valid information beyond the single studies.

## Comparison on the baseline data for EU/US versus non EU/US population

When the number of subjects from the EU was combined with that from the US, the percentages of subjects  from  the  2  combined  subpopulations  were  19.5%,  34.9%,  and  16.4%  in  PSZ-3001,  PSZ3002, and PSZ-3003, respectively. The overall proportion of subjects from combined EU and US in all 3 studies was 27.8%. The demographic and psychiatric baseline characteristics of subjects from EU/US were similar to those of subjects from the non-EU/non-US in Studies PSZ-3001, PSZ-3002 and PSZ3003. At least 90% of subjects received prior psychotropic medications across different country/regions. The percentage of subjects receiving atypical antipsychotic medications was higher for subjects from the EU/US  than  those non-EU/non-US  countries. Additionally, subject baseline characteristics in Studies PSZ-3001, PSZ-3002, and PSZ-3003 were consistent with those of subjects from published reports in adolescents with schizophrenia. Of note, the Hass study enrolled subjects from EU and US only. Since the characteristics of subjects from the EU are similar to those from the US and  the  combined  EU/US  subpopulation  for  the  3  Phase  3  studies  was  over  25%,  data  from  these studies were considered by the MAH relevant to the EU subject population.

## 2.4.4. Supportive study

## STUDY PSZ3002

The study design is presented in Figure 16.

## Figure 16:

<!-- image -->

This study was conducted at 1 site in Bulgaria, 2 sites in Estonia,1 site in Finland, 5 sites in India, 6 sites in Korea, 6 sites in Poland, 1 site in Romania, 12 sites in Russia, 6 sites in Ukraine, and the 15 sites in  the US.

## 2.4.4.1. Methods

## Study participants

This long-term study included subjects who had: a) completed double-blind treatment in PSZ-3001; b) discontinued  PSZ-3001  due  to  lack  of  efficacy  after  completing  at  least  21  days  of  double-blind

<div style=\"page-break-after: always\"></div>

treatment and who were expected to benefit from a continuation of paliperidone ER; or c) were aged between 12 and 17 years, inclusive, with K-SADS-PL confirmed DSM-IV diagnosis of schizophrenia and who were directly enrolled in the study.

## Treatments

All  enrolled  subjects  received  a  starting  dose  of  paliperidone  ER  6  mg  daily,  which  could  have  been increased  in  increments  of  3  mg  once  every  5  days  until  the  maximum  dose  of  12  mg/day  was reached. Alternatively, if the 6 mg dose was not tolerated, the dose could have been decreased to 3 or 1.5 mg/day

The washout period for current psychotropic medications (if necessary) was required only for subjects enrolling  in  this  study  directly.  For  subjects  who  enrolled  from  PSZ-3001,  the  end-of-study  or  early withdrawal visit of the double-blind study coincided with Day 1 of PSZ-3002.

Subjects entering the long-term study from PSZ-3001 were required to complete the Measurements and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) cognitive battery of tests, 23 the K-SADS-PL screening Items 'a' to 'e' for suicide, and an ECG.

End of study (EOS) laboratory assessments for PSZ-3001 counted as baseline assessments for PSZ3002. The last study day for PSZ-3001 was the same day as the baseline visit (Day 1) for PSZ-3002.

## Objectives

All  efficacy  analyses  performed  for  this  study  were  exploratory  because  this  study  did  not  have  a control  group  for  comparison  and  the  primary  objective  of  the  study  was  to  assess  the  safety  and tolerability of paliperidone ER.

## Outcomes/endpoints

The primary efficacy variable was the change from baseline in the PANSS total score at the end of the open-label  phase  (Week  104  or  the  last  post-baseline  assessment).  Other  measures  of  efficacy included the CGI-S, CGAS, the modified MATRICS cognition assessment battery, sleep VAS, and the PANSS negative symptom scale based on Marder factors .

## Sample size

No formal sample size calculation was performed for this study. Based on the discontinuation rate seen in  a  similar  study  evaluating  risperidone  in  adolescents,  approximately  400  subjects  were  to  be enrolled into this open-label study so that at least 100 subjects completed the 2-year open-label study at or above the lowest effective dose ( ≤ 3 mg) that was identified in Study R076477-PSZ-3001.

## Randomisation

As this was an open-label, single-arm study, randomization was not applicable.

## Blinding (masking)

As this was an open-label, single-arm study, blinding was not applicable. The treatment assignment in study PSZ-3001 continued to be blinded after subjects entered study PSZ-3002.

## Statistical methods

Descriptive methods were used to present efficacy data in this open label, uncontrolled study.

The following treatment groups were analysed: subjects previously randomly assigned to 1) placebo in PSZ-3001 (placebo/paliperidone); 2) to any 1 of the paliperidone ER dose groups (low, medium, or

<div style=\"page-break-after: always\"></div>

high)  in  PSZ-3001  (paliperidone  (DB)/paliperidone)  and  new  subjects  who  enrolled  in  the  study (paliperidone (NO DB)/paliperidone).

For all efficacy variables except for the cognitive assessment battery, 2 baseline values were defined and  used  in  the  analyses  of  changes  from  baseline  as  follows:  Open-label  (OL)  baseline  (latest observation prior to administration of open-label paliperidone ER in PSZ-3002 (including first day of dosing  [Day  1]  in  this  study);  Double-blind  (DB)  baseline  (observation  at  the  last  visit  prior  to administration of double-blind study drug administration in PSZ-3001 (including Day 1).

## 2.4.4.2. Results

## Participant flow

A total of 393 subjects were enrolled into PSZ-3002 receiving at least 1 dose of study medication, had a baseline and at least 1 post-baseline efficacy assessment.  A total of 237 subjects entered the study directly and 156 subjects who were enrolled from PSZ-3001. See Table 26.

Table 26: Number of subjects assigned to each treatment group

|                       | Placebo/Pali (N=39) n (%)   | Pali (DB)/Pali (N=118) n (%)   | Pali (NO DB)/Pali (N=243) n (%)   | Total (N=400) n (%)   |
|-----------------------|-----------------------------|--------------------------------|-----------------------------------|-----------------------|
| Open-Label Safety     | 39 (100)                    | 118 (100)                      | 243 (100)                         | 400 (100)             |
| Open-Label Intent-To- | 39 (100)                    | 117 (99)                       | 237 (98)                          | 393 (98)              |

Information on number of subjects who completed or withdrew the study and reasons for withdrawal is provided in Table 27. Time to withdrawal is presented in Figure 17.

Table 27: Study Completion/Withdrawal information

|                                  | Placebo/Pali (N=39) n (%)   | Pali (DB)/Pali (N=118) n (%)   | Pali (NO DB)/Pali (N=243) n (%)   | Total (N=400) n (%)   |
|----------------------------------|-----------------------------|--------------------------------|-----------------------------------|-----------------------|
| Completed                        | 24 (62)                     | 75 (64)                        | 121 (50)                          | 220 (55)              |
| Withdrawn                        | 15 (38)                     | 43 (36)                        | 122 (50)                          | 180 (45)              |
| Subject choice (subject withdrew | 5 (13)                      | 20 (17)                        | 44 (18)                           | 69 (17)               |
| consent)                         |                             |                                |                                   |                       |
| Lack of efficacy                 | 6 (15)                      | 12 (10)                        | 27 (11)                           | 45 (11)               |
| Adverse event                    | 1 (3)                       | 2 (2)                          | 23 (9)                            | 26 (7)                |
| Lost to follow-up                | 3 (8)                       | 5 (4)                          | 16 (7)                            | 24 (6)                |
| Other                            | 0                           | 4 (3)                          | 12 (5)                            | 16 (4)                |

Completed: Denotes the number of subjects who completed the study based on either the original protocol (6-month study) or the amended protocol (2-year study) period.

Withdrawn: Denotes the number of subjects who withdrew from the study based on either the original protocol or the amended protocol period.

<div style=\"page-break-after: always\"></div>

Figure 17: Time to discontinuation for any reason

<!-- image -->

Only 2% of subjects had a mode dose of 1.5 mg, while 38% of subjects had a mode dose of 6 mg and 11%  had  a  mode  dose  of  3  mg.  Approximately  30%  of  subjects  had  their  dose  increased  to  the maximum daily dose of 12 mg. A total of 109 evaluable subjects had exposure to paliperidone ER for the study duration of 2 years and 18% (n=73) had exposure to paliperidone for ≥ 2 years.

## Outcomes and estimation

## PANSS Total Score related endpoints

Results on the primary endpoint are presented in Table 28.

Table 28: Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score Change from Baseline (OL) to End Point (OL) LOCF

|                    | Placebo/Pali (N=39)   | Pali (DB)/Pali (N=117)   | Pali (NO DB)/Pali (N=237)   | Total (N=393)   |
|--------------------|-----------------------|--------------------------|-----------------------------|-----------------|
| Baseline           |                       |                          |                             |                 |
| N                  | 39                    | 117                      | 237                         | 393             |
| Mean (SD)          | 82.7 (22.11)          | 76.6 (20.48)             | 87.7 (18.89)                | 83.9 (20.27)    |
| Median (Range)     | 80.0 (36;129)         | 76.0 (33;135)            | 87.0 (44;149)               | 84.0 (33;149)   |
| End point(OL)      |                       |                          |                             |                 |
| N                  | 39                    | 117                      | 237                         | 393             |
| Mean (SD)          | 63.8 (19.51)          | 64.0 (20.77)             | 65.3 (22.27)                | 64.8 (21.53)    |
| Median (Range)     | 63.0 (33;110)         | 61.0 (32;140)            | 65.0 (31;134)               | 63.0 (31;140)   |
| ChangefromBaseline |                       |                          |                             |                 |
| N                  | 39                    | 117                      | 237                         | 393             |
| Mean (SD)          | -18.9 (21.47)         | -12.6 (19.92)            | -22.4 (22.25)               | -19.1 (21.89)   |
| Median (Range)     | -18.0 (-62;50)        | -11.0 (-67;46)           | -23.0 (-82;48)              | -17.0 (-82;50)  |

Note:Negativechangein scoreindicatesimprovement. teff01\\_teffpnss.rtf generated by teffpnss.sas,17AUG2012 17:23

Figure 18 shows the mean changes from baseline in PANSS total scores over time.

<div style=\"page-break-after: always\"></div>

Figure 18:  Mean (+/- SE) Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score - LOCF (OL ITT Analysis Set)

673

<!-- image -->

## Other endpoints

Results are presented in Table 29.

<div style=\"page-break-after: always\"></div>

Table 29: Overview of key secondary variables

|                                     | Placebo/Pali (N=39)   | Pali (DB)/Pali (N=117)   | Pali (NO DB)/Pali (N=237)   | Total (N=393)   |
|-------------------------------------|-----------------------|--------------------------|-----------------------------|-----------------|
| PANSS Factorsa                      |                       |                          |                             |                 |
| Positive symptoms                   |                       |                          |                             |                 |
| Mean baseline (SD)                  | 22.3 (6.66)           | 19.8 (5.79)              | 24.8 (6.25)                 | 23.0 (6.54)     |
| Mean change (SD)*                   | -5.1 (6.45)           | -3.4 (6.11)              | -7.0 (7.12)                 | -5.7 (6.94)     |
| Negative symptoms                   |                       |                          |                             |                 |
| Mean baseline (SD)                  | 20.6 (6.42)           | 20.6 (6.20)              | 22.3 (6.09)                 | 21.6 (6.19)     |
| Mean change (SD)b                   | -4.3 (6.30)           | -3.8 (4.80)              | -5.7 (6.68)                 | -5.0 (6.18)     |
| Disorganized thoughts               |                       |                          |                             |                 |
| Mean baseline (SD)                  | 19.8 (5.78)           | 19.1 (5.89)              | 20.1 (5.54)                 | 19.8 (5.68)     |
| Mean change (SD)6                   | -4.8 (5.57)           | -3.3 (4.41)              | -4.9 (5.52)                 | -4.4 (5.25)     |
| Uncontrolledhostility/excitement    |                       |                          |                             |                 |
| Mean baseline (SD)                  | 11.0 (4.63)           | 9.4 (3.89)               | 10.1 (4.08)                 | 10.0 (4.09)     |
| Mean change (SD)*                   | -2.6 (4.17)           | -1.2 (4.41)              | -2.1 (4.68)                 | -1.9 (4.56)     |
| Anxiety/depression                  |                       |                          |                             |                 |
| Mean baseline (SD)                  | 9.1 (3.08)            | 7.7 (2.73)               | 10.4 (3.43)                 | 9.5 (3.42)      |
| Mean change (SD)b                   | -2.1 (3.35)           | -0.9 (3.41)              | -2.8 (3.61)                 | -2.2 (3.62)     |
| 20% Responder Rate^ n (%)           | 27 (69.2%)            | 68 (58.1)                | 167(70.5%)                  | 262 (66.7%)     |
| CGI-S Score                         |                       |                          |                             |                 |
| Median (Range) Baseline             | 4.0 (1;6)             | 4.0 (1;6)                | 4.0 (2;7)                   | 4.0 (1;7)       |
| Median (Range) Change at end pointb | -1.0 (-3;2)           | -1.0 (-3;3)              | -1.0 (-5;3)                 | -1.0 (-5;3)     |
| CGAS Score                          |                       |                          |                             |                 |
| Mean (SD) Baseline                  | 54.9 (15.84)          | 57.1 (15.36)             | 46.7 (11.84)                | 50.6 (14.23)    |
| Mean (SD) Change from Baselined     | 11.3 (16.65)          | 8.7 (16.02)              | 15.6 (17.77)                | 13.1 (17.39)    |
| Sleep VAS Score?                    |                       |                          |                             |                 |
| Quality of Sleep, N                 | 36                    | 116                      | 223                         | 375             |
| Mean (SD) Baseline                  | 69.3 (24.79)          | 79.5 (20.21)             | 60.7 (27.54)                | 67.3 (26.57)    |
| Mean (SD) Change from Baselined     | 8.2 (30.51)           | 2.7 (18.48)              | 9.8 (32.47)                 | 7.4 (28.78)     |
| Mean (SD) Baseline                  | 26.4 (23.72)          | 20.9 (21.57)             | 32.9 (26.77)                | 28.5 (25.52)    |
| Mean (SD) Change from Baselineb     | -7.4 (18.83)          | -5.1 (22.39)             | -3.9 (32.30)                | -4.6 (28.42)    |

Factors derived from Marder criteria

Responder defined as those who achieved a 20% or higher reduction from baseline in the PANSS total score at end point.

b Negative change in score indicates improvement.

d Positive change in score indicates improvement.

f Based on answer to the question How often have you felt drowsy in the past 7 days? 0 for not at all, 100 for all the time.

Based on answer to the question \"How well have you slept in the past 7 nights?\" 0 for very badly, 100 for very well.

Similar  mean  changes  in  PANSS  total  score  from  double-blind  baseline  to  open-label  endpoint  were observed  for  subjects  from  EU  (-30.9,  n=10),  US  (-27.1,  n=19),  EU/US  (-28.4,  n=29),  and  nonEU/non-US countries (-26.7, n=127). Mean change in PANSS total score from open-label baseline to open-label endpoint was slightly larger in subjects from non-EU/non-US countries (-21, n=256) than those  from  EU  (-17.1,  n=78),  US  (-13.6,  n=59),  and  EU/US  (-15.6,  n=137).  Reduction  (ie, improvement) in PANSS total scores was observed from open-label baseline to open-label endpoint in both age groups of 12 to 14 and 15 to 17 years old with numerically greater decreases noted for the older group. In the total group, the magnitude of the mean decrease (improvement) from open-label baseline to endpoint in PANSS total score was higher for non-US subjects than the US subjects, and was numerically slightly greater for the non-EU subjects (-19.6, N=315) than the EU subjects (-17.1, N=78).

Across  different  regions,  over  55%  of  subjects  achieved  a  20%  or  higher  reduction  in  PANSS  total score from open-label baseline to endpoint. A slightly higher proportion of subjects from non-EU/non-

<div style=\"page-break-after: always\"></div>

US countries (69.9%) than those from EU (61.5%), US (59.3%), or EU/US (60.6%) achieved the 20% or higher reduction in PANSS total score. Similarly, a higher percentage of subjects from non-EU/nonUS (60.9%) than those from EU (48.7%), US (54.2%), or EU/US (51.1%) achieved a 30% or higher reduction in PANSS total score from open-label baseline to open-label endpoint.

Figure 19 shows the mean (+/-SE) PANSS total scores over time for the 2 age groups (12 to 14 and 15 to17  years).  Decrease  (ie,  improvement)  in  the  PANSS  total  scores  was  observed  from  open-label baseline to open-label endpoint in both age groups, although the improvement was numerically better for the older group.

Figure 19: Mean (±SE) positive and negative syndrome scale for PANSS total Score by age

505

<!-- image -->

## 2.4.5. Additional analyses

At the CHMP request, additional analyses were presented by the MAH including efficacy data by age and weight groups. Analyses for the primary efficacy endpoint, change from baseline to endpoint on the total PANSS total score,  are presented below.

589

<div style=\"page-break-after: always\"></div>

Table 30: PANSS total score - Change from baseline to endpoint (LOCF) by age -PSZ-3001ITT set

| Age Group: 12-14 Parameter: Total PANSS   | Placebo (6=N)   | Paliperidone ER Paliperidone ER Paliperidone ER Low (N=16)   | Medium (N=15)                                                   | High (N=13)   |
|-------------------------------------------|-----------------|--------------------------------------------------------------|-----------------------------------------------------------------|---------------|
| Baseline                                  |                 |                                                              |                                                                 |               |
| N                                         | 9               | 16                                                           | 15                                                              | 13            |
| Mean (SD)                                 | 89.4 (12.93)    | 89.6 (11.47)                                                 | 93.5 (13.77)                                                    | 93.0 (15.92)  |
| Median (Range)                            | 83.0 (78;114)   | 89.5 (71;111)                                                | 94.0 (71;119)                                                   | 90.0 (70;119) |
| End Point                                 |                 |                                                              |                                                                 |               |
| N                                         | 9               | 16                                                           | 15                                                              | 13            |
| Mean (SD)                                 | 77.9 (7.46)     | 83.0 (20.46)                                                 | 77.9 (23.43)                                                    | 86.1 (20.82)  |
| Median (Range)                            | 80.0 (61;87)    | 84.0 (45;111)                                                | 84.0 (43;112)                                                   | 78.0 (62;135) |
| Change from Baseline                      |                 |                                                              |                                                                 |               |
| N                                         | 9               | 16                                                           | 15                                                              | 13            |
| Mean (SD)                                 | -11.6 (12.30)   | -6.6 (18.28)                                                 | -15.5 (12.66)                                                   | -6.9 (19.73)  |
| Median (Range)                            | -8.0 (-33;2)    | -4.0 (-52;23)                                                | -16.0 (-35;4)                                                   | -5.0 (-49;30) |
| Age Group: 15-17                          |                 |                                                              |                                                                 |               |
| Parameter: Total PANSS                    | Placebo (N=42)  | Low (N=38)                                                   | Paliperidone ER  Paliperidone ER  Paliperidone ER Medium (N=33) | High (N=34)   |
| Baseline                                  |                 |                                                              |                                                                 |               |
| N                                         | 42              | 38                                                           | 33                                                              | 34            |
| Mean (SD)                                 | 90.9 (12.10)    | 92.5 (13.02)                                                 | 89.4 (14.14)                                                    | 91.0 (13.21)  |
| Median (Range)                            | 89.0 (65;118)   | 92.0 (70;118)                                                | 85.0 (69;116)                                                   | 89.5 (63;117) |
| End Point                                 |                 |                                                              |                                                                 |               |
| N                                         | 42              | 38                                                           | 33                                                              | 34            |
| Mean (SD)                                 | 83.8 (23.32)    | 81.4 (19.40)                                                 | 71.2 (21.35)                                                    | 74.5 (16.37)  |
| Median (Range)                            | 82.0 (36;129)   | 79.0 (45;121)                                                | 69.0 (33;126)                                                   | 75.0 (49;114) |
| Change from Baseline                      |                 |                                                              |                                                                 |               |
| N                                         | 42              | 38                                                           | 33                                                              | 34            |
| Mean (SD)                                 | -7.1 (21.49)    | -11.1 (15.47)                                                | -18.1 (15.14)                                                   | -16.5 (13.34) |
| Median (Range)                            | -4.0 (-59;28)   | -6.5 (-45;10)                                                | -17.0 (-53;19)                                                  | -13.5 (-62;1) |

Note: Negative change in score indicates improvement.

LOCF=last observation carried forward, SD=standard deviation

<div style=\"page-break-after: always\"></div>

Table 31:  PANSS total score - Change from baseline to endpoint (LOCF): weight based treatment groups- by weight-PSZ-3001- ITT set

## set

| Parameter: Total PANSS   | Placebo (N=14)   | Paliperidone ER Low (1.5 mg) (N=19)   | Paliperidone ER Medium (3 mg) (N=16)   | Paliperidone ER High (6 mg) (N=13)   |
|--------------------------|------------------|---------------------------------------|----------------------------------------|--------------------------------------|
| Baseline                 |                  |                                       |                                        |                                      |
| N                        | 14               | 19                                    | 16                                     | 13                                   |
| Mean (SD)                | 93.9 (13.98)     | 88.3 (12.67)                          | 92.1 (16.88)                           | 93.0 (16.37)                         |
| Median (Range)           | 91.0 (78;118)    | 89.0 (71;118)                         | 91.0 (70;119)                          | 90.0 (63;118)                        |
| End Point                |                  |                                       |                                        |                                      |
| N                        | 14               | 19                                    | 16                                     | 13                                   |
| Mean (SD)                | 79.4 (23.66)     | 76.3 (21.24)                          | 73.1 (26.55)                           | 85.6 (20.67)                         |
| Median (Range)           | 78.5 (44;120)    | 79.0 (45;121)                         | 70.0 (33;115)                          | 79.0 (51;135)                        |
| ChangefromBaseline       |                  |                                       |                                        |                                      |
| N                        | 14               | 19                                    | 16                                     | 13                                   |
| Mean (SD)                | -14.4 (19.07)    | -11.9 (17.49)                         | -19.0 (15.45)                          | -7.4 (15.32)                         |
| Median (Range)           | -9.0 (-54;10)    | -6.0 (-45;13)                         | -19.0 (-53;3)                          | -4.0 (-34;30)                        |

Baseline Body Weight Category: &gt;=51 kg

Parameter:TotalPANSS

|                    | Placebo (N=37)   | Paliperidone ER Low (1.5 mg) (N=35)   | Paliperidone ER Medium (6 mg) (N=32)   | Paliperidone ER High (12 mg) (N=34)   |
|--------------------|------------------|---------------------------------------|----------------------------------------|---------------------------------------|
| Baseline           |                  |                                       |                                        |                                       |
| N                  | 37               | 35                                    | 32                                     | 34                                    |
| Mean (SD)          | 89.4 (11.32)     | 93.5 (12.27)                          | 89.9 (12.57)                           | 91.0 (13.00)                          |
| Median (Range)     | 88.0 (65;112)    | 93.0 (70;118)                         | 85.5 (69;111)                          | 89.0 (70;119)                         |
| End Point          |                  |                                       |                                        |                                       |
| N                  | 37               | 35                                    | 32                                     | 34                                    |
| Mean (SD)          | 84.0 (20.76)     | 84.9 (18.16)                          | 73.4 (19.80)                           | 74.7 (16.57)                          |
| Median (Range)     | 82.0 (36;129)    | 86.0 (55;117)                         | 70.0 (42;126)                          | 73.0 (49;115)                         |
| ChangefromBaseline |                  |                                       |                                        |                                       |
| N                  | 37               | 35                                    | 32                                     | 34                                    |
| Mean (SD)          | -5.4 (20.23)     | -8.6 (15.77)                          | -16.5 (13.91)                          | -16.3 (15.41)                         |
| Median (Range)     | -5.0 (-59;28)    | -4.0 (-52;23)                         | -15.0 (-51;19)                         | -15.0 (-62;18)                        |

Note: Negative change in score indicates improvement.

LOCF=last observation carried forward, SD=standard deviation

<div style=\"page-break-after: always\"></div>

Table 32:  PANSS total score - Change from baseline to endpoint (LOCF) by age and weight group - -PSZ-3001- ITT set

| Age and Weight Group: <15 yrs / <51kg   | Placebo (N=6)   | Paliperidone ER Low (N=8)   | Paliperidone ER Medium (N=8)   | Paliperidone ER High (N=4)   |
|-----------------------------------------|-----------------|-----------------------------|--------------------------------|------------------------------|
| Baseline                                |                 |                             |                                |                              |
| N                                       | 6               | 8                           | 8                              | 4                            |
| Mean (SD)                               | 91.5 (15.25)    | 82.8 (9.53)                 | 89.1 (16.23)                   | 97.8 (17.44)                 |
| Median (Range)                          | 82.5 (80;114)   | 83.0 (71;98)                | 86.0 (71;119)                  | 97.5 (78;118)                |
| End Point                               |                 |                             |                                |                              |
| N                                       | 6               | 8                           | 8                              | 4                            |
| Mean (SD)                               | 76.2 (8.23)     | 76.4 (21.01)                | 73.0 (28.53)                   | 97.0 (26.62)                 |
| Median (Range)                          | 78.5 (61;83)    | 80.0 (45;102)               | 70.0 (43;112)                  | 89.5 (74;135)                |
| ChangefromBaseline                      |                 |                             |                                |                              |
| N                                       | 6               | 8                           | 8                              | 4                            |
| Mean (SD)                               | -15.3 (13.35)   | -6.4 (13.53)                | -16.1 (14.14)                  | -0.8 (22.47)                 |
| Median (Range)                          | -15.0 (-33;2)   | -5.0 (-26;13)               | -16.0 (-35;3)                  | -4.5 (-24;30)                |
| Age and Weight Group: <15 yrs/ ≥ 51 kg  |                 |                             |                                |                              |
|                                         |                 | Paliperidone                | Paliperidone                   | Paliperidone                 |
|                                         | Placebo         | ER Low                      | ER Medium                      | ER High                      |
|                                         | (N=3)           | (N=8)                       | (N=7)                          | (N=9)                        |
| Baseline                                |                 |                             |                                |                              |
| N                                       | 3               | 8                           | 7                              | 9                            |
| Mean (SD)                               | 85.3 (7.02)     | 96.4 (9.23)                 | 98.4 (9.02)                    | 90.9 (15.80)                 |
| Median (Range)                          | 86.0 (78;92)    | 93.0 (86;111)               | 96.0 (84;109)                  | 85.0 (70;119)                |
| End Point                               |                 |                             |                                |                              |
| N                                       | 3               | 8                           | 7                              | 9                            |
| Mean (SD)                               | 81.3 (5.13)     | 89.6 (18.86)                | 83.6 (16.20)                   | 81.2 (17.28)                 |
| Median (Range)                          | 80.0 (77;87)    | 88.5 (56;111)               | 88.0 (56;98)                   | 75.0 (62;115)                |
| Change from Baseline                    |                 |                             |                                |                              |
| N                                       | 3               | 8                           | 7                              | 9                            |
| Mean (SD)                               | -4.0 (5.57)     | -6.8 (23.09)                | -14.9 (11.82)                  | -9.7 (19.16)                 |
| Median (Range)                          | -5.0 (-9;2)     | -3.0 (-52;23)               | -11.0 (-29;4)                  | -9.0 (-49;18)                |

<div style=\"page-break-after: always\"></div>

Table 33:  PANSS total score - Change from baseline to endpoint (LOCF) by age and weight group - -PSZ-3001- ITT set

| Age and Weight Group: ≥ 15 years/ <51 kg   | Age and Weight Group: ≥ 15 years/ <51 kg   |                            |                              |                            |
|--------------------------------------------|--------------------------------------------|----------------------------|------------------------------|----------------------------|
|                                            | Placebo (N=8)                              | Paliperidone ER Low (N=11) | Paliperidone ER Medium (N=8) | Paliperidone ER High (6=N) |
| Baseline                                   |                                            |                            |                              |                            |
| N                                          | 8                                          | 11                         | 8                            | 9                          |
| Mean (SD)                                  | 95.6 (13.73)                               | 92.3 (13.54)               | 95.1 (18.06)                 | 90.9 (16.48)               |
| Median (Range)                             | 98.0 (78;118)                              | 89.0 (73;118)              | 98.0 (70;116)                | 90.0 (63;116)              |
| End Point                                  |                                            |                            |                              |                            |
| N                                          | 8                                          | 11                         | 8                            | 9                          |
| Mean (SD)                                  | 81.9 (31.23)                               | 76.3 (22.42)               | 73.3 (26.40)                 | 80.6 (16.77)               |
| Median (Range)                             | 86.5 (44;120)                              | 75.0 (45;121)              | 74.0 (33;115)                | 78.0 (51;114)              |
| ChangefromBaseline                         |                                            |                            |                              |                            |
| N                                          | 8                                          | 11                         | 8                            | 9                          |
| Mean (SD)                                  | -13.8 (23.38)                              | -16.0 (19.49)              | -21.9 (17.11)                | -10.3 (11.43)              |
| Median (Range)                             | -4.0 (-54;10)                              | -23.0 (-45;10)             | -20.5 (-53;-1)               | -4.0 (-34;1)               |
| Age and Weight Group: ≥ 15 years/ ≥ 51 kg  |                                            |                            |                              |                            |
|                                            |                                            | Paliperidone               | Paliperidone                 | Paliperidone               |
|                                            | Placebo                                    | ER Low                     | ER Medium                    | ER High                    |
|                                            | (N=34)                                     | (N=27)                     | (N=25)                       | (N=25)                     |
| Baseline                                   |                                            |                            |                              |                            |
| N                                          | 34                                         | 27                         | 25                           | 25                         |
| Mean (SD)                                  | 89.7 (11.62)                               | 92.6 (13.06)               | 87.5 (12.52)                 | 91.0 (12.22)               |
| Median (Range)                             | 88.5 (65;112)                              | 95.0 (70;118)              | 84.0 (69;111)                | 89.0 (72;117)              |
| End Point                                  |                                            |                            |                              |                            |
| N                                          | 34                                         | 27                         | 25                           | 25                         |
| Mean (SD)                                  | 84.2 (21.63)                               | 83.5 (18.08)               | 70.6 (20.06)                 | 72.3 (16.00)               |
| Median (Range)                             | 82.0 (36;129)                              | 79.0 (55;117)              | 69.0 (42;126)                | 72.0 (49;102)              |
| Change from Baseline                       |                                            |                            |                              |                            |
| N                                          | 34                                         | 27                         | 25                           | 25                         |
| Mean (SD)                                  | -5.5 (21.08)                               | -9.1 (13.43)               | -16.9 (14.63)                | -18.7 (13.48)              |
| Median (Range)                             | -4.0 (-59;28)                              | -6.0 (-43;9)               | -15.0 (-51;19)               | -18.0 (-62;1)              |

Negative change indicates improvement.

<div style=\"page-break-after: always\"></div>

Table 34:  PANSS total score - Change from baseline to endpoint acute (day 56) (LOCF) by age group- PSZ-3003- ITT set

| Age Group: 12-14         | Paliperidone ER (N=33)   | Aripiprazole (N=30)   |
|--------------------------|--------------------------|-----------------------|
| Baseline                 |                          |                       |
| N                        | 33                       | 30                    |
| Mean (SD)                | 94.2 (10.56)             | 96.7 (12.35)          |
| Median (Range)           | 94.0 (69;112)            | 96.0 (77;116)         |
| End Point Acute (Day 56) |                          |                       |
| N                        | 33                       | 30                    |
| Mean (SD)                | 76.8 (15.07)             | 73.0 (15.02)          |
| Median (Range)           | 79.0 (48;101)            | 72.0 (36;98)          |
| Change from Baseline     |                          |                       |
| N                        | 33                       | 30                    |
| Mean (SD)                | -17.5 (10.31)            | -23.7 (10.53)         |
| Median (Range)           | -18.0 (-41;3)            | -22.0 (-53;-11)       |
| Age Group: 15-17         |                          |                       |
|                          | Paliperidone ER (N=79)   | Aripiprazole (N=84)   |
| Baseline                 |                          |                       |
| N                        | 79                       | 84                    |
| Mean (SD)                | 87.6 (12.39)             | 90.3 (11.62)          |
| Median (Range)           | 87.0 (63;122)            | 92.0 (65;113)         |
| End Point Acute (Day 56) |                          |                       |
| N                        | 79                       | 84                    |
| Mean (SD)                | 67.5 (17.02)             | 71.9 (17.42)          |
| Median (Range)           | 68.0 (35;106)            | 69.5 (30;128)         |
| Change from Baseline     |                          |                       |
| N                        | 79                       | 84                    |
| Mean (SD)                | -20.1 (15.01)            | -18.5 (15.57)         |
| Median (Range)           | -19.0 (-79;5)            | -17.5 (-49;26)        |

Note: Negative change in score indicates improvement.

tefpant21.rtf generated by r\\_efpnss.sas, 19JUL2012 15:24

Source: PSZ-3003/Table 32.

<div style=\"page-break-after: always\"></div>

Table 35:  PANSS total score - Change from baseline to endpoint acute (day 56) (LOCF) by baseline body weight group- PSZ-3003- ITT set

| Baseline Body Weight Category: <51 kg   | Paliperidone ER (N=37)   | Aripiprazole (67=N)   |
|-----------------------------------------|--------------------------|-----------------------|
| Baseline                                |                          |                       |
| N                                       | 37                       | 29                    |
| Mean (SD)                               | 89.4 (12.71)             | 87.3 (12.93)          |
| Median (Range)                          | 89.0 (63;112)            | 86.0 (65;113)         |
| End Point Acute (Day 56)                |                          |                       |
| N                                       | 37                       | 29                    |
| Mean (SD)                               | 69.4 (16.82)             | 68.4 (17.77)          |
| Median (Range)                          | 67.0 (40;103)            | 70.0 (36;115)         |
| Change from Baseline                    |                          |                       |
| N                                       | 37                       | 29                    |
| Mean (SD)                               | -20.1 (13.24)            | -18.9 (15.89)         |
| Median (Range)                          | -19.0 (-48;3)            | -17.0 (-53;17)        |
| Baseline Body Weight Category: ≥ 51 kg  |                          |                       |
|                                         | Paliperidone ER (N=75)   | Aripiprazole (N=85)   |
| Baseline                                |                          |                       |
| N                                       | 75                       | 85                    |
| Mean (SD)                               | 89.6 (12.05)             | 93.6 (11.43)          |
| Median (Range)                          | 89.0 (65;122)            | 93.0 (67;116)         |
| End Point Acute (Day 56)                |                          |                       |
| N                                       | 75                       | 85                    |
| Mean (SD)                               | 70.7 (17.08)             | 73.5 (16.32)          |
| Median (Range)                          | 71.0 (35;106)            | 72.0 (30;128)         |
| ChangefronBaseline                      |                          |                       |
| N                                       | 75                       | 85                    |
| Mean (SD)                               | -18.9 (14.14)            | -20.2 (14.16)         |
| Median (Range)                          | -18.0 (-79;5)            | -18.0 (-49;26)        |

Note: Negative change in score indicates improvement.

tefpant26\\_t1.rtf generated by tefpant26.sas, 12JUL2012 15:01 Source:PSZ-3003/Table 33.

<div style=\"page-break-after: always\"></div>

Figure 20 : Mean (+/-) PANSS Total Score by age- LOCF- study PSZ-3002: Open Label ITT set

<!-- image -->

Figure 21 : Mean (+/-) PANSS Total Score by body weight- LOCF- study PSZ-3002: Open Label ITT set

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 22: Percentage of subjects who maintained response from baseline (DB) based on PANSS 30% criteria by age  - PSZ-3002- Open Label ITT set

<!-- image -->

The denominatorforeach timepointincludessubjectswith dataforbothDay85(OPEN) and thespecified timepoint. A subject whomaintains&gt;=30%improvement fromDay85(OPEN)to the specified timepoint isconsidered a maintained baseline (DB) for those subjects enrolled from PSZ-3001. Subjects who are 18 at the start of the open-label study are considered in the 15-17 group.

Figure 23: Percentage of subjects who maintained response from baseline (DB) based on PANSS 30% criteria by weight group - PSZ-3002- Open Label ITT set

<!-- image -->

ThedenominatorforeachtimepointincludessubjectswithdataforbothDay85(OPEN)and thespecified timepoint. A subjectwhomaintains&gt;=30%improvement fromDay85(OPEN)tothespecified timepoint isconsidered amaintained responder.Improvement is detemined based on DBBaseline value Theweight group is based on the subject's weight at baseline(DB)forthosesubjectsenrolledfromPSZ-3001.

<div style=\"page-break-after: always\"></div>

## 2.4.6. Discussion on clinical efficacy

## Design and conduct of clinical studies

The presented data (study PSZ-3001, PSZ-3003 and PSZ-3002) are part of an agreed PIP. The studies were  conducted  in  line  with  the  Guideline  on  clinical  investigation  of  medicinal  products  in  the treatment of schizophrenia (EMA/CHMP/40072/2010 Rev.1). Studies in subjects younger than 12 years of age were not conducted given the low incidence of schizophrenia and the difficulty of establishing a diagnosis  in  this  age  group.  All  three  phase  3  studies  used  similar  entry  criteria,  restrictions  to concomitant  medications,  rating  scales  and  endpoints.  The  studies  however  differed  with  regard  to duration  of  treatment  and  assessment  time  points,  blinding  (double-blind  [PSZ-3001  and  3003]  or open-label [PSZ-3002]), control (placebo [PSZ-3001] or active [PSZ-3003]) and dosing regimen (fixed [PSZ-3001] or flexible dose of paliperidone ER [PSZ-3003 and 3002]). Diagnosis of schizophrenia was made according to the DSM-IV at least 1 year before screening.

Given the study designs were not the same and considering the additional assumptions that have to be made to conduct a meta-analysis, the CHMP considered highly questionable whether the meta-analysis of these studies was valid and meaningful and whether it provided valid information beyond the single studies.

The change from baseline in the PANSS total score at endpoint was the primary efficacy variable in studies PSZ-3001, PSZ-3003 and PSZ-3002 (exploratory only). Secondary endpoints included changes from baseline to endpoint in CGI-S score, CGAS score and Sleep VAS (only PSZ-3001) and PSP score (only  PSZ-3003).  The  choice  of  primary  and  secondary  endpoints  was  considered  adequate  by  the CHMP. No cognitive endpoint was included with the exception of the Cognitive Assessment Battery of Tests  which  was  performed  on  an  exploratory  basis  in  the  open-label  study  PSZ-3002.  Additional analyses  such  as  responder  rate,  change  from  baseline  in  PANSS  Factor  and  Subscale  Scores  were undertaken and underline the clinical meaningfulness of these endpoints.

Studies PSZ-3001 and PSZ-3003 included a total of 18 European patients.

## Study PSZ-3001

There was one major protocol amendment prior study enrolment. This was related to the study design with the objective of testing the entire range of effective doses of paliperidone ER in adults (3-12mg) as  well  as  a  lower  dose  (1.5mg)  to  determine  the  least  effective  dose.  Weight  based  doses  were chosen to minimize the risk of exposing lower weight adolescents (≥ 29 kg and &lt; 51 kg) to high doses of  paliperidone  ER  and  higher  weight  adolescents  (≥  51  kg)  to  too  low  of  a  dose,  considering  that lower-weight subjects could have nearly double the drug exposure of higher-weight subjects on the basis of available PK data from PSZ-1001. However with this approach, efficacy data are missing for the 3 mg dose in patients weighing ≥51 kg and for the 12 mg dose in patients weighing &lt; 51 kg.

The time pattern for total number of withdrawals was similar for all groups up to day 21 when higher withdrawal rate in the placebo group and to a lower extent in the paliperidone ER Low group became apparent. This is the time point where subjects could enter the open label phase study (PSZ-3002) and thus  this  finding  may  be  expected.The  rate  of  withdrawals  in  the  paliperidone  ER  low  group  had  a higher number of withdrawals due to Lack of Efficacy (26%) than the other dose groups.  A total of 29% withdrew from the study and of those 17% from the paliperidone ER medium treatment group withdrew. The study duration was short and the withdrawal rate was high. The study was conducted all over  the  world  with  a  very  limited  number  of  patients  from  the  EU.  Only  10  patients  (5%)  from Romania were included. Overall baseline disease severity as measured by PANSS total score and CGI-S

<div style=\"page-break-after: always\"></div>

score was comparable across all arms but the paliperidone ER group Medium had fewer subjects with moderate CGI-S score(n=19, 40%) and more subjects with high CGI-S scores than the other groups.

Taking the improvements over time observed in the placebo completers and the high drop-out rate in the placebo group into account, the LOCF analysis was not necessarily conservative. The pre-specified sensitivity  analyses  are  acknowledged;  in  particular,  the  MMRM  analysis  is  considered  relevant. However, the clinical interpretation of the worst-rank analysis is difficult as this analysis 'mixes' effects on the variables 'change in PANSS total score' and 'time to treatment discontinuation due to lack of efficacy', whereby the clinical relevance of the latter is questionable, particularly since no clear criteria to determine lack of efficacy seemed to have been applied. It is generally recommended to minimize the occurrence of missing data in a clinical trial; therefore allowing discontinuation of study for lack of efficacy  in  the  protocol  may  be  considered  as  an  issue.  The  CHMP  noted  that  the  recommended criterion  for  lack  of  efficacy  in  the  study  protocol  was  an  increase  of  20%  in  PANSS  total  score; however,  the  mean  increase  for  the  drop-outs  in  the  placebo  group  was  actually  lower  (9%).  The pattern of PANSS total scores for patients who dropped out due to lack of efficacy was found to be different from those who completed the study, supporting that lower efficacy was indeed observed at drop-out  time  .  Consequently,  the  CHMP  considered  the  worst-case  analysis  as  conservative.  The patterns of PANSS total scores for patients who dropped out due to lack of efficacy suggested that the PANSS  total  scores  were  not  temporarily  but  continuously  increased  for  most  of  these  patients, meaning that the imputation of the best value leads to an overestimation of the placebo effect. In the best observation carried forward analysis, the treatment effects were generally lower compared to the primary  analysis,  which  is  explained  by  a  higher  drop-out  rate  in  the  placebo  group,  leading  to  a conservative analysis. A significant treatment effect was however found for the medium dose group (&lt;51 Kg: 3 mg/day; ≥51 Kg:6 mg/day) but not for the high (&lt;51 Kg:6 mg/day; ≥51 Kg:12 mg/day) and the low (1.5 mg/day) dose group, which was consistent with the primary analysis.

## Studies PSZ-3003 and PSZ-3002

In study PSZ-3003, the age distribution was not homogenous as across the treatment groups 12-14 year olds were only accounted for about 1/3 of the study population.  Baseline disease severity was similar across the groups.. The LS Mean Change from baseline on PANSS total score decreases up to day 140 and then increases in both treatment groups at day 182. According to the MAH, this finding was due to the only subject enrolled in Slovakia and an analysis excluding this subject was performed showing  continuous  decrease  through  day  182  in  both  treatment  groups.  Since  consistent  findings were  observed  when  including  this  patient  and  the  region  as  a  factor  (instead  of  country)  in  the ANCOVA  analysis,  this  explanation  was  considered  plausible  by  the  CHMP.  A  total  of  15  European patients were recruited.

In study PSZ-3002, the design was open label without any comparator or placebo thus making difficult the assessment of the magnitude of treatment effect. The efficacy data for this study were considered exploratory only.Although the withdrawal rate was high with a total of 55% completing study of which 184 completed the two years which means a total of 46% completed the total two year study.  This is however not unexpected in this population as the study had a long duration.  Seventy-three (73%) of subjects were 15 years and older. Only 10 European patients were included.

## Efficacy data and additional analyses

## Study PSZ-3001

Results  indicated  that  the  study  achieved  its  primary  objective  by  demonstrating  that  at  least  one paliperidone ER weight-based group was statistically superior to placebo in improving the symptoms of schizophrenia  as  measured  by  the  change  in  PANSS  total  score  from  baseline  to  endpoint  (LOCF analysis).

<div style=\"page-break-after: always\"></div>

Only the medium paliperidone ER weight-based group (&lt;51 Kg: 3 mg/day; ≥51 Kg: 6 mg/day) was statistically  superior  to  placebo  in  improving  the  symptoms  of  schizophrenia  as  measured  by  the change  in  PANSS  total  score  from  baseline  to  endpoint  (p=0.006).  The  paliperidone  ER  Low (1.5mg/day)  and  High  (&lt;51  Kg:  6  mg/day;  ≥51  Kg:  12  mg/day)  groups  did  not  show  statistical significance in comparison to placebo on the primary endpoint (p= 0.508 and 0.086, respectively).

The analysis across weight categories indicated that for adolescents &lt; 51 kg, only the medium dose group (3 mg) separated from placebo whereas for adolescent ≥ 51 kg , the medium (6mg)  and high dose groups (12 mg) separated from placebo.

The consistency of the treatment effect across the body weight categories was explored by including the  treatment-by-baseline  body  weight  interaction  in  the  model  used  for  primary  analysis.  This interaction  was  significant  at  the  pre-specified  10%  level  (p=0.08),  possibly  indicating  inconsistent treatment effects across body weight categories.

These  findings  further  supported  the  need  for  weight  based  dosing  recommendation  (see  below justification for the dose).

Efficacy  analyses  of  the  secondary  endpoints  including  CGI-S,  CGAS,  sleep  VAS  and  PANSS  factor scores were consistent with the findings of the primary efficacy analysis. The results for the responder rates  (≥20  and  30  %)  support  the  clinical  relevance  of  the  primary  endpoint.  As  with  the  primary efficacy  endpoint  the  medium  dose  treatment  group  performed  the  best.  The  CHMP  noted  that  this completion  rate  was  higher  than  the  rates  in  the  6-week  studies  in  adults  (range  43  to  66%).The proportion of subjects who completed the study was higher in the 3 mg (81%), 6 mg (82%), and 12 mg (77%) dose groups  than  in  the  1.5  mg  dose  group  (65%)  and  the  placebo  group  (51%).  The proportion of subjects who were withdrawn due to lack of efficacy was higher in the placebo group (39%) and 1.5 mg dose group (26%) than in the other paliperidone ER dose groups (ranging from 0% in the 3 mg dose group to 9% in the 6 mg dose group).

Post-hoc analyses by actual dose received by the subjects showed statistically significant improvement relative to placebo in the PANSS total scores at endpoint (LOCF) for the paliperidone ER 3, 6, and 12 mg dose groups. However, no clear dose response pattern was observed, which might be due to the low  number  of  patients  in  the  3  mg  dose  group  (n=16).  The  difference  of  LS  mean  changes  from baseline to endpoint was -11.5, -6.8, and -9.0, respectively; nominal p values of 0.016, 0.044, and 0.014,  respectively,  with  no  multiplicity  adjustment.  Results  in  the  1.5  mg  dose  group  were  not statistically significant (difference of LS means of -2.1; p=0.507). The changes in mean PANSS total score from baseline to endpoint for the 3 mg actual dose groups were comparable to those observed in studies  in  the  adult  population  (-11.1  for  the  3mg  dose  for  the  pooled  data  of  the  three  6  week placebo-controlled studies [R076477-SCH-303, 304 and 305] in adults). However, the effect sizes of the 6mg and the 12 mg actual dose groups were less comparable (-11.0 for the 6 mg and -14.5 for the 12  mg  dose  groups  in  the  pooled  adult  studies).  The  higher  placebo  response  in  adolescents(-7.9 versus -4.8) that has been also described in the literature may be associated with such findings. The improvement in the paliperidone ER Medium group achieved statistical significance compared to the paliperidone ER Low group (p = 0.014). The differences between the paliperidone ER High and Medium group  or  High  and  Low  group  did  not  achieve  statistical  significance  (p  =  0.289  and  p  =  0.170, respectively).

Similarly to the overall study results, the medium dose group showed better improvement in PANSS total score in all analysed subgroups : (a) &lt;15 yrs/&lt;51kg, (b) &lt;15 yrs/≥ 51 kg, (c) ≥ 15 yrs/&lt;51 kg, and (d) ≥15 yrs/≥51 kg (see Tables 32-33).  Among patients between 12-14 years and patients &lt;51 kg, a better improvement in PANSS total score compared to placebo was observed only in  the medium (3 mg) dose group, while a better dose-improvement trend was observed in patients 15-17 years old

<div style=\"page-break-after: always\"></div>

or patients ≥51kg (See Tables 30-31). However the relatively small proportion of patients aged 12-14 years is of concern to conclude on these efficacy findings. In addition, the effect on the PANSS total score was considered weaker in this population, in the medium dose group, the difference of LS mean changes from baseline to endpoint was -15.5 in patients aged 12-14 years and -18.1 in patients aged 15-17 years, respectively.

Based  on  additional  ANCOVA  and  regression  analyses,  the  treatment  response  was  claimed  to  be independent of age when body weight was taken into account. However, as the sample sizes are even smaller  in  these  subgroups,  these  comparisons  should  be  only  taken  into  account  as  exploratory findings.

## Study PSZ-3003

This study provided maintenance data over 26 weeks. However, it did not meet its primary objective, i.e.  paliperidone  ER  did  not  demonstrate  superior  efficacy  compared  to  aripiprazole.  Nevertheless, robust  and  clinically  meaningful  reductions  (ie,  improvements)  in  mean  PANSS  total  score  from baseline  to  endpoint  acute  (Day  56,  LOCF)  in  the  paliperidone  ER  (-19.3)  and  aripiprazole  (-19.8) groups  were  observed.  The  confidence  interval  of  the  difference  between  the  two  groups  excluded larger changes than 3.8 to the advantage of aripiprazole. This finding cannot be considered a clinically relevant difference between the two treatments and therefore the study could only be interpreted as showing non inferiority.  The changes from baseline for aripiprazole are of a similar magnitude as in previous studies in a paediatric population, and for paliperidone ER in the same magnitude as in study 3001. A PP analysis was provided and was found consistent with the ITT analysis, with a larger upper bound  of  the  95%  CI  (4.38  versus  3.76).  In  the  absence  of  adequate  justification  for  the  assay sensitivity in study PSZ-3003, the CHMP considered that non inferiority conclusions could not be fully claimed based on this study.

The analyses of the secondary efficacy endpoints were consistent with the findings from the primary efficacy  analyses.  The  results  indicated  that  paliperidone ER  and  aripiprazole  had  similar  treatment effects  with  regard  to  decreasing  the  PANSS  total  scores  over  the  26-week  period.  The  mean  (SD) decrease in PANSS  total score from baseline to endpoint (Day 182)  was  -25.6 (16.88) for paliperidone ER  and  -26.8  (18.82)  for  aripiprazole.  From  endpoint  acute  (Day 56)  to  endpoint (Day 182), over 50% of the subjects in both treatment groups remained clinically stable. Comparable long-term improvements by Day 182 for paliperidone ER and aripiprazole treatments were noted with regard to the change from baseline to endpoint (Day 182) for the CGI-S score and in the PSP scale. In addition,  there  was  no  statistical  significant  differences  in  responder  rates  (paliperidone:  76%, aripiprazole:  81.6%,  p=0.444).  However  it  is  difficult  to  draw  any  conclusions  on  the  magnitude  of difference since no confidence intervals have been presented. Furthermore, at least 75% of subjects completed the 26-week study in both groups and the withdrawal rates due to lack of efficacy were low (4% for paliperidone and 10% for aripiprazole). The longitudinal analysis using MMRM performed on the observed-case data and the worst-rank analysis corroborated the findings from the LOCF analysis. An analysis using the per-protocol analysis set (excluding subjects who had major protocol deviations from the ITT analysis set) was also conducted as a sensitivity analysis for the primary analysis. Results from this analysis were consistent with the ITT analysis.

In subgroup analyses, concerning the primary study endpoint related to change in PANSS total score, similar  results  were  obtained  in  age  and  weight  groups,  at  day  56  comparing  aripiprazole  and paliperidone treated patients.  Similarly to the short term efficacy, the maintenance of the effect on the PANSS  total  score  was  considered  weaker  in  this  population  in  the  paliperidone  ER  group,  the difference of LS mean changes from baseline to endpoint was -17.5 in patients aged 12-14 years and 20.1  in  patients  aged  15-17  years,  respectively.  However,  slightly  better  results  for  aripiprazole treatment  compared  to  paliperidone  in  subjects  aged  between  12-14  years,  15-17  years  and subjects≥51 kg were observed in maintaining clinical stability over 26 weeks (see Tables 34-35).

<div style=\"page-break-after: always\"></div>

## Study PSZ-3002

Improvement in the PANSS total scores were observed during the first  3 months  of  the  open-label treatment in all 3 treatment groups. The improvements in PANSS total scores observed during the first 3 months were maintained during the remaining portion of the study. The subjects who entered the open label study directly without prior participation in PSZ-3001 and those who rolled over from the placebo  arm  in  study  PSZ-3001  showed  a  greater  decrease  from  baseline  in  PANSS  total  score compared to those rolling over from the active treatment arms. This is probably due to a higher open label baseline PANSS total score, and therefore expected. All groups seem to converge towards similar levels  in  PANSS  total  score  over  time.  The  primary  efficacy  variable  for  the  exploratory  secondary objective was the change from open-label baseline to open-label endpoint in the PANSS total score. The efficacy analysis was based on the ITT analysis set which comprised of 393 subjects. There were mean decreases in PANSS total scores (indicating improvement) after administration of paliperidone ER from open-label baseline to open-label endpoint, the highest means (SD) change (-22.4 [22.25]) was noted in the Paliperidone (NO DB)/Paliperidone treatment group and the lowest change (-12.6 [19.92]) was noted in the Paliperidone (DB)/Paliperidone treatment group. The mean (SD) change in PANSS total  score  from  double-blind  baseline  to  open-label  endpoint  was  slightly  higher  in  the  Paliperidone (DB)/Paliperidone treatment group (-27.5 [19.09]) than in the Placebo/Paliperidone treatment group (25.7 [16.01]).Other efficacy analyses including the CGI-S, CGAS, sleep VAS, and PANSS factor scores corroborated the findings of the primary efficacy variable. Small improvements in performance on tests of cognitive function were observed in all groups from open-label baseline to the 6-month time point for  most  domains.  These  data  are  supportive  that  the  clinical  efficacy  of  paliperidone  ER  continues beyond 6 weeks and is maintained with long-term therapy up to two years.

According  to  the  Schizophrenia  Guideline  (EMA/CHMP/40072/2010  Rev.1),  data  on  maintenance  of effect may be extrapolated from adults to adolescents as of the age of 15 years. The overall data to support  extrapolation  of  long-term  efficacy  from  12  years  onwards  were  not  considered  to  be sufficient.  Subgroup  analyses  based  on  age  and  weight  did  not  reveal  any  significant  difference  in improvement in PANSS during the course of 2 year treatment. However, among younger adolescents a lower  percentage  of  subjects  who  maintained  a  30%  PANSS  response  over  time  was  observed compared to patients in 15-17 years. No difference was observed between weight groups (See Figures 20-23).Hence  the  CHMP  maintains  its  previous  conclusion  that  the  maintenance  of  the  efficacy  in patients younger than 15 years remains to be established.

## Overall discussion on efficacy

Following the CHMP concerns over the lack of sufficient evidence of short term and long term efficacy in  subjects  aged  between  12-14  years,  the  MAH  proposed  to  restrict  the  proposed  indication  to treatment  of  schizophrenia  in  adolescents  15  years  and  older.  As  discussed  above,  better  doseimprovement  trend  in  PANSS  total  score  was  observed  in  patients  15-17  years  old.  In  addition, consistent efficacy findings were observed for the subgroup analyses (≥15 years, ≥51 kg and &lt;51 kg) provided at the CHMP request on the secondary efficacy endpoints of particular clinical relevance. To provide further supporting evidence for the short term efficacy in the 15 to 17 year age range, the MAH repeated the ANCOVA analysis for the primary and secondary efficacy variables in the placebo controlled study (PSZ-3001) in the 15 to 17 year subgroup. Statistically significant differences versus placebo were observed in both the Medium (&lt;51 Kg: 3 mg/day; ≥51 Kg: 6 mg/day, p=0.005) and High  (&lt;51  Kg:  6  mg/day;  ≥51  Kg:  12  mg/day,  p=0.012)  dose  groups  of  paliperidone  ER  for  the primary  endpoint  (change  from  baseline  to  endpoint  in  PANSS  total  score).  According  to  the  MAH, these results are more robust than those observed for the total population (12 to 17 years), which only

<div style=\"page-break-after: always\"></div>

showed  a  statistically  significant  difference  versus  placebo  for  the  Medium  dose  level  (&lt;51  Kg:  3 mg/day; ≥51 Kg: 6 mg/day,).

Taking  into  account  the  overall  short  term  and  long  term  efficacy  data  (as  discussed  above)  and additional subgroup analyses provided for the 15 to 17 year subgroup, the CHMP considered there was sufficient  evidence  to  support  the  efficacy  of  paliperidone  ER  in  the  treatment  of  schizophrenia  in patients 15 years and older.

## Justification of the dose

According to the MAH, results from the double-blind placebo-controlled study PSZ-3001 established the efficacy  of  paliperidone  ER  in  improving  the  symptoms  and  severity  of  schizophrenia  compared  to placebo based on the primary analysis of weight-based dose groups. Analyses by actual dose received indicated  efficacy  across  the  dose  range  of  3  to  12  mg/day,  with  3  mg/day  being  the  minimum effective dose; whereas no statistical separation from placebo was demonstrated for the 1.5 mg for any of the efficacy variables. Only the medium dose group comprising the doses of 3 mg and 6 mg (for adolescents &lt; 51 kg and ≥ 51 kg, respectively) was efficacious from a strict interpretation viewpoint, as the high dose group (&lt;51 Kg: 6 mg/day; ≥51 Kg: 12 mg/day) was not statistically significantly different  from  placebo  (p=0.086).  Post-hoc  analysis  by  actual  dose  group  indicated  that  there  is  a treatment effect of paliperidone ER in the dose range of 3 mg to 12 mg/day.

From the CHMP viewpoint, no clear dose-response pattern was identified with respect to efficacy for the  primary  endpoint  for  the  paliperidone  ER  3,  6  and  12  mg  dose  groups  (difference  of  LS  mean changes from baseline to endpoint of -11.5, -6.8, and -9.0, respectively; nominal p values of 0.016, 0.044, and 0.014, respectively). This might be due to the low number of patients in the 3 mg dose group (n=16). The improvement in the paliperidone ER Medium group achieved statistical significance compared to the paliperidone ER Low group (p = 0.014). The differences between the paliperidone ER High and Medium group or High and Low group did not achieve statistical significance (p = 0.289 and p = 0.170, respectively). A statistically significant dose-response relationship was found using a linear trend  test  and  the  non-parametric  Jonckhere-Terpstra  trend  test  (post-hoc  analyses).  However, considering the observed responses for the actual dose groups, a (linear) trend in the dose-response relationship appears unlikely, i.e. the fit of the linear model to describe the dose-response relationship is probably poor. The statistical significance of the trend tests is most likely driven by the differences between the placebo group/low dose group and the higher dose groups, but there is no clear evidence of a dose-response relationship for the higher doses 3, 6 and 12mg.  Overall, the number of patients in the lower age group (the only one that received the 3 mg) was only around one quarter of the whole study population and data in this subpopulation are very limited. On this basis and considering the PK findings suggesting a dependence of paliperidone clearance on the patient's body weight (see 2.3.4), the  CHMP  considered  that  the  proposed  dose  ranging  (3  to  12  mg/day)  was  not  adequate  for  the lower-weight patients, although the efficacy results were overall consistent with the adult data. This is not only due to the efficacy data but also due to the safety data where a clear dose-response pattern was observed for several safety parameters including common adverse events (somnolence, akathisia, tremor,  and  dystonia);  EPS  related  adverse  events  (hyperkinesia,  dystonia,  and  tremor)  and associated use of anticholinergic medications; and mean increases in body weight and BMI (see 2.5.7). Regarding patients older than 15 years and ≥ 51 kg, the CHMP was of the opinion that the proposed dose range (3 to 12 mg/day) could be considered since these patients are more likely to have similar PK  profile  than  in  adults.  To  address  the  dosing  concern  over  the  lower  weight  patients,  the  MAH proposed to revise the initial dosing recommendation by setting a lower maximum recommended dose of 6 mg for children weighing &lt;51 kg instead of 12 mg. The maximum recommended dose for children weighing ≥ 51 kg was proposed to be maintain ed at 12 mg, similarly to the adult population. Given an individual dose titration strategy was supported by PK/PD data, the CHMP agreed with the proposed

<div style=\"page-break-after: always\"></div>

revised posology. Taking into account the pharmacokinetic profile of the product (prolonged release formulation) and the available efficacy data on the 1.5 mg dose of paliperidone ER, a lower increasing increment of 1.5 mg was not considered beneficial in the intended population.

## Relevance of the data in the EU population

According to the MAH, difficulties were encountered in enrolling subjects from the EU in Study PSZ3001 due to the use of a placebo control. Enrolment of subjects into Study PSZ-3003 from the EU was also difficult as the active control (aripiprazole) was already approved for use in adolescents within the EU  and  is  often  used  as  a  first  line  treatment.  This  accounted  for  the  relatively  low  proportion  of subjects from the EU in the Phase 3 studies. There were only 5% and 6.6% of subjects enrolled from EU  countries  in  PSZ-3001  and  PSZ-3003,  respectively.  In  the  long-term,  open-label  safety  and tolerability study PSZ-3002, 19.8% of subjects were from the EU countries.

On  the  other  hand  comparative  data  with  respect  to  baseline  characteristics  and  pre-treatment patterns in US/EU versus non-EU/non-US were presented.  Overall, it can be concluded that subject population  in  paliperidone  ER  studies  could  be  considered  to  be  representative  of  the  adolescent schizophrenia  population  in  Europe.  Subjects  in  the  US  were  generally  heavier  in  comparison  with subjects from Asia and Eastern Europe but subjects with heavier body weight ( ≥ 51 kg) showed similar or  slightly  better  efficacy  compared  to  those  with  lighter  body  weight  (&lt;51  kg)  and  there  were  no apparent differences with regard to safety findings between the 2 weight subgroups. Even though a higher proportion of subjects from  EU/US  than  those  from  non-EU/non-US  received  atypical antipsychotics, the most frequently used atypical or typical antipsychotics were similar. Overall, it can be accepted that the data from the 3 paliperidone ER studies are applicable to the adolescent patients in Europe.

## 2.4.7. Conclusions on the clinical efficacy

Overall, the CHMP concluded that the efficacy (short term and maintenance of the effect) of Invega for the treatment of schizophrenia in 15 years and older has been sufficiently demonstrated.

## 2.5. Clinical safety

The  safety  of  paliperidone  ER  in  the  treatment  of  schizophrenia  in  children  and  adolescents  was evaluated in the clinical studies that were already discussed in the clinical efficacy: PSZ-3001, PSZ3002, PSZ-3003 and PSZ-1001. No pooled data have been provided due to a different study design for these studies.

Known safety issues with paliperidone are extrapyramidal side effects (EPS), glucose related adverse events,  potentially  prolactin  levels  as  well  as  other  adverse  events  of  special  interest  such  as suicidality,  aggression,  agitation,  somnolence,  sedation,  seizures,  convulsions,  neuroleptic  malignant syndrome (NMS), sexual maturation, weight gain and cardiac events.

Subjects with a history or presence of significant cardiac events/diseases and endocrine diseases were excluded from the studies.

## 2.5.1. Patient exposure

In total, 545 adolescent subjects with schizophrenia received at least 1 dose of paliperidone ER during the three Phase III studies. The mean duration of exposure to paliperidone ER for these subjects was 379.4 days. Data are presented in Tables 36 and 37.

<div style=\"page-break-after: always\"></div>

Table 36: Cumulative Frequency Distribution of Duration (Days) of Exposure to Study Drug (PSZ-3003).

| Duration Days   | Paliperidone ER (N=113) n (%)   | Aripiprazole (N=114) n (%)   |
|-----------------|---------------------------------|------------------------------|
| ≥1 day          | 113 (100)                       | 114 (100)                    |
| ≥15 days        | 111 (98)                        | 112 (98)                     |
| ≥29 days        | 109 (96)                        | 107 (94)                     |
| ≥57 days        | 99 (88)                         | 98 (86)                      |
| ≥99 days        | 93 (82)                         | 95 (83)                      |
| ≥141 days       | 87 (77)                         | 90 (79)                      |
| ≥180 days       | 75 (66)                         | 80 (70)                      |

Exposure days on drug only.

Table 37: Cumulative Frequency Distribution of Duration (Days) of Paliperidone ER Exposure - Double - Blind and Open-Label Studies (PSZ-3001/PSZ-3002).

| Duration Days   | Placebo/Pali (N=39) n (%)   | Pali (DB)/Pali (N=118) n (%)   | Pali (NO DB)/Pali (N=243) n (%)   | Pali/NO OL (N=32) n (%)   | Total (N=432) n (%)   |
|-----------------|-----------------------------|--------------------------------|-----------------------------------|---------------------------|-----------------------|
| ≥1 days         | 39 (100)                    | 118 (100)                      | 243 (100)                         | 32 (100)                  | 432 (100)             |
| ≥31 days        | 35 (90)                     | 118 (100)                      | 220 (91)                          | 16 (50)                   | 389 (90)              |
| ≥61 days        | 32 (82)                     | 115 (97)                       | 205 (84)                          | 0                         | 352 (81)              |
| ≥91 days        | 31 (79)                     | 111 (94)                       | 198 (81)                          | 0                         | 340 (79)              |
| ≥ 121 days      | 30 (77)                     | 107 (91)                       | 192 (79)                          | 0                         | 329 (76)              |
| ≥ 151 days      | 27 (69)                     | 104 (88)                       | 180 (74)                          | 0                         | 311 (72)              |
| ≥181 days       | 27 (69)                     | 101 (86)                       | 170 (70)                          | 0                         | 298 (69)              |
| ≥211 days       | 22 (56)                     | 95 (81)                        | 159 (65)                          | 0                         | 276 (64)              |
| ≥241 days       | 22 (56)                     | 77 (65)                        | 156 (64)                          | 0                         | 255 (59)              |
| ≥271 days       | 21 (54)                     | 77 (65)                        | 147 (60)                          | 0                         | 245 (57)              |
| ≥301 days       | 21 (54)                     | 76 (64)                        | 147 (60)                          | 0                         | 244 (56)              |
| ≥331 days       | 21 (54)                     | 76 (64)                        | 146 (60)                          | 0                         | 243 (56)              |
| ≥361 days       | 21 (54)                     | 76 (64)                        | 142 (58)                          | 0                         | 239 (55)              |
| ≥391 days       | 21 (54)                     | 73 (62)                        | 142 (58)                          | 0                         | 236 (55)              |
| ≥451 days       | 21 (54)                     | 72 (61)                        | 134 (55)                          | 0                         | 227 (53)              |
| ≥511 days       | 20 (51)                     | 68 (58)                        | 128 (53)                          | 0                         | 216 (50)              |
| ≥571 days       | 20 (51)                     | 66 (56)                        | 124 (51)                          | 0                         | 210 (49)              |
| ≥631 days       | 20 (51)                     | 64 (54)                        | 115 (47)                          | 0                         | 199 (46)              |
| ≥691 days       | 19 (49)                     | 59 (50)                        | 108 (44)                          | 0                         | 186 (43)              |
| ≥ 731 days      | 11 (28)                     | 58 (49)                        | 40 (16)                           | 0                         | 109 (25)              |

Table includes subjects who were exposed to the drug in PSZ-3001 but not in PSZ-3002

## 2.5.2. Adverse events

Data are presented in Tables 38 -40.

<div style=\"page-break-after: always\"></div>

Table 38: PSZ-3001- Treatment emergent adverse events (TEAEs) in at least 5% of Subjects in any dose group

| BodySystemorOrgan Class                      | Placebo (N=51)   | Pali ER 1.5 mg (N=54)   | Pali ER 3 mg (N=16)   | Pali ER 6mg (N=45)   | Pali ER 12 mg (N=35)   | Total Paliperidone (N=150)   |
|----------------------------------------------|------------------|-------------------------|-----------------------|----------------------|------------------------|------------------------------|
| Dictionary-Derived Term                      | n (%)            | n (%)                   | n (%)                 | n (%)                | n (%)                  | n (%)                        |
| Total no.subjects with adverse events        | 30 (58.8)        | 27 (50.0)               | 8 (50.0)              | 30 (66.7)            | 27 (77.1)              | 92 (61.3)                    |
| Ner'voussystemdisorder's                     | 6 (11.8)         | 14 (25.9)               | 7 (43.8)              | 16 (35.6)            | 23 (65.7)              | 60 (40.0)                    |
| Somnolence                                   | 1 (2.0)          | 3 (5.6)                 | 2 (12.5)              | 6 (13.3)             | 9 (25.7)               | 20 (13.3)                    |
| Akathisia                                    | 0                | 2 (3.7)                 | 1 (6.3)               | 5 (11.1)             | 6 (17.1)               | 14 (9.3)                     |
| Headache                                     | 2 (3.9)          | 5 (9.3)                 | 1(6.3)                | 2 (4.4)              | 5 (14.3)               | 13 (8.7)                     |
| Tremor                                       | 0                | 1(1.9)                  | 1 (6.3)               | 3 (6.7)              | 4 (11.4)               | 9 (6.0)                      |
| Dystonia                                     | 0                | 1 (1.9)                 | 0                     | 2 (4.4)              | 3 (8.6)                | 6 (4.0)                      |
| Cogwheel rigidity                            | 0                | 0                       | 0                     | 0                    | 4 (11.4)               | 4(2.7)                       |
| Dizziness                                    | 0                | 1(1.9)                  | 1 (6.3)               | 1(2.2)               | 1(2.9)                 | 4(2.7)                       |
| Dyskinesia                                   | 0                | 1(1.9)                  | 1 (6.3)               | 1 (2.2)              | 1(2.9)                 | 4(2.7)                       |
| Extrapyramidal disorder                      | 0                | 0                       | 1(6.3)                | 0                    | 0                      | 1(0.7)                       |
| Psychiatricdisorders                         | 18 (35.3)        | 12 (22.2)               | 1(6.3)                | 6 (13.3)             | 9 (25.7)               | 28 (18.7)                    |
| Insomnia                                     | 11 (21.6)        | 5 (9.3)                 | 1 (6.3)               | 3 (6.7)              | 5 (14.3)               | 14 (9.3)                     |
| Schizophrenia                                | 4 (7.8)          | 6 (11.1)                | 0                     | 1(2.2)               | 2 (5.7)                | 9 (6.0)                      |
| Agitation                                    | 2 (3.9)          | 3 (5.6)                 | 0                     | 1(2.2)               | 0                      | 4(2.7)                       |
| Anxiety                                      | 2 (3.9)          | 0                       | 0                     | 1(2.2)               | 3 (8.6)                | 4 (2.7)                      |
| Gastrointestinal disorder's                  | 10 (19.6)        | 2 (3.7)                 | 3 (18.8)              | 7 (15.6)             | 5 (14.3)               | 17 (11.3)                    |
| Vomiting                                     | 5 (9.8)          | 0                       | 1 (6.3)               | 5 (11.1)             | 1(2.9)                 | 7 (4.7)                      |
| Nausea                                       | 6 (11.8)         | 0                       | 0                     | 1(2.2)               | 3 (8.6)                | 4(2.7)                       |
| Salivary hypersecretion                      | 0                | 1(1.9)                  | 1(6.3)                | 1(2.2)               | 0                      | 3 (2.0)                      |
| Gastritis                                    | 0                | 0                       | 1 (6.3)               | 0                    | 0                      | 1(0.7)                       |
| Mallory-Weiss syndrome                       | 0                | 0                       | 1(6.3)                | 0                    | 0                      | 1(0.7)                       |
| Infections and infestations                  | 4 (7.8)          | 5 (9.3)                 | 1 (6.3)               | 4 (8.9)              | 1(2.9)                 | 11 (7.3)                     |
| Pharyngitis                                  | 0                | 0                       | 1 (6.3)               | 0                    | 0                      | 1(0.7)                       |
| Investigations                               | 3 (5.9)          | 6 (11.1)                | 1 (6.3)               | 1 (2.2)              | 1 (2.9)                | 9 (6.0)                      |
| Weight increased                             | 0                | 4(7.4)                  | 1 (6.3)               | 1 (2.2)              | 1 (2.9)                | 7 (4.7)                      |
| Cardiac disorder's                           | 0                | 0                       | 1(6.3)                | 4 (8.9)              | 2 (5.7)                | 7 (4.7)                      |
| Tachycardia                                  | 0                | 0                       | 1(6.3)                | 3 (6.7)              | 2 (5.7)                | 6 (4.0)                      |
| Reproductivesystemand breast disorder's      | 0                | 0                       | 1(6.3)                | 2 ( 4.4)             | 1 (2.9)                | 4 (2.7)                      |
| Amenorrhoea                                  | 0                | 0                       | 1 (6.3)               | 0                    | 0                      | 1(0.7)                       |
| Dysmenorrhoea                                | 0                | 0                       | 1(6.3)                | 0                    | 0                      | 1(0.7)                       |
| Metabolismandnutritiondisorder's             | 3 (5.9)          | 1(1.9)                  | 0                     | 0                    | 1(2.9)                 | 2 (1.3)                      |
| Decreased appetite                           | 3 (5.9)          | 1(1.9)                  | 0                     | 0                    | 0                      | 1(0.7)                       |
| Injuy,poisoning and procedural complications | 1 (2.0)          | 0                       | 1(6.3)                | 0                    | 0                      | 1(0.7)                       |
| Wound                                        | 0                | 0                       | 1 (6.3)               | 0                    | 0                      | 1(0.7)                       |

Source:Mod5.3.5.1PSZ-3001Table 34

Note: Incidence is based on the number of subjects experiencing at least one AE, not the number of events.

Adverse events are coded using MedDRA Version 11.0.

Pali=paliperidone

<div style=\"page-break-after: always\"></div>

Table 39: PSZ-3002- TEAEs in at least 5% of Subjects in any dose group

|                                              | Placebo/Pali   | Pali (DB)/Pali   | Pali (NO DB)/Pali   | Total      |
|----------------------------------------------|----------------|------------------|---------------------|------------|
| BodySystemor Organ Class                     | (N=39)         | (N=118)          | (N=243)             | (N=400)    |
| Dictionary-derived Term                      | n (%)          | n (%)            | n (%)               | n (%)      |
| Total no.subjectswithadverseevents           | 32 (82.1)      | 88 (74.6)        | 221 (90.9)          | 341 (85.3) |
| Nervoussystemdisorders                       | 15 (38.5)      | 52 (44.1)        | 161 (66.3)          | 228 (57.0) |
| Somnolence                                   | 10 (25.6)      | 18 (15.3)        | 45 (18.5)           | 73 (18.3)  |
| Headache                                     | 4 (10.3)       | 9 (7.6)          | 46 (18.9)           | 59 (14.8)  |
| Akathisia                                    | 0              | 10 (8.5)         | 42 (17.3)           | 52 (13.0)  |
| Tremor                                       | 1 (2.6)        | 12 (10.2)        | 31 (12.8)           | 44 (11.0)  |
| Dizziness                                    | 4 (10.3)       | 8 (6.8)          | 13 (5.3)            | 25 (6.3)   |
| Dystonia                                     | 1 (2.6)        | 6 (5.1)          | 14 (5.8)            | 21 (5.3)   |
| Psychiatricdisorders                         | 14 (35.9)      | 35 (29.7)        | 120 (49.4)          | 169 (42.3) |
| Insomnia                                     | 7 (17.9)       | 11 (9.3)         | 40 (16.5)           | 58 (14.5)  |
| Schizophrenia                                | 7 (17.9)       | 12 (10.2)        | 31 (12.8)           | 50 (12.5)  |
| Suicidal ideation                            | 0              | 0                | 34 (14.0)           | 34 (8.5)   |
| Anxiety                                      | 4 (10.3)       | 7 (5.9)          | 15 (6.2)            | 26 (6.5)   |
| Infections and infestations                  | 11 (28.2)      | 28 (23.7)        | 77 (31.7)           | 116 (29.0) |
| Nasopharyngitis                              | 3 (7.7)        | 18 (15.3)        | 32 (13.2)           | 53 (13.3)  |
| Gastrointestinal disorder's                  | 4 (10.3)       | 20 (16.9)        | 83 (34.2)           | 107 (26.8) |
| Salivary hypersecretion                      | 2 (5.1)        | 9 (7.6)          | 22 (9.1)            | 33 (8.3)   |
| Nausea                                       | 1 (2.6)        | 3 (2.5)          | 27 (11.1)           | 31 (7.8)   |
| Vomiting                                     | 0              | 3 (2.5)          | 23 (9.5)            | 26 (6.5)   |
| Investigations                               | 3 (7.7)        | 15 (12.7)        | 77 (31.7)           | 95 (23.8)  |
| Weight increased                             | 2 (5.1)        | 12 (10.2)        | 59 (24.3)           | 73 (18.3)  |
| Musculoskeletalandconnectivetissue disorders | 2 (5.1)        | 10 (8.5)         | 56 (23.0)           | 68 (17.0)  |
| Muscle rigidity                              | 1 (2.6)        | 6 (5.1)          | 19 (7.8)            | 26 (6.5)   |

Note: Incidence is based on the number of subjects experiencing at least one AE, not the number of events. Adverse events are coded using MedDRA version 15.0

tae01a\\_tsfae01a.rtfgeneratedbytsfae01a.sas,17AUG201217:26

Source:Mod5.3.5.2\\PSZ-3002\\Table48

Table 40: PSZ-3003- TEAEs in at least 5% of Subjects in any dose group

| Body System or Organ Class                       | Paliperidone ER (N=113)   | Aripiprazole (N=114)   |
|--------------------------------------------------|---------------------------|------------------------|
| Dictionary-Derived Term                          | n (%)                     | n (%)                  |
| Total no.subjects with adverseevents             | 87 (77.0)                 | 76 (66.7)              |
| Nervoussystem disorders                          | 55 (48.7)                 | 41 (36.0)              |
| Akathisia                                        | 13 (11.5)                 | 9 (7.9)                |
| Headache                                         | 12 (10.6)                 | 5 (4.4)                |
| Somnolence                                       | 12 (10.6)                 | 12 (10.5)              |
| Tremor                                           | 12 (10.6)                 | 11 (9.6)               |
| Sedation                                         | 6 (5.3)                   | 3 (2.6)                |
| Psychiatricdisorders                             | 23 (20.4)                 | 28 (24.6)              |
| Anxiety                                          | 6 (5.3)                   | 3 (2.6)                |
| Insomnia                                         | 6 (5.3)                   | 9 (7.9)                |
| Schizophrenia                                    | 4 (3.5)                   | 13 (11.4)              |
| Gastrointestinal disorders                       | 19 (16.8)                 | 13 (11.4)              |
| Vomiting                                         | 8 (7.1)                   | 1 (0.9)                |
| Nausea                                           | 4 (3.5)                   | 7 (6.1)                |
| Investigations                                   | 17 (15.0)                 | 14 (12.3)              |
| Weight increased                                 | 12 (10.6)                 | 7 (6.1)                |
| Generaldisorder'sandadministrationsiteconditions | 13 (11.5)                 | 5 (4.4)                |
| Asthenia                                         | 6 (5.3)                   | 1 (0.9)                |
| Musculoskeletal andconnectivetissuedisorder's    | 13 (11.5)                 | 5 (4.4)                |
| Muscle rigidity                                  | 7(6.2)                    | 3 (2.6)                |
| Metabolismandnutritiondisorders                  | 8 (7.1)                   | 9 (7.9)                |
| Decreased appetite                               | 2 (1.8)                   | 6 (5.3)                |

Note: Incidence is based on the number of subjects experiencing at least one AE, not the number of events.

Adverse events are coded using MedDRA version 15.0

tsfae02b.rtf generated by r\\_ae.sas,19JUL2012 15:41

<div style=\"page-break-after: always\"></div>

## Extrapyramidal Syndrome (EPS) related symptoms

## PSZ-3001

EPS related TEAEs have not been reported for placebo but for all other paliperidone ER dosing groups (1.5mg,  3mg,  6mg,  and  12mg).  A  dose-related  trend  could  be  shown  for  Akathisia  (3.7%,  6.3%, 11.1%, and 17.1%), Dystonia (1.9%, 0%, 4.4%, and 8.6%), Tremor (1.9%, 6.3%, 6.7%, 11.4%), and Muscle rigidity (0%, 0%, 2.2%, and 2.9%).

Treatment-emergent EPS assessed by rating scale (Barnes for Akathisia) revealed 0% for placebo and paliperidone ER 1.5mg and higher incidences for paliperidone ER 3mg, 6mg, and 12mg (6%, 9%, and 6%). Parkinsonism as per Simpson-Angus Scale was highest in the paliperidone ER 1.5mg group.

A  dose-related  use  of  anticholinergic  medication  was  found  (4%,  13%,  18%,  and  31%  in  the paliperidone  ER  1.5mg,  3mg,  6mg,  12mg  group)  with  no  anticholinergic  medication  in  the  placebo group.

Incidences  of  parkinsonism  and  akathisia  and  use  of  anticholinergic  medications  were  higher  in subjects &lt;15 years old and &lt;51 kg than those ≥15 years old and ≥51 kg, respectively.

## PSZ-3003

EPS  related  TEAEs  were  (slightly)  higher  for  paliperidone  ER  compared  to  aripiprazole  for  all  EPS categories except for Dyskinesia. No cases of tardive dyskinesia were reported. The rates of dyskinesia (based on AIMS score) and anticholinergic medication use were slightly higher in the paliperidone ER group than in the aripiprazole group (3% vs. 0%, and 25% vs. 22%). Parkinsonism and Akathisia were similar  between  treatment  groups  based  on  rating  scale  results.  However,  in  the  &lt;15  years  old subgroup, the incidences of parkinsonism and akathisia were higher in subjects receiving paliperidone ER (6%) than those receiving aripiprazole (3%).

## PSZ-3002

EPS-related  TEAEs  within  the  categories  of  Parkinsonism  and  Hyperkinesia  were  most  frequently reported and highest in the paliperidone (NO DB)/paliperidone group . The most commonly occurring (&gt;5%) EPS-related event was akathisia (13.0%), followed by tremor (11.0%), muscle rigidity (6.5%), and  dystonia  (5.3%).  These  TEAEs  were  mostly  mild  to  moderate  in  severity.  No  case  of  tardive dyskinesia  was  reported.  Further  analysis  was  conducted  regarding  the  time  course  of  EPS-related TEAEs.  Overall,  treatment-emergent  EPS  occurred  more  frequently  in  the  first  3  months  than  in subsequent months (See Table 41).

Table 41: Treatment-Emergent EPS Assessed by Rating Scale Incidence and Use of Anticholinergics - Open-Label Study (PSZ-3002).

| Scale                             | Placebo/Pali (N=39) n (%)   | Pali (DB)/Pali (N=118) n (%)   | Pali (NO DB)/Pali (N=243) n (%)   | Total (N=400) n (%)   |
|-----------------------------------|-----------------------------|--------------------------------|-----------------------------------|-----------------------|
| Use of AnticholinergicMedications | 5 (13)                      | 27 (23)                        | 69 (28)                           | 101 (25)              |
| Parkinsonism                      | 0                           | 2 (2)                          | 17 (7)                            | 19 (5)                |
| Akathisia                         | 0                           | 3 (3)                          | 6 (2)                             | 9 (2)                 |
| Dyskinesia                        | 0                           | 0                              | 2 (1)                             | 2 (1)                 |

Use of Anti-EPS Medication during open-label study.

Percent of subjects with Simpson-Angus Scale Global Score &gt; 0.3 at End Point(OL) (Global Score defined as total sum ofitems score divided by the number of items).

Percent of subjects with Barnes Akathisia Rating Scale Global Clinical Rating Score ≥2 at End Point (OL).

Percent of subjects with a score≥3 on any of the first seven items or a score≥2 on two or more of any of the first sevenitemsof theAbnormalInvoluntaryMovementScale atEndPoint(OL)

Note: Percentages are calculated based on number of subjects in the OL safety analysis set per treatment group.

<div style=\"page-break-after: always\"></div>

Thirty-five (35)% of the subjects received anti-EPS medication and antihistamines drug/therapy prior to the open-label study compared to 25.0% of subjects during the open-label study.

## Suicide related events

## PSZ-3001

No  suicidality-related  TEAEs  were  reported  in  this  study.  Evaluation  of  the  Columbia  Classification Algorithm of Suicide Assessment (C-CASA, retrospective assessment) revealed two patients who were suspect of potentially suicidality-related AEs, one in the placebo group and one in the paliperidone ER medium  group.  However,  these  events  turned  out  to  be  not  related  after  review.  There  was  no indication  of  an  increased  suicidality  risk  in  subjects  receiving  paliperidone  ER  compared  with  those receiving placebo.

## PSZ-3003

Suicidality-related TEAEs occurred in 3 subjects, all in the paliperidone ER treatment group. The TEAEs were  suicidal  ideation  in  2  subjects  (1.8%)  and  suicide  attempt  in  2  subjects  (1.8%).  The  C-SSRS assessment based on C-CASA classification confirmed the majority of subjects from the paliperidone ER group with no suicidal event at baseline remained non suicidal post-baseline (96.4%). The same was true for aripiprazole (98.2%).

## PSZ-3002

Suicidality-related TEAEs occurred in 37 subjects in the Total group (9.3% overall). These were suicidal ideation in 34 (8.5%) subjects, suicide attempt in 3 (0.8%) subjects, and suicidal behaviour in 1 (0.3%) subject. TEAEs in this category were reported only in the paliperidone (NO DB)/ paliperidone treatment group.

Further data on suicidality assessment are presented in Tables 42 and 43.

Table 42: Treatment-Emergent Potentially Suicide-Related Events (PSREs) - Retrospective Columbia Classification Algorithm of Suicide Assessment (C-CASA) for Subjects Who Completed the Study Prior to the Initiation of C-SSRS - Open-Label Study (PSZ-3002).

| C-CASA                                             | Placebo/Pali (N=14) n (%)   | Pali (DB)/Pali (N=46) n (%)   | Pali (NO DB)/Pali (N=51) n (%)   | Total (N=111) n (%)   |
|----------------------------------------------------|-----------------------------|-------------------------------|----------------------------------|-----------------------|
| Total no. subjects with PSRE                       | 2 (14.3)                    | 1 (2.2)                       | 13 (25.5)                        | 16 (14.4)             |
| Suicidal Behavior (Codes 1-4)                      | 0                           | 0                             | 5 (9.8)                          | 5 (4.5)               |
| Completed suicide                                  | 0                           | 0                             | 0                                | 0                     |
| Suicide attempt                                    | 0                           | 0                             | 2 (3.9)                          | 2 (1.8)               |
| Preparatory acts toward imminent suicidal behavior | 0                           | 0                             | 0                                | 0                     |
| Suicidal ideation                                  | 0                           | 0                             | 3 (5.9)                          | 3 (2.7)               |
| Indeterminate (Codes 5-6, 9)                       | 1 (7.1)                     | 1 (2.2)                       | 4 (7.8)                          | 6 (5.4)               |
| Self-injurious behavior, intent unknown            | 1 (7.1)                     | 0                             | 2 (3.9)                          | 3 (2.7)               |
| Not enough information, fatal                      | 0                           | 0                             | 0                                | 0                     |
| Not enough information, nonfatal                   | 0                           | 1 (2.2)                       | 2 (3.9)                          | 3 (2.7)               |
| Non-Suicidal (Codes 7-8)                           | 1 (7.1)                     | 0                             | 5 (9.8)                          | 6 (5.4)               |
| Self-injuriousbehavior, no suicidal intent         | 0                           | 0                             | 1 (2.0)                          | 1 (0.9)               |
| Other: accident, psychiatric, medical              | 1 (7.1)                     | 0                             | 4 (7.8)                          | 5 (4.5)               |

<div style=\"page-break-after: always\"></div>

Table 43: Incidence of Any Post Baseline (OL) PSREs - Columbia Classification Algorithm of Suicide Assessment (C-CASA) Based on C-SSRS - for Subjects Who Completed the Study After Initiation of C-SSRS - Open-Label Study (PSZ-3002).

| Cssrs Score                                         | Placebo/Pali (N=25) n (%)   |   Pali (DB)/Pali (N=72) n (%) | Pali (NO DB)/Pali (N=192) n (%)   | Total (N=289) n (%)   |
|-----------------------------------------------------|-----------------------------|-------------------------------|-----------------------------------|-----------------------|
| Total no.subjects withPSRE                          | 1 (4.0)                     |                             0 | 36 (18.8)                         | 37 (12.8)             |
| Suicidal Behavior (Codes 1-4)                       | 1 (4.0)                     |                             0 | 30 (15.6)                         | 31 (10.7)             |
| Completed suicide                                   | 0                           |                             0 | 0                                 | 0                     |
| Suicide attempt                                     | 0                           |                             0 | 0                                 | 0                     |
| Preparatory acts toward imminent suicidal behaviour | 0                           |                             0 | 3 (1.6)                           | 3 (1.0)               |
| Suicidal ideation                                   | 1 ( 4.0)                    |                             0 | 27 (14.1)                         | 28 (9.7)              |
| Indeterminate (Codes 5-6, 9)                        | 0                           |                             0 | 1 (0.5)                           | 1 (0.3)               |
| Self-injurious behaviour,intent unknown             | 0                           |                             0 | 1 (0.5)                           | 1 (0.3)               |
| Not enough information, fatal                       | 0                           |                             0 | 0                                 | 0                     |
| Not enough information, nonfatal                    | 0                           |                             0 | 0                                 | 0                     |
| Non-Suicidal (Codes 7-8)                            | 0                           |                             0 | 5 (2.6)                           | 5 (1.7)               |
| Self-injurious behaviour, no suicidal intent        | 0                           |                             0 | 3 (1.6)                           | 3 (1.0)               |
| Other: accident, psychiatric, medical               | 0                           |                             0 | 2 (1.0)                           | 2 (0.7)               |

Only subjects with CSSRS data during open label are included in this summary.

For subjects with multiple post baseline(OL) events, the worst score was selected. A score of 9 was considered more severe than a score of 7 or 8.

## Other psychiatric adverse events

## PSZ-3001

TEAEs related to worsening of psychosis occurred at a lower incidence with paliperidone ER (6.7%) than with placebo (11.8%). Agitation occurred in a higher rate in placebo compared to paliperidone ER (7.8% vs. 4.7%). Aggression was only reported for placebo-treated patients. No TEAEs of seizure or convulsion were reported. Somnolence (including sedation) was highest and dose-related in the total paliperidone ER group compared to placebo (16.7% vs. 3.9%).

## PSZ-3003

TEAEs related to worsening of psychosis occurred at a lower incidence with paliperidone ER (4.4%) than with aripiprazole (12.3%). Similarly, schizophrenia was reported more frequently with aripiprazole compared to paliperidone ER (11.4% vs. 3.5%). Depressed mood was slightly higher in paliperidone ER-treated  patients  compared  to  aripiprazole  (2.7%  vs.  1.8%).  There  were  only  isolated  reports  of agitation  and  aggression  for  both  treatment  options.  No  reports  of  NMS,  seizure  or  convulsion. Somnolence was similar for paliperidone ER and aripiprazole (10.6% vs. 10.5%). The percentage of subjects with TEAEs of sedation was higher in paliperidone ER group (5.3%) than in the aripiprazole group  (2.6%).  Most  of  the  TEAEs  were  mild  to  moderate  in  severity.  None  of  these  events  were serious.

## PSZ-3002

The incidence of psychosis TEAEs and schizophrenia was higher compared to the other studies. A total 55 subjects (13.8%) had a TEAE related to worsening of psychosis. In the Total group, 50 subjects (12.5%) had a TEAE of schizophrenia. Depressed mood happened in 5.5% of subjects. A total of 17 subjects  (4.3%)  had  a  TEAE  related  to  agitation,  and  6  subjects  (1.5%)  had  a  TEAE  related  to aggression. Most of these events were mild to moderate in severity. Two subjects (0.8% overall) had

<div style=\"page-break-after: always\"></div>

TEAEs  related  to  seizures  and  convulsions  (one  case  of  petit  mal  epilepsy  and  one  case  of  tonic convulsion). Somnolence was reported for 23% of subjects.

## Weight gain related adverse events

Potentially clinically significant weight gain of 7% and more was reported for 26% of patients in study PSZ-3003 and for 47% in study PSZ-3002, reflecting a high risk of weight gain associated with various comorbidities,  particularly  in  a  schizophrenic  population.  This  risk  is  clearly  more  pronounced  with higher doses. However, post-marketing data from adolescents in the US did not indicate a difference in weight increase reporting compared to adults.

In  the  26-week active-controlled study PSZ-3003, although there were 26% of patients with weight gain  of  ≥7%,  the  changes  from  baseline  in  z-score  for  weight  and  BMI  were  0.09  and  0.13, respectively, indicating the change in weight was clinically insignificant (changes from baseline in zscore exceeding 0.5 would be judged a significant observation). In the 2-year long-term safety study PSZ-3002, the mean weight increase from open-label baseline to open-label endpoint was 4.7 kg ( n = 400).  Overall,  47.0%  (73/157)  of  subjects  experienced  weight  gain  of  at  least  7.0%  at  open-label endpoint relative to double-blind baseline. The mean change in z-score was 0.1 for both weight and BMI from open-label baseline to endpoint.

The percentage change in body weight at endpoint relative to open-label baseline in Study PSZ-3002 is displayed in Figure 24.

## Figure 24 Histogram of percentage change in body weight (kg) from open label baseline to endpoint (study PS-3002)

<!-- image -->

Percent Change from Baseline (OL) to End Point (OL) in Body Weight (kg)

<div style=\"page-break-after: always\"></div>

## 2.5.3. Serious adverse event/deaths/other significant events

No death cases have been reported in studies with adolescents.

## PSZ-3001

There were 5 treatment emergent SAEs that occurred ; 1 from the placebo group (psychotic disorder), 2 from the paliperidone ER 1.5 mg group (schizophrenia and agitation), 1 from the paliperidone ER 3mg group (Mallory Weiss syndrome) and 1 from the paliperidone ER 6mg group (schizophrenia).

## PSZ-3002

SAEs occurred in 59 subjects (14.8%). Most of these were in the SOC psychiatric disorders with the most common being schizophrenia (n=30) indicating worsening of illness. Other SAEs that occurred in more than 1 subject were suicidal ideation (n=7) and agression and anxiety (in 4 subjects each). There were 3 suicide attempts; all in the paliperidone(NO/DB)paliperidone group.

## PSZ-3003

There  were  6.2%  of  Treatment  Emergent  SAEs  in  the  paliperidone  ER  group  and  6.1%  in  the aripiprazole group. The most common was the SOC Psychiatric Disorders for both groups (5.3% each).

## 2.5.4. Laboratory, ECG and other findings

No  clinically significant laboratory abnormalities  other than  prolactin  levels  have  been  noted. Measurement of testosterone for assessing a potential long-term endocrine effect of elevated prolactin levels  did  not  point  towards  a  significant  change  in  testosterone  levels  in  male  adolescents  with schizophrenia.  Fasting  glucose  abnormalities  and  glucose-related  TEAEs  occasionally  occurred  with paliperidone  ER;  Homeostatic  Model  Assessment  (HOMA)  assessment  revealed  a  pre-existing  insulin resistance  at  baseline  in  all  studies  and  all  treatment  groups  and  beta  cell  function  was  similarly increased at baseline. During treatment with paliperidone ER, the insulin resistance slightly increased and beta cell function slightly decreased, but not dose-related.

## Prolactin levels

## PSZ-3001

Abnormally high prolactin values were found more frequently in the paliperidone ER groups compared to placebo and for more than half of the male patients and almost half of the female patients with no clear relation to dose (placebo: 10% male and 17% female). A clear dose effect could be established for females with mean increases of 10.39 ng/ml, 26.93 ng/ml, and 29.96 ng/ml for the 3mg, 6mg, and 12mg  dose  group.  These  laboratory  abnormalities  did  not  generally  translate  into  prolactin-related adverse  events:  two  patients  from  the  paliperidone  ER  6mg  dose  group  were  reported  with galactorrhoea and one female patient from the paliperidone ER 3mg group with amenorrhoea.

Higher incidences of treatment-emergent abnormal high prolactin results were observed in &lt;15 years old subgroup than in ≥15 years old subgroup. It did not appear there was a dose-related trend in both age subgroups.

## PSZ-3003

Abnormally  high  prolactin  values  could  be  shown  for  paliperidone  ER:  59%  of  males  and  57%  of females. In contrast,  aripiprazole-treated  patients  were  affected  to  a  smaller  extend  by  high  values due to its pharmacological properties (3% for males and 9% for females) but did show more decreases in prolactin (males: 52% and females: 29%).

<div style=\"page-break-after: always\"></div>

Again, there was no significant increase in TEAEs related to high prolactin values and only single cases were reported regarding galactorrhoea, gynaecomastia, libido decreased, erectile dysfunction, amenorrhoea, menstruation irregular. Except for one case of galactorrhoea, no TEAE showed up in the aripiprazole group.

Higher incidences of treatment-emergent abnormal high prolactin results were observed in &lt;15 years old than in ≥15 years old subgroup in paliperidone ER group, whereas higher incidences of treatmentemergent  abnormal  low  prolactin  results  were  observed  in  &lt;15  years  old  than  in  ≥15  years  old subgroup in aripiprazole group.

## PSZ-3002

Incidences of treatment-emergent abnormal prolactin results by sex relative to baseline (open-label and double-blind) were shown to be higher for males through all treatment groups.

The mean prolactin levels for both males and females increased and reached a peak within the first 6 months of treatment, and then either stabilized or gradually declined over time. 60% of male subjects and 48% of female subjects had elevated prolactin levels from open-label baseline to endpoint during this study. 9.3% subjects experienced a prolactin-related TEAE (18.5% in females and 3.3% in males).

Higher incidences  of  treatment-emergent  abnormal  high  prolactin  results  were  observed  in  the  &lt;15 years old than the ≥15 years old subgroup from double-blind baseline to endpoint.

From  open-label  baseline  to  endpoint,  similar  incidences  of  treatment-emergent  abnormal  high prolactin results were observed for male subjects regardless of age, whereas higher incidences were observed for female subjects who were &lt;15 years old compared ≥15 years old.

## Electrocardiograms

## PSZ-3001

Abnormally high heart rates occurred in greater percentages of subjects in the paliperidone ER dose groups than in the placebo group (1.5mg: 14%, 3mg: 33%, 6mg: 5%, 12mg: 18% vs. placebo: 4%). Tachycardia-related events occurred in 4.7% of the total paliperidone group and in no patient from placebo.

All subjects in each dose group had normal average pre-dose and maximum post-dose values for QTcF. No subject had a maximum post-dose value &gt;480msec. Most subjects had increases in QTc values from average pre-dose to maximum post-dose of &lt;30 ms. No subject in any dose group had an increase that was greater than 60 msec.

## PSZ-3003

Abnormally high heart rate was observed in more subjects in the paliperidone ER group (8 subjects, 8%) compared to the aripiprazole group (6 subjects, 6%). There were no clinically relevant mean or median changes in heart rate, PR interval, QRS interval, QT interval, RR interval, QTcB, QTcF, QTlc, or QTcLD. TEAEs of tachycardia were reported with a higher incidence in the paliperidone ER group compared to aripiprazole (2.7% vs. 1.8%). One TEAE of sinus tachycardia was reported from the paliperidone ER group only. Most subjects in the paliperidone ER and aripiprazole group had a maximum increase of QTcF of 30msec and less (94% and 97%). 6% of subjects from the paliperidone ER group and 2% of subjects from the aripiprazole group had QTcF changes of 30 to 60msec. One subject on aripiprazole had a QTcF change of more than 60msec.

## PSZ-3002

<div style=\"page-break-after: always\"></div>

Abnormally  high  heart  rate  was  reported  for  13%  of  total  paliperidone  ER-treated  subjects.  One subject had a TEAE related to cardiac arrhythmias (sinus bradycardia). Two subjects had TEAEs related to proarrhythmic potential; one subject each had a TEAE of seizure and syncope.

With respect to QTcF changes from open-label baseline to endpoint, 88% of the total paliperidone ER group had changes of 30msec or less. 5% of subjects from the placebo/ paliperidone group, 8% from the paliperidone (DB)/ paliperidone group, and 14% from the paliperidone (No DB)/ paliperidone group had QTcF changes of &gt;30 to 60msec. A total of three patients had QTcF changes of more than 60msec.

## Tanner staging

## PSZ-3001

Most  male  and  female  subjects  had  the  same  Tanner  ratings  at  endpoint  as  at  baseline  in  each treatment  group.  No  significant  differences  have  been  found  between  paliperidone  ER  groups  and placebo.

## PSZ-3002

Most  male  and  female  subjects  had  the  same  Tanner  ratings  at  endpoint  as  at  open-label  baseline (ratings were predominantly 4 and 5 indicating a mostly post-pubertal population). Adolescents aged 12 to 13 years showed an expected shift from lower to higher Tanner ratings during the 2-year study.

## 2.5.5. Discontinuation due to adverse events

The  most  common  adverse  events  leading  to  discontinuation  across  the  3  Phase  III  studies  were adverse events coded to the Nervous System Disorders and Psychiatric Disorders SOCs. Other events led  to  withdrawal  infrequently  and  showed  no  pattern  related  to  treatment  or  to  the  dose  of paliperidone ER.

Treatment discontinuations due to TEAEs occurred at low rates in subjects treated with paliperidone ER in all Phase 3 studies (in study PSZ-3001, 2%; in study PSZ-3003, 4.4%; in the 2-year study PSZ3002, 6.3%).The incidences of TEAEs that resulted in discontinuation of treatment were also low in adults who received paliperidone ER (≤7% in double-blind and open-label studies) and adolescents who received risperidone (≤9% in double-blind and open-label studies).

## PSZ-3001

One patient each discontinued due to an adverse event from the paliperidone ER 1.5 mg (dermatitis allergic), 3mg (Mallory-Weiss Syndrome) and 12mg group (Dystonia), no patient from the placebo and the paliperidone ER 6 mg group.

## PSZ-3003

Five  patients  from  the  paliperidone  ER  group  and  no  patient  from  the  aripiprazole  treatment  had  a TEAE leading to treatment discontinuation. Four of these patients (3.5%) discontinued during the acute phase (through Day 56) of the study. The respective adverse events did not reveal a specific pattern (Oculogyric crisis, Lethargy, Anxiety, Galactorrhoea, and Rash).

## PSZ-3002

Twenty-five patients (6.3%) discontinued due to TEAEs with the highest number in the paliperidone (No  DB)/paliperidone  group  amounting  to  23  patients.  Three  of  these  23  patients  discontinued subsequently to a suicide attempt and two due to suicidal ideation. Three patients discontinued due to Akathisia. All other TEAE-related treatment discontinuations happened in single subjects only.

<div style=\"page-break-after: always\"></div>

## 2.5.6. Post marketing experience

A  cumulative  review  was  performed  by  the  MAH  (cut-off  date:  11  September  2012)  to  provide  an overall safety information about paliperidone in this patient population. All spontaneous cases reported with paliperidone or paliperidone palmitate, were compared by age group (&lt;18 years versus all other age groups, ie, those patients ≥18 years of age) using a measure of disproportionality. Preferred terms (PTs)  of  interest  were  identified  if  disproportionality  (ie,  higher  proportion  of  total  events  among paediatric patients than all other age groups) was present in the cumulative data.

There were 360 cases involving paediatric patients (&lt;18 years) received during the cumulative review period, of which 40% were serious. The patterns of disproportionately reported ADRs with Preferred Terms (PTs) observed were generally consistent with adult clinical trials and post-marketing experience or were specific to the paediatric population.

The PTs that demonstrated disproportionality vs adults were as follows: Accidental overdose; Breast discharge;  Dystonia;  Gynaecomastia;  Increased  appetite;  Oculogyric  crisis;  Somnolence;  Suicidal ideation;  Lethargy;  Increased  appetite;  Trismus;  Breast  enlargement;  Swollen  tongue;  Chest  pain; Irritability;  Medication  residue;  Sluggishness;  Therapeutic  response  unexpected;  Muscle  twitching; Convulsion; Disturbance in attention; Drooling; Hypersomnia; Restless legs syndrome; Tic; Abnormal behaviour; Aggression; Anger; Catatonia; Priapism; Swelling face; and Urticaria.

There  were  no  fatal  cases  reported  in  paediatric  patients  treated  with  paliperidone  during  the cumulative review period. No disproportionality  of  reporting  was  noted  for  paediatric  patients  when compared to all other age groups during this review with respect to any of the predefined areas of clinical interest, including the collective group of all extrapyramidal symptoms, weight gain, prolactinrelated events, glucose metabolism disorders, cardiac events, suicidality, or sedation.

Adverse events reported in association with the predefined areas of clinical interest were consistent with the known safety profile for paliperidone ER and paliperidone palmitate and included EPS-related events, isolated cases of excessive weight gain, and prolactin-related events. PTs such as Accidental drug intake by child and Drug administered to patient of inappropriate age would not be reported in the adult population.

The disproportionate reporting of off-label use may be reflective of the limited indicated age range of paliperidone ER (schizophrenia in adolescents aged 12 to 17 years) and paliperidone palmitate (not indicated in children or adolescents) per the CCDS and the off label use for disorders found mostly in children (eg, attention deficit hyperactivity disorder and autism).

## 2.5.7. Discussion on clinical safety

The clinical development program for Paliperidone ER in adolescents included 3 phase III studies and one phase one study which included 653 subjects exposed to paliperidone ER. The number of patients for  whom  safety  data  is  available  seems  adequate.  No  particular  safety  issues  have  been  identified during  the  clinical  development  program.    The  type  of  adverse  events  reported  in  545  adolescent subjects  with  schizophrenia  receiving  once-daily  treatment  with  paliperidone  ER  in  the  3  studies included in this submission were generally consistent with those reported for paliperidone ER in adult subjects and those known to be associated with risperidone treatment in adolescent subjects.

However, patients aged 12 to 14 years represented a minority across the three phase 3 studies 3001, 3003, and 3002. For example, dose range evaluation of TEAEs in study 3001 relied on a maximum of 16 patients aged 12 to 14 years in each treatment group. Similarly and with regard to clinical efficacy data, there are few safety data for patients weighing less than 51 kg compared to those weighing more than 51 kg. Whist further data were provided to support an individual dose titration depending on body

<div style=\"page-break-after: always\"></div>

weight,  the CHMP was still of the opinion that  a positive benefit-risk  in the younger age group 12 to 14 years was insufficiently demonstrated due to the lack of data.

Following ADR analyses on all data from the adolescent studies, the MAH identified the following new ADRs  that  had  previously  not  been  identified  in  the  use  in  adults:  Bundle  branch  block  right,  Eye movement  disorder,  Alanine  aminotransferase  increased,  Aspartate aminotransferase  increased, Nuchal  rigidity,  Muscle  contractions  involuntary,  Opisthotonus,  Speech  disorder,  Tongue  paralysis, Insomnia, Anxiety, Epistaxis, and hypertension. These have been added to the current paliperidone ER CCDS. In addition, 'weight circumference increased' was also identified and is considered related to 'weight increase' which is already listed in the SmPC. Similarly to the adult population, the highest incidence  of  TEAEs  emerged  from  the  Nervous  System  Disorders  SOC.  Dose-related  trends  were observed for Somnolence, Akathisia, Tremor, Dystonia, and Cogwheel rigidity.

Compared to paliperidone ER in adults, the frequency of EPS-related adverse events was clearly higher for  adolescents  in  studies  PSZ-3001,  -3003,  and  -3002  (around  36.5%  of  subjects  affected  during open-label treatment). This finding is confirmed by the high concomitant use of anticholinergics (up to one-third  of  patients).  EPS  symptoms  were  highest  during  the  first  three  months  of  treatment  and reaching a plateau from six months of treatment up to 24 months. The CHMP however noted that the incidences of EPS related events observed in the open label study were in the range of that reported for other antipsychotics. In addition, there was no evidence of a dose effect with regard to either the incidences of treatment-emergent EPS as assessed by the results of the EPS scales or in the rate of anticholinergic  medication  use  in  the  Paliperidone  ER  Total  group.  There  were  also  no  apparent differences  in  treatment-emergent  EPS-related  AEs  by  rating  scales  and  use  of  anticholinergic medications with regard to age or weight. The CHMP concluded that a general SmPC warning related to regular examination of EPS symptoms for the paediatric population should be included.

Potentially clinically significant weight gain of 7% and more was reported for 26% of patients in study PSZ-3003 and for 47% in study PSZ-3002, reflecting a high risk of weight gain associated with various comorbidities,  particularly  in  a  schizophrenic  population.  This  risk  is  clearly  more  pronounced  with higher doses. Post-marketing data from adolescents in the US did not indicate a difference in weight increase reporting compared to adults. During the course of treatment in Phase 3 studies, there were no clinically significant mean changes in z-scores (adjusted for sex- and age-specific normative values) for  weight  or  BMI.  In  the  2-year  long-term  study,  the  majority  of  subjects  had  z-scores  below  the clinically significant threshold of 0.5 in all categories. Subgroup analyses did not reveal apparent trends of  weight gain related AEs with regard to age or body weight. The CHMP however recommended to include information related to weight gain as warning in the SmPC.

No  clinically  relevant  changes  in  laboratory  parameters  were  noted  during  short  and  long-term treatment  with  paliperidone  ER  in  adolescents  with  schizophrenia  except  for  serum  prolactin.  In addition, pre-existing insulin resistance was found in all treatment groups and slightly increased over time, whereas the compensatory increase in beta cell functioning slightly decreased.

Elevation  in  serum  prolactin  has  been  noted  across  all  paliperidone  ER  treatment  groups  clearly increased by dose, whereas females were more affected than males. However, abnormalities did not simultaneously lead to TEAEs with regard to prolactin. The highest rate was observed in study 3002 with near 10% of all paliperidone ER-treated subjects. Serum prolactin was highest during the first six months  of  treatment  and  remained  stable  thereafter.Higher  incidences  of  treatment-emergent abnormal prolactin results were observed in younger (&lt;15 years) subjects than in older (≥15 years) subjects across all studies with adolescents. There were no corresponding increased incidences in AEs in  the  subgroups  with  younger  subjects.Prolactin  increases  appeared  to  be  in  line  with  those  from paliperidone  ER  in  adults  and  with  risperidone  in  adolescents.  Because  of  the  potential  effects  of

<div style=\"page-break-after: always\"></div>

prolonged hyperprolactinemia on growth and sexual maturation, a SmPC warning related to regular clinical  evaluation  of  endocrinological  status  for  the  paediatric  population  was  recommended  by  the CHMP.

Increase  in  blood  triglycerides  was  common  in  open  label  study  3002  and  the  frequency  was  more commonly observed in adolescents than in adults. However, treatment with paliperidone ER did not appear to alter blood triglyceride profile and triglyceride related AEs are not common. The increase in mean triglyceride levels in PSZ-3003 was not replicated in the longer and larger study PSZ-3002. The ADR rate of hypertriglyceridemia is higher in the pediatric population than the adult population.

A dose relationship was observed for somnolence, subgroup analyses by age and weight groups did not reveal a higher incidence of somnolence related AEs in the younger and lighter patients (&lt;15 years and &lt;51 kg). However, somnolence was found to be higher in adolescents compared to adults, doserelated (6 to 26%) and higher compared to placebo and also detected in 23% of patients during longterm  treatment.  Consequently,  a  SmPC  warning  related  to  close  monitoring  for  sedative  effect  of paliperidone ER for the paediatric population was recommended by the CHMP.

No death cases have been reported during studies with adolescents. The overall number of serious adverse events was low, similar for paliperidone ER, placebo and active comparator, and most of all related to the underlying psychiatric illness.

ECG  changes  in  adolescents  were  found  to  be  in  line  with  those  in  adults,  e.g.  the  potential  of paliperidone ER to increase heart rate ( ≥ 100 bpm). There were no clinically relevant mean or median changes in PR interval,  QRS  interval,  QT  interval,  RR  interval,  or  corrected  QT  intervals  in  subjects treated with paliperidone ER in any of the Phase 3 studies.

No  retardation  in  growth  as  represented  by  changes  in  height,  weight,  and  BMI  based  on  Z-score analyses,  as  well  as  in  sexual  maturation  (Tanner  staging)  was  noted,  which  would  indicate  an abnormal adolescent maturation.

Based on post-marketing data, there were 360 cases involving paediatric patients (&lt;18 years) during the cumulative review period, of which 40% were serious. The patterns of disproportionately reported ADRs with Preferred Terms (PTs) observed were generally consistent with adult clinical trials and postmarketing experience or were specific to the paediatric population.

## 2.5.8. Conclusions on clinical safety

Overall, the CHMP concluded that the safety of Invega for the treatment of schizophrenia in 15 years and  older  has  been  sufficiently  characterised.  From  the  safety  database  all  the  adverse  reactions reported in paediatric clinical trials have been included in the SmPC.

## 2.5.9. PSUR cycle

Having considered the data submitted in the application and following the MAH proposal to restrict the proposed indication to treatment of schizophrenia in adolescents 15 years and older, the CHMP was of the opinion that the PSUR cycle for paliperidone should remain unchanged.

## 2.6. Risk management plan

## 2.6.1. PRAC advice

The CHMP received the following PRAC advice on the submitted Risk Management Plan.

<div style=\"page-break-after: always\"></div>

## PRAC Advice

The  MAH  has  submitted  an  updated  RMP  (version  4.0)  in  which  the  results  from  studies  including adolescent  patient  with  schizophrenia  have  been  added.  However,  no  new  safety  issues  have  been proposed  and  therefore  the  pharmacovigilance  and  risk  minimisation  plans  are  unchanged.  This  is acceptable.

Additionally, the MAH has removed the safety issue 'Neonatal withdrawal Syndrome' and 'Antiemetic Effect' in accordance with the PRAC opinion during the recent PSUR assessment.

The CHMP endorsed this advice without changes.

Following  the  MAH  proposal  to  restrict  the  proposed  indication  to  treatment  of  schizophrenia  in adolescents 15 years and older, updates of the RMP were proposed with regard to module SIII.2 and SVII.3. In addition, changes in line with the latest PRAC recommendation on the PSUR (January 2014) were  made.  These  changes  were  agreed  by  the  CHMP  and  RMP  (version  5.1)  was  considered acceptable.

## 2.7. Update of the product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC have been updated to include efficacy and safety information resulting from the submitted paediatric studies. The Package Leaflet has been updated accordingly. The SmPC changes are summarised below:

Final recommended indication, posology and warnings are as follows:

## Section 4.1

INVEGA is indicated for the treatment of schizophrenia in adolescents 15 years and older.

## Section 4.2

## Paediatric population

Schizophrenia: The  recommended  starting  dose  of  INVEGA  for  the  treatment  of  schizophrenia  in adolescents 15 years and older is 3 mg once daily, administered in the morning.

Adolescents weighing &lt; 51 kg : the maximum recommended daily dose of INVEGA is 6 mg.

Adolescents weighing ≥ 51 kg: the maximum recommended daily dose of INVEGA is 12 mg.

Dosage adjustment, if indicated, should occur only after clinical reassessment based on the individual need of the patient. When dose increases are indicated, increments of 3 mg/day are recommended and generally  should  occur  at  intervals  of  5  days  or  more.  The  safety  and  efficacy  of  INVEGA  in  the treatment  of  schizophrenia  in  adolescents  between  12  and  14  years  old  has  not  been  established. Currently available data are described in section 4.8 and 5.1 but no recommendation on a posology can be made. There is no relevant use of INVEGA in children aged less than 12 years.

## Section 4.4

## Paediatric population

The sedative effect of INVEGA should be closely monitored in this population. A change in the time of administration of INVEGA may improve the impact of sedation on the patient.

Because of the potential effects of prolonged hyperprolactinemia on growth and sexual maturation in adolescents, regular clinical evaluation of endocrinological status should be considered, including

<div style=\"page-break-after: always\"></div>

measurements of height, weight, sexual maturation, monitoring of menstrual functioning, and other potential prolactin-related effects.

During treatment with INVEGA regular examination for extrapyramidal symptoms and other movement disorders should also be conducted.

For specific posology recommendations in the paediatric population see section 4.2.

In addition:

- A summary of safety profile related to the paediatric population was also added to section 4.8, listing ADRs that were reported more frequently in adolescents than in adults receiving Invega (and more frequently  than  placebo).  Furthermore,  the  list  of  adult  ADRs  in  the  'Summary  of  safety  profile' subsection  of  SmPC  section  4.8  has  been  updated  as  a  result  of  changes  in  frequency  calculations resulting  from  the  removal  of  the  paediatric  study  PSZ-3001  when  calculating  ADR  reporting frequency. In this subsection, the identification of those ADRs that are 'most frequently reported' were based on a cut-off of &gt; 2% from the original analysis and led to the addition of cough (a common ADR). In addition, the tabulated list of adverse reactions considered all ADRs reported in clinical trials and post-marketing experience with paliperidone with a frequency category estimated from the adult trials  and thus resulted in change in frequencies for some of the listed adverse reactions (e.g white blodd cell count decreased, thrombocytopenia, hyperprolactinemia, tardive dyskinesia, atrioventricular block, eczema);

- Sections 5.1 and 5.3 were updated to add the main results from the paediatric clinical studies and juvenile toxicity studies, respectively;

- Section 5.2 was updated to reflect the main findings from the pharmacokinetic modelling analyses.;

- Section 4.5 was updated to include a statement that 'interaction studies have only been performed in adults'.

No  full  user  consultation  with  target  patient  groups  on  the  package  leaflet  been  performed  and  no bridging  report  was  submitted  making  reference  to  the  assessment  of  the  initial  patient  leaflet  for INVEGA prolonged release tablets, that was approved on 25 June 2007. The MAH states that since no additional safety issues have been identified and no new route of administration is proposed, there is no need for a user testing. The justification submitted by the MAH has been found acceptable.

In addition, the list of local representatives in the Package Leaflet has been revised to amend contact details for the representatives of Luxembourg and Belgium.

## 3. Benefit-risk balance

## Beneficial effects

In study PSZ-3001, results indicated that the study achieved its primary objective by demonstrating that at least one paliperidone ER weight-based group (&lt;51 Kg: 3 mg/day; ≥51 Kg: 6 mg/day) was statistically  superior  to  placebo  in  improving  the  symptoms  of  schizophrenia  as  measured  by  the change  in  PANSS  total  score  from  baseline  to  endpoint  (week  6,  difference  of  LS  means:  -10.1; p=0.006). Efficacy analyses of the secondary endpoints including CGI-S, CGAS, sleep VAS and PANSS factor scores were consistent with the findings of the primary efficacy analysis.

Similarly  to  the  overall  study  results  for  this  short  term  trial,  the  medium  dose  group  (&lt;51  Kg:  3 mg/day;  ≥51  Kg:  6  mg/day)  showed  better  improvement  in  PANSS  total  score  in  all  analysed

<div style=\"page-break-after: always\"></div>

subgroups  based  on  age  and/or  weight.  In  patients  aged  15-17  years  old,  statistically  significant differences versus placebo were observed in both the Medium (&lt;51 Kg: 3 mg/day; ≥51 Kg: 6 mg/day, p=0.005) and High (&lt;51 Kg: 6 mg/day; ≥51 Kg: 12 mg/day, p=0.012) dose groups of paliperidone ER for  the  primary  endpoint  (change  from  baseline  to  endpoint  in  PANSS  total  score).  In  addition, consistent  efficacy  findings  were  observed  for  the  subgroup  analyses  on  the  secondary  efficacy endpoints

In study PSZ-3003, maintenance data was provided over 26 weeks. The primary objective was not met i.e. paliperidone ER did not demonstrate superior efficacy compared to aripiprazole. However, robust and clinically meaningful reductions in mean PANSS total score from baseline to endpoint acute (Day 56,  LOCF)  in  the  paliperidone  ER  (-19.3)  and  aripiprazole  (-19.8)  groups  were  observed.  Similar treatment  effects  with  regard  to  decreasing  the  PANSS  total  scores  over  the  26-week  period  for paliperidone ER and aripiprazole were also noted.

In study PSZ-3002, improvement in the PANSS total scores in patients treated with paliperidone ER were observed during the first  3  months  of  the  open-label  treatment.  The  improvements  in  PANSS total scores observed during the first 3 months were maintained during the remaining portion of this 2 year study. Subgroup analyses based on age and weight did not reveal any significant difference in improvement in PANSS during the course of 2 year treatment.

## Uncertainty in the knowledge about the beneficial effects

The time course of PANSS score and the influence of exposure to paliperidone and other covariates has not been evaluated by modelling as compared to the presented popPK analysis. This makes it difficult to draw any conclusion about the relation between paliperidone exposure and clinical effect.

Although  post-hoc  analyses  by  actual  dose  received  by  the  subjects  showed  statistically  significant improvement relative to placebo in the PANSS total scores at endpoint for the paliperidone ER 3, 6, and 12 mg dose groups, no clear dose response pattern was observed for the efficacy parameters.

The proportion of patients aged 12-14 years was relatively small to conclude on the efficacy (short term and maintenance of the effect) in this population. In both short term and long term studies, the effect on the PANSS total score was also considered weaker in this age group as compared to patients aged 15-17 years. In study PSZ-3001, the difference of LS mean changes from baseline to endpoint was -15.5 in patients aged 12-14 years and -18.1 in patients aged 15-17 years, respectively. In study PSZ-3003, the difference of LS mean changes from baseline to endpoint was -17.5 in patients aged 12-14 years and -20.1 in patients aged 15-17 years, respectively. In study PSZ-3002 (open label), among younger adolescents a lower percentage of subjects who maintained a 30% PANSS response over time was observed compared to patients in 15-17 years.

## Risks

## Unfavourable effects

Identified risks did not differ by nature between the adult and adolescent population but in terms of frequencies  of  EPS  symptoms,  weight  gain,  somnolence/sedation,  triglycerides  level  and  a  slightly higher rate of suicidality-related events.

Weight  increases  have  occurred  at  higher  incidence  in  younger  adolescents  compared  to  older adolescents.

Somnolence was found to be higher in adolescents compared to adults, dose-related (6 to 26%) and higher compared to placebo (4%) and also detected in 23% of patients during long-term treatment.

<div style=\"page-break-after: always\"></div>

A clear dose-response pattern was observed for several safety parameters including common adverse events  (somnolence,  akathisia,  tremor,  and  dystonia),  EPS  related  adverse  events  (hyperkinesia, dystonia, and tremor) and associated use of anticholinergic medications, and mean increases in body weight and BMI. In addition, elevation in serum prolactin has been noted across all paliperidone ER treatment groups and was clearly increased by dose.

## Uncertainty in the knowledge about the unfavourable effects

There are limited data on the long term safety of paliperidone in the paediatric population, especially in patients aged 12-14 years.

## Importance of favourable and unfavourable effects

Paliperidone  (Invega)  is  an  oral  prolonged-release  formulation,  and  do  not  require  dose  titration  at initiation  treatment.  The  clinical  programme  was  part  of  an  agreed  PIP.  Currently,  authorised antipsychotics  are  limited  for  the  treatment  of  schizophrenia  in  the  paediatric  population.  There  is therefore  a  need  for  evidence-based  therapeutic  options  in  this  patient  population.  The  efficacy  of paliperidone ER was demonstrated over placebo in adolescent patients with schizophrenia at week 6, for the medium dose group only. The proportion of patients aged 12-14 years was relatively small to conclude on the efficacy (short term and maintenance of effect) in this population. In patients aged 1517  years  old,  statistically  significant  differences  versus  placebo  were  observed  in  both  the  Medium (p=0.005) and High (p=0.012) dose groups of paliperidone ER for the primary endpoint at week 6. In addition,  consistent  efficacy  findings  were  observed  for  the  subgroup  analyses  on  the  secondary efficacy endpoints. Although the maintenance study did not meet its primary objective ie paliperidone ER  did  not  demonstrate  superior  efficacy  compared  to  aripiprazole,  robust  and  clinically  meaningful reductions  in  mean  PANSS  total  score  were  observed  for  both  paliperidone  ER  and  aripiprazole  and were numerically similar.

In the studied paediatric population, the overall safety profile appeared similar to that seen in adults..

Following the CHMP concerns over the lack of sufficient evidence of short term and long term efficacy in  subjects  aged  between  12-14  years,  the  MAH  proposed  to  restrict  the  proposed  indication  to treatment of schizophrenia in adolescents 15 years and older. According to the Schizophrenia Guideline (EMA/CHMP/40072/2010 Rev.1), data on maintenance of effect may be extrapolated from adults to adolescents  as  of  the  age  of  15  years.  Furthermore,  considering  individual  dose  strategy  was supported by PK/PD data (including weight based dosing recommendation) and that the pharmacokinetic profile is expected to be similar between adolescents (15 years and older) and adults, the  CHMP  considered  that  the  efficacy  was  established  in  patients  over  15  years  and  older  at  a recommended starting dose of 3 mg.

## Benefit-risk balance

Considering  the  efficacy  and  safety  data  across  paediatric  age  groups  from  12-17  years,  the  CHMP considered  that  limited  data  were  available  to  conclude  on  a  positive  benefit-risk  balance  of paliperidone ER in the treatment of schizophrenia in patients aged 12-14 years old. In contrast, the efficacy and safety in the older paediatric population (15-17 years) have been sufficiently established. Therefore, in agreement with the MAH, the CHMP concluded on a positive benefit-risk balance in the following indication:

'INVEGA is indicated for the treatment of schizophrenia in adolescents 15 years and older.'

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation(s) to the terms of the Marketing Authorisation, concerning the following change(s):

| Variation(s) requested   | Variation(s) requested                                                                                                         | Type   |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a                  | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

Extension  of  indication  to  add  the  treatment  of  schizophrenia  in  adolescents  15  years  and  older. Consequential changes were made in sections 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 to include efficacy and  safety  information  resulting  from  the  submitted  paediatric  studies.  The  Package  Leaflet  has been amended accordingly. In addition, the list of local representatives in the Package Leaflet has been revised to amend contact details for the representatives of Luxembourg and Belgium.

The  requested  variation  proposed  amendments  to  the  Summary  of  Product  Characteristics  and Package Leaflet.

## Paediatric data

Furthermore,  the  CHMP  reviewed  the  available  paediatric  data  of  studies  subject  to  the  agreed Paediatric Investigation Plan PIP P/154/2011 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.